# ESC Guidelines: Endocarditis (2023)

**Source**: `2023_Endocarditis.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 95

---

## Table of Contents

- [2023 ESC Guidelines for the management of endocarditis](#2023-esc-guidelines-for-the-management-of-endocard) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 6)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 8)*
  - [3. Prevention](#3-prevention) *(p. 12)*
    - [3.1. Rationale](#31-rationale) *(p. 12)*
    - [3.2. Populations at risk of infective endocarditis](#32-populations-at-risk-of-infective-endocarditis) *(p. 13)*
    - [3.3. Situations and procedures at risk](#33-situations-and-procedures-at-risk) *(p. 14)*
      - [3.3.1. Dental procedures](#331-dental-procedures) *(p. 14)*
      - [3.3.2. Non-dental procedures](#332-non-dental-procedures) *(p. 14)*
      - [3.3.3. Cardiac or vascular interventions](#333-cardiac-or-vascular-interventions) *(p. 15)*
    - [3.4. Patient education](#34-patient-education) *(p. 15)*
  - [4. The Endocarditis Team](#4-the-endocarditis-team) *(p. 16)*
  - [5. Diagnosis](#5-diagnosis) *(p. 18)*
    - [5.1. Clinical features](#51-clinical-features) *(p. 18)*
    - [5.2. Laboratory findings](#52-laboratory-findings) *(p. 19)*
    - [5.3. Microbiological diagnosis](#53-microbiological-diagnosis) *(p. 19)*
      - [5.3.1. Blood culture-positive infective endocarditis](#531-blood-culture-positive-infective-endocarditis) *(p. 19)*
      - [5.3.2. Blood culture-negative infective endocarditis](#532-blood-culture-negative-infective-endocarditis) *(p. 19)*
      - [5.3.3. Proposed strategy for a microbiological diagnostic algorithm in suspected infective endocarditis](#533-proposed-strategy-for-a-microbiological-diagno) *(p. 20)*
    - [5.4. Imaging techniques](#54-imaging-techniques) *(p. 20)*
      - [5.4.1. Echocardiography](#541-echocardiography) *(p. 20)*
      - [5.4.2. Computed tomography](#542-computed-tomography) *(p. 22)*
      - [5.4.3. Magnetic resonance imaging](#543-magnetic-resonance-imaging) *(p. 22)*
      - [5.4.4. Nuclear imaging positron emission tomography/computed tomography (angiography) and single photon emission tomography/computed tomography](#544-nuclear-imaging-positron-emission-tomography/c) *(p. 23)*
    - [5.5. Diagnostic criteria](#55-diagnostic-criteria) *(p. 24)*
      - [5.5.1. Modifications for the diagnosis of infective endocarditis](#551-modifications-for-the-diagnosis-of-infective-e) *(p. 24)*
        - [5.5.1.1. Major criteria – microbiology](#5511-major-criteria-–-microbiology) *(p. 26)*
        - [5.5.1.2. Major criteria – imaging](#5512-major-criteria-–-imaging) *(p. 26)*
        - [5.5.1.3. Minor criteria](#5513-minor-criteria) *(p. 27)*
        - [5.5.1.4. Microbiological criteria](#5514-microbiological-criteria) *(p. 27)*
        - [5.5.1.5. Infective endocarditis classification](#5515-infective-endocarditis-classification) *(p. 28)*
      - [5.5.2. The new 2023 European Society of Cardiology diagnostic algorithms](#552-the-new-2023-european-society-of-cardiology-di) *(p. 28)*
  - [6. Prognostic assessment at admission](#6-prognostic-assessment-at-admission) *(p. 28)*
  - [7. Antimicrobial therapy: principles and methods](#7-antimicrobial-therapy:-principles-and-methods) *(p. 28)*
    - [7.1. General principles](#71-general-principles) *(p. 28)*
    - [7.2. Penicillin-susceptible oral streptococci and Streptococcus gallolyticus group](#72-penicillin-susceptible-oral-streptococci-and-st) *(p. 30)*
    - [7.3. Oral streptococci and Streptococcus gallolyticus group susceptible, increased exposure or resistant to penicillin](#73-oral-streptococci-and-streptococcus-gallolyticu) *(p. 30)*
    - [7.4. Streptococcus pneumoniae, β-haemolytic streptococci (groups A, B, C, and G)](#74-streptococcus-pneumoniae,-β-haemolytic-streptoc) *(p. 32)*
    - [7.5. Granulicatella and Abiotrophia (formerly nutritionally variant streptococci)](#75-granulicatella-and-abiotrophia-(formerly-nutrit) *(p. 32)*
    - [7.6. Staphylococcus aureus and coagulase-negative staphylococci](#76-staphylococcus-aureus-and-coagulase-negative-st) *(p. 32)*
    - [7.7. Methicillin-resistant staphylococci](#77-methicillin-resistant-staphylococci) *(p. 32)*
    - [7.8. Enterococcus spp.](#78-enterococcus-spp) *(p. 35)*
    - [7.9. Gram-negative bacteria](#79-gram-negative-bacteria) *(p. 36)*
      - [7.9.1. Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, and Kingella-related species](#791-haemophilus,-aggregatibacter,-cardiobacterium,) *(p. 36)*
      - [7.9.2. Non-Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, and Kingella species](#792-non-haemophilus,-aggregatibacter,-cardiobacter) *(p. 37)*
    - [7.10. Blood culture-negative infective endocarditis](#710-blood-culture-negative-infective-endocarditis) *(p. 37)*
    - [7.11. Fungi](#711-fungi) *(p. 37)*
    - [7.12. Empirical therapy](#712-empirical-therapy) *(p. 37)*
    - [7.13. Outpatient parenteral or oral antibiotic therapy for infective endocarditis](#713-outpatient-parenteral-or-oral-antibiotic-thera) *(p. 38)*
      - [7.13.1. Parenteral and oral step-down antibiotic treatment](#7131-parenteral-and-oral-step-down-antibiotic-trea) *(p. 39)*
      - [7.13.2. Other considerations for outpatient oral or parenteral antimicrobial therapy](#7132-other-considerations-for-outpatient-oral-or-p) *(p. 39)*
  - [8. Indications for surgery and management of main infective endocarditis complications](#8-indications-for-surgery-and-management-of-main-i) *(p. 40)*
    - [8.1. Pre-operative risk assessment](#81-pre-operative-risk-assessment) *(p. 40)*
    - [8.2. Heart failure](#82-heart-failure) *(p. 40)*
      - [8.2.1. Heart failure in infective endocarditis](#821-heart-failure-in-infective-endocarditis) *(p. 40)*
      - [8.2.2. Indications and timing of surgery in the presence of heart failure in infective endocarditis](#822-indications-and-timing-of-surgery-in-the-prese) *(p. 42)*
    - [8.3. Uncontrolled infection](#83-uncontrolled-infection) *(p. 42)*
      - [8.3.1. Septic shock and persistent infection](#831-septic-shock-and-persistent-infection) *(p. 42)*
      - [8.3.2. Locally uncontrolled infection](#832-locally-uncontrolled-infection) *(p. 42)*
      - [8.3.3 Indications and timing of surgery in the presence of uncontrolled infection](#833-indications-and-timing-of-surgery-in-the-prese) *(p. 43)*
        - [8.3.3.1. Persistent infection](#8331-persistent-infection) *(p. 43)*
        - [8.3.3.2. Locally uncontrolled infection](#8332-locally-uncontrolled-infection) *(p. 43)*
        - [8.3.3.3. Infection with resistant or virulent organisms](#8333-infection-with-resistant-or-virulent-organism) *(p. 43)*
    - [8.4. Prevention of systemic embolism](#84-prevention-of-systemic-embolism) *(p. 43)*
      - [8.4.1. Incidence of embolic events in infective endocarditis](#841-incidence-of-embolic-events-in-infective-endoc) *(p. 43)*
      - [8.4.2. Predicting the risk of embolism](#842-predicting-the-risk-of-embolism) *(p. 43)*
      - [8.4.3. Indications and timing of surgery to prevent embolism in infective endocarditis](#843-indications-and-timing-of-surgery-to-prevent-e) *(p. 43)*
  - [9. Other complications of infective endocarditis](#9-other-complications-of-infective-endocarditis) *(p. 44)*
    - [9.1. Neurological complications](#91-neurological-complications) *(p. 44)*
      - [9.1.1. The role of cerebral imaging in infective endocarditis](#911-the-role-of-cerebral-imaging-in-infective-endo) *(p. 45)*
    - [9.2. Infective aneurysms](#92-infective-aneurysms) *(p. 45)*
    - [9.3. Splenic complications](#93-splenic-complications) *(p. 45)*
    - [9.4. Myocarditis and pericarditis](#94-myocarditis-and-pericarditis) *(p. 46)*
    - [9.5. Heart rhythm and conduction disturbances](#95-heart-rhythm-and-conduction-disturbances) *(p. 46)*
    - [9.6. Musculoskeletal manifestations](#96-musculoskeletal-manifestations) *(p. 46)*
      - [9.6.1. Osteoarticular infective endocarditis-related infections](#961-osteoarticular-infective-endocarditis-related-) *(p. 46)*
      - [9.6.2. Rheumatological manifestations](#962-rheumatological-manifestations) *(p. 47)*
    - [9.7. Acute renal failure](#97-acute-renal-failure) *(p. 47)*
  - [10. Surgical therapy: principles and methods](#10-surgical-therapy:-principles-and-methods) *(p. 47)*
    - [10.1. Pre-operative and peri-operative management](#101-pre-operative-and-peri-operative-management) *(p. 47)*
      - [10.1.1. Coronary angiography](#1011-coronary-angiography) *(p. 47)*
      - [10.1.2. Extracardiac infection](#1012-extracardiac-infection) *(p. 48)*
      - [10.1.3. Intra-operative echocardiography](#1013-intra-operative-echocardiography) *(p. 48)*
    - [10.2. Other intra-operative considerations](#102-other-intra-operative-considerations) *(p. 48)*
    - [10.3. Surgical approach and techniques](#103-surgical-approach-and-techniques) *(p. 48)*
      - [10.3.1. Choice of valve prosthesis](#1031-choice-of-valve-prosthesis) *(p. 49)*
    - [10.4. Timing of surgery after ischaemic and haemorrhagic stroke](#104-timing-of-surgery-after-ischaemic-and-haemorrh) *(p. 50)*
    - [10.5. Post-operative complications](#105-post-operative-complications) *(p. 50)*
    - [10.6. Management of antithrombotic therapy after surgery](#106-management-of-antithrombotic-therapy-after-sur) *(p. 51)*
  - [11. Outcome after discharge: follow-up and long-term prognosis](#11-outcome-after-discharge:-follow-up-and-long-ter) *(p. 51)*
    - [11.1. Recurrences: relapses and reinfections](#111-recurrences:-relapses-and-reinfections) *(p. 51)*
    - [11.2. First year follow-up](#112-first-year-follow-up) *(p. 52)*
    - [11.3. Long-term prognosis](#113-long-term-prognosis) *(p. 52)*
  - [12. Management of specific situations](#12-management-of-specific-situations) *(p. 52)*
    - [12.1. Prosthetic valve endocarditis](#121-prosthetic-valve-endocarditis) *(p. 52)*
      - [12.1.1. Definition and pathophysiology](#1211-definition-and-pathophysiology) *(p. 53)*
      - [12.1.2. Diagnosis](#1212-diagnosis) *(p. 53)*
      - [12.1.3. Prognosis and treatment](#1213-prognosis-and-treatment) *(p. 53)*
    - [12.2. Endocarditis in the elderly](#122-endocarditis-in-the-elderly) *(p. 53)*
    - [12.3. Transcatheter prosthetic valve endocarditis](#123-transcatheter-prosthetic-valve-endocarditis) *(p. 54)*
      - [12.3.1. Endocarditis following transcatheter aortic valve implantation](#1231-endocarditis-following-transcatheter-aortic-v) *(p. 54)*
        - [12.3.1.1. Diagnosis](#12311-diagnosis) *(p. 54)*
        - [12.3.1.2. Prognosis and treatment](#12312-prognosis-and-treatment) *(p. 54)*
      - [12.3.2. Endocarditis following transcatheter pulmonary valve implantation](#1232-endocarditis-following-transcatheter-pulmonar) *(p. 54)*
        - [12.3.2.1. Diagnosis](#12321-diagnosis) *(p. 55)*
        - [12.3.2.2. Prognosis and treatment](#12322-prognosis-and-treatment) *(p. 55)*
    - [12.4. Infective endocarditis affecting cardiac implantable electronic devices](#124-infective-endocarditis-affecting-cardiac-impla) *(p. 55)*
      - [12.4.1. Definitions of cardiac device infections](#1241-definitions-of-cardiac-device-infections) *(p. 55)*
      - [12.4.2. Pathophysiology and microbiology](#1242-pathophysiology-and-microbiology) *(p. 55)*
      - [12.4.3. Risk factors](#1243-risk-factors) *(p. 55)*
      - [12.4.4. Prophylaxis](#1244-prophylaxis) *(p. 55)*
      - [12.4.5. Diagnosis](#1245-diagnosis) *(p. 55)*
      - [12.4.6. Antimicrobial therapy](#1246-antimicrobial-therapy) *(p. 57)*
      - [12.4.7. Device extraction](#1247-device-extraction) *(p. 57)*
      - [12.4.8. Device reimplantation](#1248-device-reimplantation) *(p. 57)*
    - [12.5. Infective endocarditis in patients admitted to intensive care units](#125-infective-endocarditis-in-patients-admitted-to) *(p. 58)*
      - [12.5.1. Causative microorganisms](#1251-causative-microorganisms) *(p. 58)*
      - [12.5.2. Diagnosis](#1252-diagnosis) *(p. 58)*
      - [12.5.3. Management](#1253-management) *(p. 58)*
    - [12.6. Right-sided infective endocarditis](#126-right-sided-infective-endocarditis) *(p. 58)*
      - [12.6.1. Diagnosis and complications](#1261-diagnosis-and-complications) *(p. 59)*
      - [12.6.2. Endocarditis in people who inject drugs](#1262-endocarditis-in-people-who-inject-drugs) *(p. 59)*
      - [12.6.3. Prognosis and treatment](#1263-prognosis-and-treatment) *(p. 59)*
        - [12.6.3.1. Antimicrobial therapy](#12631-antimicrobial-therapy) *(p. 59)*
        - [12.6.3.2. Surgery](#12632-surgery) *(p. 59)*
    - [12.7. Infective endocarditis in congenital heart disease](#127-infective-endocarditis-in-congenital-heart-dis) *(p. 60)*
    - [12.8. Infective endocarditis in rheumatic heart disease](#128-infective-endocarditis-in-rheumatic-heart-dise) *(p. 61)*
    - [12.9. Infective endocarditis during pregnancy](#129-infective-endocarditis-during-pregnancy) *(p. 61)*
    - [12.10. Infective endocarditis in immunocompromised patients](#1210-infective-endocarditis-in-immunocompromised-p) *(p. 61)*
      - [12.10.1. Solid organ transplant recipients](#12101-solid-organ-transplant-recipients) *(p. 61)*
      - [12.10.2. Patients with human immunodeficiency virus](#12102-patients-with-human-immunodeficiency-virus) *(p. 61)*
      - [12.10.3. Patients with neutropaenia](#12103-patients-with-neutropaenia) *(p. 62)*
    - [12.11. Antithrombotic and anticoagulant therapy in infective endocarditis](#1211-antithrombotic-and-anticoagulant-therapy-in-i) *(p. 62)*
    - [12.12. Non-bacterial thrombotic endocarditis](#1212-non-bacterial-thrombotic-endocarditis) *(p. 62)*
    - [12.13. Infective endocarditis and malignancy](#1213-infective-endocarditis-and-malignancy) *(p. 63)*
  - [13. Patient-centred care and shared decision-making in infective endocarditis](#13-patient-centred-care-and-shared-decision-making) *(p. 63)*
    - [13.1. What is patient-centred care and shared decision-making and why is it important?](#131-what-is-patient-centred-care-and-shared-decisi) *(p. 63)*
    - [13.2. Patient-centred care and shared decision-making in infective endocarditis](#132-patient-centred-care-and-shared-decision-makin) *(p. 63)*
  - [14. Sex differences](#14-sex-differences) *(p. 64)*
  - [15. Key messages](#15-key-messages) *(p. 65)*
  - [16. Gaps in evidence](#16-gaps-in-evidence) *(p. 66)*
  - [17. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#17-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 67)*
  - [18. Supplementary data](#18-supplementary-data) *(p. 73)*
  - [19. Data availability](#19-data-availability) *(p. 73)*
  - [20. Author information](#20-author-information) *(p. 73)*
  - [Appendix](#appendix) *(p. 74)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2023 ESC Guidelines for the management 
of endocarditis
Developed by the task force on the management of endocarditis 
of the European Society of Cardiology (ESC)
Endorsed by the European Association for Cardio-Thoracic Surgery 
(EACTS) and the European Association of Nuclear Medicine (EANM)
Authors/Task Force Members: Victoria Delgado  *†, (Chairperson) (Spain),  
Nina Ajmone Marsan  
‡, (Task Force Co-ordinator) (Netherlands),  
Suzanne de Waha‡, (Task Force Co-ordinator) (Germany), Nikolaos Bonaros  
(Austria), Margarita Brida  
(Croatia), Haran Burri  
(Switzerland), 
Stefano Caselli  
(Switzerland), Torsten Doenst  
(Germany), 
Stephane Ederhy  
(France), Paola Anna Erba  
1 (Italy), Dan Foldager (Denmark), 
Emil L. Fosbøl  
(Denmark), Jan Kovac (United Kingdom), Carlos A. Mestres  
(South Africa), Owen I. Miller  
(United Kingdom), Jose M. Miro  
2 (Spain), 
Michal Pazdernik  
(Czech Republic), Maria Nazarena Pizzi  
(Spain), 
Eduard Quintana  
3 (Spain), Trine Bernholdt Rasmussen  
(Denmark),  
Arsen D. Ristić  
(Serbia), Josep Rodés-Cabau (Canada), Alessandro Sionis  
(Spain), Liesl Joanna Zühlke  
(South Africa), Michael A. Borger  *†, 
(Chairperson) (Germany), and ESC Scientific Document Group
© The European Society of Cardiology 2023. All rights reserved. For permissions please e-mail: journals.permissions@oup.com.
* Corresponding authors: Victoria Delgado, Cardiology, Hospital University Germans Trias i Pujol, Badalona, Spain, and Institute for Health Science Research Germans Trias i Pujol (IGTP), 
Badalona, Spain. Tel: +34 934 65 12 00, E-mail: videlga@gmail.com; and Michael A. Borger, University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. Tel: +49-341- 
865-0, E-mail: Michael.Borger@helios-gesundheit.de
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the European Association of Nuclear Medicine (EANM)
2 Representing the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
3 Representing the European Association for Cardio-Thoracic Surgery (EACTS)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
and Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Stroke.
Working Groups: Adult Congenital Heart Disease, Cardiovascular Surgery.
Patient Forum  
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC 
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
https://doi.org/10.1093/eurheartj/ehad193
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Bernard Iung, (CPG Review Co-ordinator) (France), Bernard Prendergast, (CPG Review  
Co-ordinator) (United Kingdom), Magdy Abdelhamid (Egypt), Marianna Adamo (Italy), Riccardo Asteggiano 
(Italy), Larry M. Baddour (Unites States of America), Jelena Čelutkienė (Lithuania), John Chambers  
(United Kingdom), Jean-Claude Deharo (France), Wolfram Doehner (Germany), Laura Dos Subira (Spain), 
Xavier Duval (France), Volkmar Falk (Germany), Laurent Fauchier (France), Nuria Fernandez-Hidalgo (Spain), 
Christian Giske2 (Sweden), Anežka Gombošová (Czechia), Gilbert Habib (France), Borja Ibanez (Spain), 
Tiny Jaarsma (Sweden), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha  
(United Kingdom), Ulf Landmesser (Germany), Sandra B. Lauck (Canada), Basil S. Lewis (Israel), Maja-Lisa Løchen 
(Norway), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom),  
Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark),  
Jean-François Obadia (France), Agnes A. Pasquet (Belgium), Steffen Petersen (United Kingdom), Eva Prescott 
(Denmark), Susanna Price (United Kingdom), Amina Rakisheva (Kazakhstan), Archana Rao (United Kingdom),  
François Rouzet (France), Jonathan Sandoe (United Kingdom), Renate B. Schnabel (Germany),  
Christine Selton-Suty (France), Lars Sondergaard (Denmark), Martin Thornhill (United Kingdom), 
Konstantinos Toutouzas (Greece), Nico Van de Veire (Belgium), Isidre Vilacosta (Spain),  
Christiaan Vrints (Belgium), and Olaf Wendler (United Kingdom)
All experts involved in the development of these guidelines have submitted declarations of interest. These have 
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The 
report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary documents that include background information and 
evidence tables.
Keywords 
Guidelines • Antibiotics • Cardiac imaging • Cardiac implantable electronic device • Cardiac surgery • Complications 
• Computed tomography • Congenital heart disease • Diagnosis • Echocardiography • Endocarditis • Infection • 
Nuclear imaging • Positron emission tomography • Prevention • Prognosis • Prosthetic heart valve • Valve disease
Table of contents
1. Preamble .............................................................................................................. 3953
2. Introduction ....................................................................................................... 3955
2.1. What is new .............................................................................................
3955
3. Prevention ........................................................................................................... 3959
3.1. Rationale .....................................................................................................
3959
3.2. Populations at risk of infective endocarditis ...............................
3960
3.3. Situations and procedures at risk ....................................................
3961
3.3.1. Dental procedures ......................................................................... 3961
3.3.2. Non-dental procedures ............................................................... 3961
3.3.3. Cardiac or vascular interventions ............................................ 3962
3.4. Patient education ....................................................................................
3962
4. The Endocarditis Team ................................................................................. 3963
5. Diagnosis .............................................................................................................. 3965
5.1. Clinical features .......................................................................................
3965
5.2. Laboratory findings ................................................................................
3966
5.3. Microbiological diagnosis .....................................................................
3966
5.3.1. Blood culture-positive infective endocarditis ..................... 3966
5.3.2. Blood culture-negative infective endocarditis .................... 3966
5.3.3. Proposed strategy for a microbiological diagnostic 
algorithm in suspected infective endocarditis ................................. 3967
5.4. Imaging techniques .................................................................................
3967
5.4.1. Echocardiography ........................................................................... 3967
5.4.2. Computed tomography ............................................................... 3969
5.4.3. Magnetic resonance imaging ...................................................... 3969
5.4.4. Nuclear imaging positron emission tomography/ 
computed tomography (angiography) and single photon 
emission tomography/computed tomography ............................... 3970
5.5. Diagnostic criteria ..................................................................................
3971
5.5.1. Modifications for the diagnosis of infective endocarditis
3971
5.5.1.1. Major criteria – microbiology ...........................................
3973
5.5.1.2. Major criteria – imaging .......................................................
3973
5.5.1.3. Minor criteria ...........................................................................
3974
5.5.1.4. Microbiological criteria ........................................................
3974
5.5.1.5. Infective endocarditis classification .................................
3975
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular, in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the 
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; 
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from 
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case 
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices at the time of prescription.
ESC Guidelines                                                                                                                                                                                          3949


<!-- PAGE 3 -->

### Page 3

5.5.2. The new 2023 European Society of Cardiology diagnostic 
algorithms ....................................................................................................... 3975
6. Prognostic assessment at admission ........................................................ 3975
7. Antimicrobial therapy: principles and methods .................................. 3975
7.1. General principles ..................................................................................
3975
7.2. Penicillin-susceptible oral streptococci and 
Streptococcus gallolyticus group ..................................................................
3977
7.3. Oral streptococci and Streptococcus gallolyticus group 
susceptible, increased exposure or resistant to penicillin .............
3977
7.4. Streptococcus pneumoniae, β-haemolytic streptococci  
(groups A, B, C, and G) ................................................................................
3979
7.5. Granulicatella and Abiotrophia (formerly nutritionally variant 
streptococci) .....................................................................................................
3979
7.6. Staphylococcus aureus and coagulase-negative staphylococci
3979
7.7. Methicillin-resistant staphylococci ...................................................
3979
7.8. Enterococcus spp. .....................................................................................
3982
7.9. Gram-negative bacteria ........................................................................
3983
7.9.1. Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, 
and Kingella-related species .................................................................... 3983
7.9.2. Non-Haemophilus, Aggregatibacter, Cardiobacterium, 
Eikenella, and Kingella species ................................................................. 3984
7.10. Blood culture-negative infective endocarditis .........................
3984
7.11. Fungi ..........................................................................................................
3984
7.12. Empirical therapy .................................................................................
3984
7.13. Outpatient parenteral or oral antibiotic therapy for infective 
endocarditis .......................................................................................................
3985
7.13.1. Parenteral and oral step-down antibiotic treatment .... 3986
7.13.2. Other considerations for outpatient oral or parenteral 
antimicrobial therapy ................................................................................. 3986
8. Indications for surgery and management of main infective 
endocarditis complications ............................................................................... 3987
8.1. Pre-operative risk assessment ..........................................................
3987
8.2. Heart failure ..............................................................................................
3987
8.2.1. Heart failure in infective endocarditis .................................... 3987
8.2.2. Indications and timing of surgery in the presence of heart 
failure in infective endocarditis .............................................................. 3989
8.3. Uncontrolled infection .........................................................................
3989
8.3.1. Septic shock and persistent infection .................................... 3989
8.3.2. Locally uncontrolled infection ................................................... 3989
8.3.3 Indications and timing of surgery in the presence of 
uncontrolled infection ............................................................................... 3990
8.3.3.1. Persistent infection ................................................................
3990
8.3.3.2. Locally uncontrolled infection ..........................................
3990
8.3.3.3. Infection with resistant or virulent organisms ...........
3990
8.4. Prevention of systemic embolism ...................................................
3990
8.4.1. Incidence of embolic events in infective endocarditis ..... 3990
8.4.2. Predicting the risk of embolism ................................................ 3990
8.4.3. Indications and timing of surgery to prevent embolism in 
infective endocarditis ................................................................................. 3990
9. Other complications of infective endocarditis .................................... 3991
9.1. Neurological complications ................................................................
3991
9.1.1. The role of cerebral imaging in infective endocarditis .... 3992
9.2. Infective aneurysms ...............................................................................
3992
9.3. Splenic complications ............................................................................
3992
9.4. Myocarditis and pericarditis ...............................................................
3993
9.5. Heart rhythm and conduction disturbances ..............................
3993
9.6. Musculoskeletal manifestations ........................................................
3993
9.6.1. Osteoarticular infective endocarditis-related infections
3993
9.6.2. Rheumatological manifestations ............................................... 3994
9.7. Acute renal failure ..................................................................................
3994
10. Surgical therapy: principles and methods ........................................... 3994
10.1. Pre-operative and peri-operative management ......................
3994
10.1.1. Coronary angiography ............................................................... 3994
10.1.2. Extracardiac infection ................................................................. 3995
10.1.3. Intra-operative echocardiography ......................................... 3995
10.2. Other intra-operative considerations .........................................
3995
10.3. Surgical approach and techniques ................................................
3995
10.3.1. Choice of valve prosthesis ....................................................... 3996
10.4. Timing of surgery after ischaemic and haemorrhagic stroke
3997
10.5. Post-operative complications .........................................................
3997
10.6. Management of antithrombotic therapy after surgery ........
3998
11. Outcome after discharge: follow-up and long-term prognosis . 3998
11.1. Recurrences: relapses and reinfections ......................................
3998
11.2. First year follow-up .............................................................................
3999
11.3. Long-term prognosis ..........................................................................
3999
12. Management of specific situations ......................................................... 3999
12.1. Prosthetic valve endocarditis ..........................................................
3999
12.1.1. Definition and pathophysiology ............................................. 4000
12.1.2. Diagnosis .......................................................................................... 4000
12.1.3. Prognosis and treatment .......................................................... 4000
12.2. Endocarditis in the elderly ...............................................................
4000
12.3. Transcatheter prosthetic valve endocarditis ............................
4001
12.3.1. Endocarditis following transcatheter aortic valve 
implantation ................................................................................................... 4001
12.3.1.1. Diagnosis .................................................................................
4001
12.3.1.2. Prognosis and treatment ..................................................
4001
12.3.2. Endocarditis following transcatheter pulmonary valve 
implantation ................................................................................................... 4001
12.3.2.1. Diagnosis .................................................................................
4002
12.3.2.2. Prognosis and treatment ..................................................
4002
12.4. Infective endocarditis affecting cardiac implantable 
electronic devices ............................................................................................
4002
12.4.1. Definitions of cardiac device infections .............................. 4002
12.4.2. Pathophysiology and microbiology ....................................... 4002
12.4.3. Risk factors ..................................................................................... 4002
12.4.4. Prophylaxis ...................................................................................... 4002
12.4.5. Diagnosis .......................................................................................... 4002
12.4.6. Antimicrobial therapy ................................................................. 4004
12.4.7. Device extraction ......................................................................... 4004
12.4.8. Device reimplantation ................................................................ 4004
12.5. Infective endocarditis in patients admitted to intensive care 
units ......................................................................................................................
4005
12.5.1. Causative microorganisms ....................................................... 4005
12.5.2. Diagnosis .......................................................................................... 4005
12.5.3. Management ................................................................................... 4005
12.6. Right-sided infective endocarditis .................................................
4005
12.6.1. Diagnosis and complications ................................................... 4006
12.6.2. Endocarditis in people who inject drugs ............................ 4006
12.6.3. Prognosis and treatment .......................................................... 4006
12.6.3.1. Antimicrobial therapy ........................................................
4006


<!-- PAGE 4 -->

### Page 4

12.6.3.2. Surgery .....................................................................................
4006
12.7. Infective endocarditis in congenital heart disease ..................
4007
12.8. Infective endocarditis in rheumatic heart disease ..................
4008
12.9. Infective endocarditis during pregnancy ....................................
4008
12.10. Infective endocarditis in immunocompromised patients .
4008
12.10.1. Solid organ transplant recipients ........................................ 4008
12.10.2. Patients with human immunodeficiency virus ............... 4008
12.10.3. Patients with neutropaenia ................................................... 4009
12.11. Antithrombotic and anticoagulant therapy in infective 
endocarditis .......................................................................................................
4009
12.12. Non-bacterial thrombotic endocarditis ..................................
4009
12.13. Infective endocarditis and malignancy ......................................
4010
13. Patient-centred care and shared decision-making in infective 
endocarditis ............................................................................................................. 4010
13.1. What is patient-centred care and shared decision-making 
and why is it important? ...............................................................................
4010
13.2. Patient-centred care and shared decision-making in infective 
endocarditis .......................................................................................................
4010
14. Sex differences ............................................................................................... 4011
15. Key messages .................................................................................................. 4012
16. Gaps in evidence ............................................................................................ 4013
17. ‘What to do’ and ‘What not to do’ messages from the 
Guidelines ................................................................................................................. 4014
18. Supplementary data ...................................................................................... 4020
19. Data availability ............................................................................................... 4020
20. Author information ...................................................................................... 4020
21. Appendix ........................................................................................................... 4021
Tables of Recommendations
Recommendation Table 1 — Recommendations for antibiotic 
prophylaxis in patients with cardiovascular diseases undergoing 
oro-dental procedures at increased risk for infective endocarditis
3961
Recommendation Table 2 — Recommendations for infective 
endocarditis prevention in high-risk patients ............................................ 3963
Recommendation Table 3 — Recommendations for infective 
endocarditis prevention in cardiac procedures ....................................... 3963
Recommendation Table 4 — Recommendations for the 
Endocarditis Team ................................................................................................ 3965
Recommendation Table 5 — Recommendations for the role of 
echocardiography in infective endocarditis ................................................ 3969
Recommendation Table 6 — Recommendations for the role of 
computed tomography, nuclear imaging, and magnetic resonance in 
infective endocarditis ........................................................................................... 3970
Recommendation Table 7 — Recommendations for antibiotic 
treatment of infective endocarditis due to oral streptococci and 
Streptococcus gallolyticus group ........................................................................ 3977
Recommendation Table 8 — Recommendations for antibiotic 
treatment of infective endocarditis due to Staphylococcus spp. ........ 3980
Recommendation Table 9 — Recommendations for antibiotic 
treatment of infective endocarditis due to Enterococcus spp. ..................
3982
Recommendation Table 10 — Recommendations for antibiotic 
regimens for initial empirical treatment of infective endocarditis 
(before pathogen identification) ..................................................................... 3985
Recommendation Table 11 — Recommendations for outpatient 
antibiotic treatment of infective endocarditis ........................................... 3987
Recommendation Table 12 — Recommendations for the main 
indications of surgery in infective endocarditis (native valve 
endocarditis and prosthetic valve endocarditis) ....................................... 3991
Recommendation Table 13 — Recommendations for the treatment 
of neurological complications of infective endocarditis ....................... 3992
Recommendation Table 14 — Recommendations for pacemaker 
implantation in patients with complete atrioventricular block and 
infective endocarditis ........................................................................................... 3993
Recommendation Table 15 — Recommendations for patients with 
musculoskeletal manifestations of infective endocarditis .................... 3994
Recommendation Table 16 — Recommendations for pre-operative 
coronary anatomy assessment in patients requiring surgery for 
infective endocarditis ........................................................................................... 3995
Recommendation Table 17 — Indications and timing of cardiac 
surgery after neurological complications in active infective 
endocarditis ............................................................................................................. 3997
Recommendation Table 18 — Recommendations for 
post-discharge follow-up ................................................................................... 3999
Recommendation Table 19 — Recommendations for prosthetic 
valve endocarditis .................................................................................................. 4000
Recommendation Table 20 — Recommendations for cardiovascular 
implanted electronic device-related infective endocarditis ................. 4004
Recommendation Table 21 — Recommendations for the surgical 
treatment of right-sided infective endocarditis ........................................ 4007
Recommendation Table 22 — Recommendations for the use of 
antithrombotic therapy in infective endocarditis .................................... 4009
List of tables
Table 1 Classes of recommendations .......................................................... 3953
Table 2 Levels of evidence ................................................................................ 3953
Table 3 New recommendations .................................................................... 3955
Table 4 Revised recommendations ............................................................... 3957
Table 5 General prevention measures to be followed in patients at 
high and intermediate risk of infective endocarditis .............................. 3960
Table 6 Prophylactic antibiotic regime for high-risk dental 
procedures ............................................................................................................... 3961
Table 7 Members of the Endocarditis Team ............................................ 3963
Table 8 Cardiac and non-cardiac risk factors ........................................... 3965
Table 9 Investigation of rare causes of blood culture-negative 
infective endocarditis ........................................................................................... 3967
Table 10 Definitions of the 2023 European Society of Cardiology 
modified diagnostic criteria of infective endocarditis ............................. 3971
Table 11 Antibiotic treatment of blood culture-negative infective 
endocarditis ............................................................................................................. 3984
Table 12 Features favouring a non-mechanical valve substitute in the 
setting of surgery for acute infective endocarditis ................................. 3997
Table 13 Factors associated with an increased rate of relapse of 
infective endocarditis ........................................................................................... 3999
Table 14 ‘What to do’ and ‘What not to do’ .......................................... 4014
List of figures
Figure 1 Management of patients with infective endocarditis ........... 3954
Figure 2 Education of high-risk patients to prevent infective 
endocarditis ............................................................................................................. 3962
Figure 3 Management of patients with infective endocarditis: 
positioning of the Endocarditis Team .......................................................... 3964
ESC Guidelines                                                                                                                                                                                          3951


<!-- PAGE 5 -->

### Page 5

Figure 4 Microbiological diagnostic algorithm in culture-positive and 
culture-negative infective endocarditis ........................................................ 3968
Figure 5 European Society of Cardiology 2023 algorithm for 
diagnosis of native valve infective endocarditis ........................................ 3972
Figure 6 European Society of Cardiology 2023 algorithm for diagnosis 
of prosthetic valve infective endocarditis ...........................................................
3973
Figure 7 European Society of Cardiology 2023 algorithm for 
diagnosis of cardiac device-related infective endocarditis ................... 3974
Figure 8 Phases of antibiotic treatment for infective endocarditis in 
relation to outpatient parenteral antibiotic therapy and partial oral 
endocarditis treatment ....................................................................................... 3976
Figure 9 Flowchart to assess clinical stability based on the Partial Oral 
Treatment of Endocarditis trial ...................................................................... 3986
Figure 10 Proposed surgical timing for infective endocarditis ........... 3988
Figure 11 Surgery for infective endocarditis following stroke ........... 3996
Figure 12 Algorithm differentiating relapse from reinfection ............ 3998
Figure 13 Management of cardiovascular implanted electronic 
device-related infective endocarditis ............................................................ 4003
Figure 14 Concept of patient-centred care in infective endocarditis
4011
Abbreviations and acronyms
[18F]FDG
18F-fluorodeoxyglucose
99mTc-HMPAO
99mTechnetium-hexamethylpropyleneamine 
oxime
AIDS
Acquired immune deficiency syndrome
AEPEI
Association for the Study and Prevention of 
Infective Endocarditis Study
ANCLA
Anaemia, NYHA class IV, critical state, large 
intracardiac destruction, surgery of thoracic aorta
APLs
Antiphospholipid syndrome
AUC
Area under the curve
AVB
Atrioventricular block
AVN
Atrioventricular node
BCNIE
Blood culture-negative infective endocarditis
BMI
Body mass index
CAD
Coronary artery disease
CHD
Congenital heart disease
CI
Confidence interval
CIED
Cardiovascular implanted electronic device
CNS
Central nervous system
CoNS
Coagulase-negative staphylococci
CPB
Cardio-pulmonary bypass
CRT
Cardiac resynchronization therapy
CT
Computed tomography
CTA
Computed tomography angiography
DIC
Disseminated intravascular coagulation
DNA
Deoxyribonucleic acid
DSA
Digital subtraction angiography
ECG
Electrocardiogram
EHRA
European Heart Rhythm Association
ESC
European Society of Cardiology
EUCAST
European Committee on Antimicrobial 
Susceptibility Testing
EURO-ENDO
European Infective Endocarditis Registry
HACEK
Haemophilus, Aggregatibacter, Cardiobacterium, 
Eikenella, and Kingella
HF
Heart failure
HIV
Human immunodeficiency virus
HLAR
High-level aminoglycoside resistance i.m.
Intramuscular i.v.
Intravenous
ICD
Implantable cardioverter defibrillator
ICE-PCS
International Collaboration on 
Endocarditis-Prospective Cohort Study
ICU
Intensive care unit
IE
Infective endocarditis
Ig
Immunoglobulin
MALDI-TOF MS
Matrix-assisted laser desorption ionization 
time-of-flight mass spectrometry
MIC
Minimum inhibitory concentration
MRA
Magnetic resonance angiography
MRI
Magnetic resonance imaging
MRSA
Methicillin-resistant Staphylococcus aureus
MSSA
Methicillin-susceptible Staphylococcus aureus
NBTE
Non-bacterial thrombotic endocarditis
NIHSS
National Institutes of Health Stroke Scale Score
NVE
Native valve endocarditis
NYHA
New York Heart Association
OPAT
Outpatient parenteral antibiotic therapy
PADIT
Previous procedure on same pocket; Age; 
Depressed renal function; Immunocompromised; 
Type of procedure
PALSUSE
Prosthetic valve, age ≥70, large intracardiac 
destruction, Staphylococcus spp., urgent surgery, 
sex (female), EuroSCORE ≥10
PBP
Penicillin-binding protein
PCR
Polymerase chain reaction
PET/CT
Positron emission tomography/computed 
tomography
POET
Partial Oral Treatment of Endocarditis (trial)
PPV
Positive predictive value
PVE
Prosthetic valve endocarditis
PWID
People who inject drugs
RCT
Randomized clinical trial
RHD
Rheumatic heart disease rRNA
Ribosomal ribonucleic acid
SAPS
Simplified Acute Physiology Score
SLE
Systemic lupus erythematous
SOT
Solid organ transplantation
SPECT/CT
Single photon emission tomography/computed 
tomography
STS
Society of Thoracic Surgeons
TAVI
Transcatheter aortic valve implantation
TOE
Transoesophageal echocardiography
TPVI
Transcatheter pulmonary valve implantation
TTE
Transthoracic echocardiography
WBC
White blood cell
WRAP-IT
Worldwide Randomized Antibiotic Envelope 
Infection Prevention Trial


<!-- PAGE 6 -->

### Page 6

### 1 Preamble

Guidelines evaluate and summarize available evidence, with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeutic 
approach for an individual patient with a given condition. Guidelines are in­
tended for use by health professionals and the European Society of 
Cardiology (ESC) makes its Guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consideration 
of each patient’s health condition and in consultation with that patient or 
the patient’s caregiver where appropriate and/or necessary. It is also the 
health professional’s responsibility to verify the rules and regulations ap­
plicable in each country to drugs and devices at the time of prescription, 
and, where appropriate, to respect the ethical rules of their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated. ESC Policies and Procedures for for­
mulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines).
The Members of this Task Force were selected by the ESC to represent 
professionals involved with the medical care of patients with this 
Table 1 Classes of recommendations
©ESC 2023
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2023
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2023
© ESC 2023
ESC Guidelines                                                                                                                                                                                          3953


<!-- PAGE 7 -->

### Page 7

Yes
No
Yes
No
Emergency
Urgent
Non-urgent
Patient with infective endocarditis
Imaging
Blood culture
Adjust antibiotic according to results of blood cultures
Endocarditis Team
Empiric antibiotic therapy i.v.
Continue appropriate antibiotic therapy
Complications
Complications
Cardiac surgery
Antibiotic therapy i.v. in hospital or OPAT
Patient-centred care
Recovery plan
Patient education - oral and general hygiene
Continue appropriate antibiotic therapy
Continue appropriate antibiotic therapy
Endocarditis Team
Figure 1 Management of patients with infective endocarditis. i.v., intravenous; OPAT, outpatient parenteral antibiotic therapy.


<!-- PAGE 8 -->

### Page 8

pathology. The selection procedure aimed to include members from 
across the whole of the ESC region and from relevant ESC Subspecialty 
Communities. Consideration was given to diversity and inclusion, notably 
with respect to gender and country of origin. The Task Force performed a 
critical evaluation of diagnostic and therapeutic approaches, including as­
sessment of the risk-benefit ratio. The strength of every recommendation 
and the level of evidence supporting them were weighed and scored ac­
cording to predefined scales as outlined below. The Task Force followed 
ESC voting procedures, and all approved recommendations were subject 
to a vote and achieved at least 75% agreement among voting members.
The experts of the writing and reviewing panels provided declaration of 
interest forms for all relationships that might be perceived as real or po­
tential sources of conflicts of interest. Their declarations of interest were 
reviewed according to the ESC declaration of interest rules and can be 
found on the ESC website (http://www.escardio.org/Guidelines) and 
have been compiled in a report published in a supplementary document 
with the guidelines. The Task Force received its entire financial support 
from the ESC without any involvement from the healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises and 
co-ordinates the preparation of new guidelines and is responsible for the 
approval process. ESC Guidelines undergo extensive review by the CPG 
Committee and external experts, including members from across the 
whole of the ESC region and from relevant ESC Subspecialty 
Communities and National Cardiac Societies. After appropriate revisions, 
the guidelines are signed off by all the experts involved in the Task Force. 
The finalized document is signed off by the CPG Committee for publica­
tion in the European Heart Journal. The guidelines were developed after 
careful consideration of the scientific and medical knowledge and the evi­
dence available at the time of their writing. Tables of evidence summariz­
ing the findings of studies informing development of the guidelines are 
included. The ESC warns readers that the technical language may be mis­
interpreted and declines any responsibility in this respect.
Off-label use of medication may be presented in this guideline if a suf­
ficient level of evidence shows that it can be considered medically ap­
propriate for a given condition. However, the final decisions 
concerning an individual patient must be made by the responsible health 
professional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
Infective endocarditis (IE) is a major public health challenge.1 In 2019, the 
estimated incidence of IE was 13.8 cases per 100 000 subjects per year, 
and IE accounted for 66 300 deaths worldwide.2 Due to the associated 
high morbidity and mortality (1723.59 disability-adjusted life years and 
0.87 death cases per 100 000 population, respectively), identification of 
the best preventive strategies has been the focus of research.2,3 Since the 
publication of the 2015 ESC Guidelines for the management of infective endo­
carditis,4 important new data have been published mandating an update of 
recommendations. First, the population at risk of IE has increased and new 
data on IE in different clinical scenarios have arisen.5–11 Furthermore, the 
emerging and increasing antibiotic resistance among oral streptococci is 
of concern. The rate of resistance to azythromycin and clarithromycin is 
higher than that to penicillin.12 Whether changes in national guidelines on 
the use of antibiotic prophylaxis have resulted in an increase in the incidence 
of IE remains unclear.13–18 It is likely that the increased use of diagnostic 
tools to diagnose IE is an important contributor to the increase in the inci­
dence of IE. The use of echocardiography has probably increased in patients 
with positive blood cultures for Enteroccus faecalis, Staphylococcus aureus, or 
streptococci due to the associated increased risk of IE.19 In addition, com­
puted tomography (CT) and nuclear imaging techniques have increased the 
number of definite IE cases particularly among patients with prosthetic 
valves and implantable cardiac devices.20–22
Data on the contemporary characterization of patients with IE have 
been taken into consideration to update the recommendations on the 
diagnosis and management of patients with IE.5,19,23–41 Furthermore, 
the recommendations on antibiotic therapy have been updated based 
on the susceptibility of various microorganisms defined by the 
European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) clinical breakpoints.42 Recommendations on outpatient par­
enteral antibiotic therapy (OPAT) or oral antibiotic treatment have 
been included based on the results of the Partial Oral Treatment of 
Endocarditis (POET) randomized trial and other trials.43–46
The main objective of the current Task Force was to provide clear 
and simple recommendations, assisting healthcare providers in their 
clinical decision-making. These recommendations were obtained by ex­
pert consensus after thorough review of the available literature (see 
Supplementary data, evidence tables online). An evidence-based scor­
ing system was used, based on a classification of the strength of recom­
mendations and the levels of evidence.
2.1. What is new
Table 3 New recommendations
Recommendation
Class
Level
Section 3. Recommendation Table 1 — Recommendations for 
antibiotic prophylaxis in patients with cardiovascular diseases 
undergoing oro-dental procedures at increased risk of infective 
endocarditis
General prevention measures are recommended in 
individuals at high and intermediate risk of IE.
I
C
Antibiotic prophylaxis is recommended in patients with 
ventricular assist devices.
I
C
Antibiotic prophylaxis may be considered in recipients 
of heart transplant.
IIb
C
Section 3. Recommendation Table 2 — Recommendations for 
infective endocarditis prevention in high-risk patients
Systemic antibiotic prophylaxis may be considered for 
high-risk patients undergoing an invasive diagnostic or 
therapeutic procedure of the respiratory, 
gastrointestinal, genitourinary tract, skin, or 
musculoskeletal systems.
IIb
C
Section 3. Recommendation Table 3 — Recommendations for 
infective endocarditis prevention in cardiac procedures
Optimal pre-procedural aseptic measures of the site of 
implantation is recommended to prevent CIED 
infections.
I
B
Continued
ESC Guidelines                                                                                                                                                                                          3955


<!-- PAGE 9 -->

### Page 9

Surgical standard aseptic measures are recommended 
during the insertion and manipulation of catheters in 
the catheterization laboratory environment.
I
C
Antibiotic prophylaxis covering for common skin flora 
including Enterococcus spp. and S. aureus should be 
considered before TAVI and other transcatheter 
valvular procedures.
IIa
C
Section 5. Recommendation Table 5 — Recommendations for 
the role of echocardiography in infective endocarditis
TOE is recommended when the patient is stable before 
switching from intravenous to oral antibiotic therapy.
I
B
Section 5. Recommendation Table 6 — Recommendations for 
the role of computed tomography, nuclear imaging, and 
magnetic resonance in infective endocarditis
Cardiac CTA is recommended in patients with possible 
NVE to detect valvular lesions and confirm the 
diagnosis of IE.
I
B
[18F]FDG-PET/CT(A) and cardiac CTA are 
recommended in possible PVE to detect valvular 
lesions and confirm the diagnosis of IE.
I
B
[18F]FDG-PET/CT(A) may be considered in possible 
CIED-related IE to confirm the diagnosis of IE.
IIb
B
Cardiac CTA is recommended in NVE and PVE to 
diagnose paravalvular or periprosthetic complications if 
echocardiography is inconclusive.
I
B
Brain and whole-body imaging (CT, [18F]FDG-PET/ 
CT, and/or MRI) are recommended in symptomatic 
patients with NVE and PVE to detect peripheral lesions 
or add minor diagnostic criteria.
I
B
WBC SPECT/CT should be considered in patients with 
high clinical suspicion of PVE when echocardiography is 
negative or inconclusive and when PET/CT is 
unavailable.
IIa
C
Brain and whole-body imaging (CT, [18F]FDG-PET/ 
CT, and MRI) in NVE and PVE may be considered for 
screening of peripheral lesions in asymptomatic 
patients.
IIb
B
Section 7. Recommendation Table 11 — Recommendations for 
outpatient antibiotic treatment of infective endocarditis
Outpatient parenteral antibiotic treatment should be 
considered in patients with left-sided IE caused by 
Streptococcus spp., E. faecalis, S. aureus, or CoNS who 
were receiving appropriate i.v. antibiotic treatment for 
at least 10 days (or at least 7 days after cardiac surgery), 
are clinically stable, and who do not show signs of 
abscess formation or valve abnormalities requiring 
surgery on TOE.
IIa
A
Outpatient parenteral antibiotic treatment is not 
recommended in patients with IE caused by highly 
difficult-to-treat microorganisms, liver cirrhosis (Child– 
Pugh B or C), severe cerebral nervous system emboli, 
untreated large extracardiac abscesses, heart valve 
complications, or other severe conditions requiring 
surgery, severe post-surgical complications, and in 
PWID-related IE.
III
C
Continued
Section 9. Recommendation Table 13 — Recommendations for 
the treatment of neurological complications of infective 
endocarditis
In embolic stroke, mechanical thrombectomy may be 
considered if the expertise is available in a timely manner.
IIb
C
Thrombolytic therapy is not recommended in embolic 
stroke due to IE.
III
C
Section 9. Recommendation Table 14 — Recommendations for 
pacemaker implantation in patients with complete 
atrioventricular block and infective endocarditis
Immediate epicardial pacemaker implantation should be 
considered in patients undergoing surgery for valvular IE 
and complete AVB if one of the following predictors of 
persistent AVB is present: pre-operative conduction 
abnormality, S. aureus infection, aortic root abscess, 
tricuspid valve involvement, or previous valvular surgery.
IIa
C
Section 9. Recommendation Table 15 — Recommendations for 
patients with musculoskeletal manifestations of infective 
endocarditis
MRI or PET/CT is recommended in patients with 
suspected spondylodiscitis and vertebral osteomyelitis 
complicating IE.
I
C
TTE/TOE is recommended to rule out IE in patients 
with spondylodiscitis and/or septic arthritis with 
positive blood cultures for typical IE microorganisms.
I
C
More than 6-week antibiotic therapy should be 
considered in patients with osteoarticular IE-related 
lesions caused by difficult-to-treat microorganisms, 
such as S. aureus or Candida spp., and/or complicated 
with severe vertebral destruction or abscesses.
IIa
C
Section 10. Recommendation Table 16 — Recommendations for 
pre-operative coronary anatomy assessment in patients 
requiring surgery for infective endocarditis
In haemodynamically stable patients with aortic valve 
vegetations who require cardiac surgery and are high 
risk of CAD, a high-resolution multislice coronary CTA 
is recommended.
I
B
Invasive coronary angiography is recommended in 
patients requiring heart surgery who are high risk of 
CAD, in the absence of aortic valve vegetations.
I
C
In emergency situations, valvular surgery without 
pre-operative coronary anatomy assessment 
regardless of CAD risk should be considered.
IIa
C
Invasive coronary angiography may be considered 
despite the presence of aortic valve vegetations in 
selected patients with known CAD or at high risk of 
significant obstructive CAD.
IIb
C
Section 10. Recommendation Table 17 — Indications and timing 
of cardiac surgery after neurological complications in active 
infective endocarditis
In patients with intracranial haemorrhage and unstable 
clinical status due to HF, uncontrolled infection, or 
persistent high embolic risk, urgent or emergency 
surgery should be considered weighing the likelihood of 
a meaningful neurological outcome.
IIa
C
Continued


<!-- PAGE 10 -->

### Page 10

Section 11. Recommendation Table 18 — Recommendations for 
post-discharge follow-up
Patient education on the risk of recurrence and 
preventive measures, with emphasis on dental health, 
and based on the individual risk profile, is 
recommended during follow-up.
I
C
Addiction treatment for patients following 
PWID-related IE is recommended.
I
C
Cardiac rehabilitation including physical exercise 
training should be considered in clinically stable patients 
based on an individual assessment.
IIa
C
Psychosocial support may be considered to be 
integrated in follow-up care, including screening for 
anxiety and depression, and referral to relevant 
psychological treatment.
IIb
C
Section 12. Recommendation Table 19 — Recommendations for 
prosthetic valve endocarditis
Surgery is recommended for early PVE (within 6 
months of valve surgery) with new valve replacement 
and complete debridement.
I
C
Section 12. Recommendation Table 20 — Recommendations for 
cardiovascular implanted electronic device-related infective 
endocarditis
Complete system extraction without delay is 
recommended in patients with definite CIED-related IE 
under initial empirical antibiotic therapy.
I
B
Extension of antibiotic treatment of CIED-related 
endocarditis to (4–)6 weeks following device 
extraction should be considered in the presence of 
septic emboli or prosthetic valves.
IIa
C
Use of an antibiotic envelope may be considered in 
select high-risk patients undergoing CIED 
reimplantation to reduce risk of infection.
IIb
B
Continued
Table 4 Revised recommendations
Recommendations in 2015 version
Class
Level
Recommendations in 2023 version
Class
Level
Section 3. Recommendation Table 1 — Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing 
oro-dental procedures at increased risk of infective endocarditis
Antibiotic prophylaxis should be considered for patients 
at highest risk of IE: 
(1) Patients with any prosthetic valve, including a 
transcatheter valve, or those in whom any 
prosthetic material was used for cardiac valve repair.
(2) Patients with a previous episode of IE.
(3) Patients with CHD: 
(a) Any type of cyanotic CHD.
(b) Any type of CHD repaired with a prosthetic 
material, whether placed surgically or by 
percutaneous techniques, up to 6 months after 
the procedure or lifelong if residual shunt.
IIa
C
Antibiotic prophylaxis is recommended in patients with 
previous IE.
I
B
Antibiotic prophylaxis is recommended in patients with 
surgically implanted prosthetic valves and with any 
material used for surgical cardiac valve repair.
I
C
Antibiotic prophylaxis is recommended in patients with 
transcatheter implanted aortic and pulmonary valvular 
prostheses.
I
C
Antibiotic prophylaxis should be considered in patients 
with transcatheter mitral and tricuspid valve repair.
IIa
C
Continued
In non-S. aureus CIED-related endocarditis without 
valve involvement or lead vegetations, and if follow-up 
blood cultures are negative without septic emboli, 2 
weeks of antibiotic treatment may be considered 
following device extraction.
IIb
C
Removal of CIED after a single positive blood culture, 
with no other clinical evidence of infection, is not 
recommended.
III
C
Section 12. Recommendation Table 21 — Recommendations for 
the surgical treatment of right-sided infective endocarditis
Tricuspid valve repair should be considered instead of 
valve replacement, when possible.
IIa
B
Surgery should be considered in patients with 
right-sided IE who are receiving appropriate antibiotic 
therapy and present persistent bacteraemia/sepsis after 
at least 1 week of appropriate antibiotic therapy.
IIa
C
Prophylactic placement of an epicardial pacing lead 
should be considered at the time of tricuspid valve 
surgical procedures.
IIa
C
Debulking of right intra-atrial septic masses by 
aspiration may be considered in select patients who are 
high risk of surgery.
IIb
C
© ESC 2023
[18F]FDG-PET, 
18F-fluorodeoxyglucose 
positron 
emission 
tomography; 
AVB, 
atrioventricular block; CAD, coronary artery disease; CIED, cardiovascular implanted 
electronic device; CoNS, coagulase-negative staphylococci; CT, computed tomography; 
CTA, computed tomography angiography; HF, heart failure; IE, infective endocarditis; i.v., 
intravenous; MRI, magnetic resonance imaging; NVE, native valve endocarditis; PET, 
positron emission tomography; PVE, prosthetic valve endocarditis; PWID, people who 
inject drugs; TAVI, transcatheter aortic valve implantation; TOE, transoesophageal 
echocardiography; TTE, transthoracic echocardiography; WBC SPECT/CT, white blood 
cell single photon emission tomography/computed tomography.
ESC Guidelines                                                                                                                                                                                          3957


<!-- PAGE 11 -->

### Page 11

Antibiotic prophylaxis is recommended in patients with 
untreated cyanotic CHD, and patients treated with 
surgery or transcatheter procedures with post-operative 
palliative shunts, conduits, or other prostheses. After 
surgical repair, in the absence of residual defects or valve 
prostheses, antibiotic prophylaxis is recommended only 
for the first 6 months after the procedure.
I
C
Section 4. Recommendation Table 4 — Recommendations for the Endocarditis Team
Patients with complicated IE should be evaluated and 
managed at an early stage in a reference centre, with 
immediate surgical facilities and the presence of a 
multidisciplinary ‘Endocarditis Team’, including an 
infectious disease specialist, a microbiologist, a 
cardiologist, imaging specialists, a cardiac surgeon and, if 
needed, a specialist in CHD.
IIa
B
Diagnosis and management of patients with complicated 
IE are recommended to be performed at an early stage in 
a Heart Valve Centre, with immediate surgical facilities 
and an ‘Endocarditis Team’ to improve the outcomes.
I
B
For patients with uncomplicated IE managed in a 
non-reference centre, early and regular communication 
with the reference centre and, when needed, visits to the 
reference centre should be made.
IIa
B
For patients with uncomplicated IE managed in a Referring 
Centre, early and regular communication between the 
local and the Heart Valve Centre Endocarditis Teams is 
recommended to improve the outcomes of the patients.
I
B
Section 5. Recommendation Table 5 — Recommendations for the role of echocardiography in infective endocarditis
TOE should be considered in patients with suspected IE, 
even in cases with positive TTE, except in isolated 
right-sided native valve IE with good quality TTE 
examination and unequivocal echocardiographic finding.
IIa
C
TOE is recommended in patients with suspected IE, even 
in cases with positive TTE, except in isolated right-sided 
native valve IE with good quality TTE examination and 
unequivocal echocardiographic findings.
I
C
Section 8. Recommendation Table 12 — Recommendations for the main indications of surgery in infective endocarditis (native valve 
endocarditis and prosthetic valve endocarditis)
Aortic or mitral NVE with vegetations >10 mm, 
associated with severe valve stenosis or regurgitation, and 
low operative risk (urgent surgery should be considered).
IIa
B
Urgent surgery is recommended in IE with vegetation 
≥10 mm and other indications for surgery.
I
C
Aortic or mitral NVE or PVE with isolated large 
vegetations (>15 mm) and no other indication for surgery 
(urgent surgery may be considered).
IIb
C
Urgent surgery may be considered in aortic or mitral IE 
with vegetation ≥10 mm and without severe valve 
dysfunction or without clinical evidence of embolism and 
low surgical risk.
IIb
B
Section 9. Recommendation Table 13 — Recommendations for the treatment of neurological complications of infective endocarditis
Intracranial infectious aneurysms should be looked for in 
patients with IE and neurological symptoms. CT or MRA 
should be considered for diagnosis. If non-invasive 
techniques are negative and the suspicion of intracranial 
aneurysm remains, conventional angiography should be 
considered.
IIa
B
Brain CT or MRA is recommended in patients with IE and 
suspected infective cerebral aneurysms.
I
B
If non-invasive techniques are negative and the suspicion 
of infective aneurysm remains, invasive angiography 
should be considered.
IIa
B
Section 12. Recommendation Table 20 — Recommendations for cardiovascular implanted electronic device-related infective 
endocarditis
Routine antibiotic prophylaxis is recommended before 
device implantation.
I
B
Antibiotic prophylaxis covering S. aureus is recommended 
for CIED implantation.
I
A
TOE is recommended in patients with suspected cardiac 
device-related infective endocarditis with positive or 
negative blood cultures, independent of the results of 
TTE, to evaluate lead-related endocarditis and heart valve 
infection.
I
C
TTE and TOE are both recommended in case of 
suspected CIED-related IE to identify vegetations.
I
B
In patients with NVE or PVE and an intracardiac device 
with no evidence of associated device infection, complete 
hardware extraction may be considered.
IIb
C
Complete CIED extraction should be considered in case 
of valvular IE, even without definite lead involvement, 
taking into account the identified pathogen and 
requirement for valve surgery.
IIa
C
Continued


<!-- PAGE 12 -->

### Page 12

### 3 Prevention

3.1. Rationale
The development of IE usually requires several conditions, including the 
presence of predisposing risk factors (i.e. a surface/structure that could 
be colonized by bacteria), pathogens entering the bloodstream, and the 
competence of the host’s immune response. The role of predisposing 
risk factors has been recently underscored by Thornhill et al.47
Predisposing risk factors conveying a moderate and high risk of IE 
had an incidence of 280 and 497 cases per 100 000 subjects per year, 
respectively.47
The portals of entry of bacteria/fungi are variable and include: (i) in­
fections of the skin, oral cavity, gastrointestinal, or genitourinary system; 
(ii) direct inoculation in people who inject drugs (PWID), or by any un­
safe or unprotected vascular puncture; (iii) healthcare exposure (in­
cluding a variety of invasive diagnostic or therapeutic procedures, 
such as transcatheter or surgical techniques).6,11,48–50
The oral cavity is colonized by relevant commensal flora, including 
oral group streptococci, and represents an important entry port. 
Oral surgery procedures (including all extractions, periodontal surgery, 
implant surgery, and oral biopsies) and dental procedures that involve 
manipulation of the gingival or periapical region of the teeth are consid­
ered at high risk of causing bacteraemia.11,48,49,51
Successful antibiotic prophylaxis assumes that reducing the bacter­
aemia associated with medical procedures will lead to a reduced risk 
of IE. This concept was supported by a few animal models and obser­
vational studies that led to the recommendation for antibiotic prophy­
laxis in a large number of patients with predisposing cardiac conditions 
undergoing a wide range of procedures.4,14,52–60
However, systematic use of antibiotic prophylaxis has been ques­
tioned based on several considerations, the most important being the 
lack of randomized clinical trials (RCTs) demonstrating the efficacy of 
antibiotic prophylaxis prior to medical procedures in preventing IE. 
Such trials would entail enrolment of a very large number of individuals 
and prolonged follow-up, making the feasibility of such studies improb­
able. Furthermore, since the standard of care for high-risk individuals is 
antibiotic prophylaxis (to date, mostly before invasive oro-dental pro­
cedures), there may not be sufficient equipoise to perform such RCTs. 
Finally, the costs of performing such trials have been considered un­
acceptable.61 To overcome these limitations, population-based studies 
Complete hardware removal should be considered on the 
basis of occult infection without another apparent source 
of infection.
IIa
C
In cases of possible CIED-related IE or occult 
Gram-positive bacteraemia or fungaemia, complete 
system removal should be considered in case 
bacteraemia/fungaemia persists after a course of 
antimicrobial therapy.
IIa
C
In cases of possible CIED-related IE with occult 
Gram-negative bacteraemia, complete system removal 
may be considered in case of persistent/relapsing 
bacteraemia after a course of antimicrobial therapy.
IIb
C
When indicated, definite reimplantation should be 
postponed if possible, to allow a few days or weeks of 
antibiotic therapy.
IIa
C
If CIED reimplantation is indicated after extraction for 
CIED-related IE, it is recommended to be performed at a 
site distant from the previous generator, as late as 
possible, once signs and symptoms of infection have 
abated and until blood cultures are negative for at least 
72 h in the absence of vegetations, and negative for at 
least 2 weeks if vegetations were visualized.
I
C
Section 12. Recommendation Table 21 — Recommendations for the surgical treatment of right-sided infective endocarditis
Surgical treatment should be considered in the following scenarios:
Surgery is recommended in patients with right-sided IE who are receiving 
appropriate antibiotic therapy for the following scenarios:
• Microorganisms difficult to eradicate (e.g. persistent 
fungi) or bacteraemia for >7 days (e.g. S. aureus, P. 
aeruginosa) despite adequate antimicrobial therapy; or
• Persistent tricuspid valve vegetations >20 mm after 
recurrent pulmonary emboli with or without 
concomitant right HF; or
• Right HF secondary to severe tricuspid regurgitation 
with poor response to diuretic therapy.
IIa
C
Right ventricular dysfunction secondary to acute severe 
tricuspid regurgitation non-responsive to diuretics.
I
B
Persistent vegetation with respiratory insufficiency 
requiring ventilatory support after recurrent pulmonary 
emboli.
I
B
Large residual tricuspid vegetations (>20 mm) after 
recurrent septic pulmonary emboli.
I
C
Patients with simultaneous involvement of left-heart 
structures.
I
C
Section 12. Recommendation Table 22 — Recommendations for the use of antithrombotic therapy in infective endocarditis
Interruption of antiplatelet therapy is recommended in 
the presence of major bleeding.
I
B
Interruption of antiplatelet or anticoagulant therapy is 
recommended in the presence of major bleeding 
(including intracranial haemorrhage).
I
C
© ESC 2023
CHD, congenital heart disease; CIED, cardiovascular implanted electronic device; CT, computed tomography; HF, heart failure; IE, infective endocarditis; MRA, magnetic resonance 
angiography; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.
ESC Guidelines                                                                                                                                                                                          3959


<!-- PAGE 13 -->

### Page 13

have evaluated the efficacy of antibiotic prophylaxis using bacteraemia 
as a surrogate of IE.16–18,52,62 However, the relationship between bac­
teraemia and IE is not straightforward. Bacteraemia may be caused by 
daily activities such as tooth brushing, flossing, and chewing, and al­
though these constitute low-level bacteraemia, they occur repetitively 
and may therefore outweigh the risk of bacteraemia associated with 
dental procedures.48,49 A meta-analysis of 36 studies, including 21 trials 
that investigated the effect of antibiotic prophylaxis on the incidence of 
bacteraemia following dental procedures, demonstrated that antibiotic 
prophylaxis is effective in reducing the incidence of bacteraemia, but did 
not lead to a statistically significant protective effect against IE in case- 
control studies.52 Additionally, the potential risk of anaphylaxis,63 or 
other adverse side effects in a small minority of patients, and the fact 
that a widespread use of antibiotics may be associated with antibiotic 
resistance, are areas of concern.57,58,64–67 While some studies did not 
demonstrate significant increases in IE-related hospitalizations and 
death rates after scaling down antibiotic prophylaxis indications,68–77
others showed an increase in the incidence of IE among individuals at 
moderate and high risk of IE.13,26,59,78–81 A meta-analysis including 16 
studies reporting over 1.3 million cases of IE has shown that restricting 
antibiotic prophylaxis to only high-risk individuals has not resulted in an 
increase in the incidence of streptococcal IE in a North American popu­
lation (despite the fact that it was unable to draw that conclusion for 
other populations).18 In contrast, a systematic review including multiple 
nationwide population-based studies in Europe has shown a 4% per 
year rise in the incidence of IE.82 These contrasting results may be ex­
plained by differences in the methodology of the studies (retrospective, 
population- or health-system-based studies that relied on claims data or 
epidemiological observations to estimate the incidence of IE), greater 
disease diagnosis with the use of newer imaging technologies, lack of 
microbiological data, and the lack of specific International 
Classification of Diseases codes for oral streptococci.83 Recently, it 
has been shown that antibiotic prophylaxis in high-risk individuals was 
associated with a significant reduction of IE after invasive dental proce­
dures (particularly extractions and oral surgical procedures).11,51 After 
careful consideration of all the new studies published after 2015, the 
present Task Force decided to revise and update the risk categories 
for IE, strengthening the recommendation of antibiotic prophylaxis, 
clarifying the definition of the population at risk, and considering the ad­
vances in transcatheter valve interventions.
3.2. Populations at risk of infective 
endocarditis
The groups of individuals at high risk of IE in whom antibiotic prophy­
laxis is recommended or should be considered include the following: 
(i) Patients with previous IE: the highest risk of IE is observed in pa­
tients with previous history of IE who have an ominous prognosis 
during IE-related hospitalization. Patients with recurrent IE more 
frequently have prosthetic valves or prosthetic material, are 
more commonly PWID, or have staphylococcal IE.47,84–86
(ii) Patients with surgically implanted prosthetic valves, with transcath­
eter implanted prosthetic valves, and with any material used for 
cardiac valve repair: the increased risk of IE in these patients, com­
bined with the ominous outcomes as compared with patients with 
native IE (NVE), make antibiotic prophylaxis advisable in this pa­
tient group. Patients with prosthetic valve endocarditis (PVE) 
have an in-hospital mortality rate that is twice as high with more 
complications (e.g. heart failure [HF], conduction disturbances) 
as compared with patients with NVE, regardless of the 
pathogen.87,88 Furthermore, mitral and aortic bioprostheses may 
be associated with increased risk of IE as compared with mechan­
ical prostheses,89,90 and bioprostheses are being implanted in an 
ever-increasing proportion of patients requiring valve replacement 
therapy. The indication for prophylaxis also expands to transcath­
eter aortic and pulmonic prosthetic valves, since IE is also asso­
ciated with a high risk of morbidity and mortality in these 
patients.91–94 In terms of transcatheter mitral and tricuspid valve 
interventions, the data on the risk of IE are limited.95 Patients 
with septal defect closure devices, left atrial appendage closure de­
vices, vascular grafts, vena cava filters, and central venous system 
ventriculo-atrial shunts are considered within this risk category in 
the first 6 months after implantation.96
(iii) Patients with congenital heart disease (CHD) (not including iso­
lated congenital valve abnormalities) are at increased risk of 
IE.8,47,97–99 The cumulative incidence over time is influenced 
strongly by the improved long-term survival of children with 
CHD into adulthood.98 Indeed, there are now more adults living 
with CHD than children with CHD.100 The overall incidence 
rate of IE among adult patients with CHD is 27–44 times that re­
ported for contemporary adults of the general population (1.33 
cases per 1000 persons per year)8 while in children with CHD 
the incidence of IE is 0.41 cases per 1000 persons per year.101
CHD groups at increased risk include those with untreated cyan­
otic CHD, and those whose surgery includes prosthetic material, 
including valved conduits or systemic to pulmonary shunts.8,47,97
The risk of post-operative IE for CHD patients undergoing trans­
catheter atrial or ventricular septal defect closure with devices or 
surgery with non-valve-related prosthetic material is also in­
creased, but predominantly for the first 6 months after surgery.8
(iv) Patients with ventricular assist devices as destination therapy are 
also considered at high risk because of associated morbidity and 
mortality, and prophylaxis is also recommended in such patients.102
Patients at intermediate risk of IE include those with: (i) rheumatic 
heart disease (RHD); (ii) non-rheumatic degenerative valve disease; 
(iii) congenital valve abnormalities including bicuspid aortic valve dis­
ease; (iv) cardiovascular implanted electronic devices (CIEDs); and (v) 
hypertrophic cardiomyopathy.47,103,104 Some epidemiological data sug­
gest that certain conditions stratified as intermediate risk are associated 
Table 5 General prevention measures to be followed in 
patients at high and intermediate risk of infective 
endocarditis
Patients should be encouraged to maintain twice daily tooth cleaning and 
to seek professional dental cleaning and follow-up at least twice yearly 
for high-risk patients and yearly for others.
Strict cutaneous hygiene, including optimized treatment of chronic skin 
conditions.
Disinfection of wounds.
Curative antibiotics for any focus of bacterial infection.
No self-medication with antibiotics.
Strict infection control measures for any at-risk procedure.
Discouragement of piercing and tattooing.
Limitation of infusion catheters and invasive procedures. when possible. 
Strict adherence to care bundles for central and peripheral cannulae 
should be performed.
© ESC 2023


<!-- PAGE 14 -->

### Page 14

with a higher risk of IE compared with the background popula­
tion,47,90,103 but further studies are required. In patients at intermediate 
risk of IE, antibiotic prophylaxis is not routinely recommended and may 
be considered on an individual basis. However, prevention measures 
(Table 5) are strongly encouraged in these patients.7
Most of the IE in recipients of solid organ transplant is nosocomial. A 
recent systematic review of patient-level data including 57 heart trans­
plant patients has shown that IE occurs frequently during the first year 
post-transplant, and the most common pathogen is S. aureus followed 
by Aspergillus fumigatus.105 Oral streptococci are a very infrequent 
cause of IE, making the value of antibiotic prophylaxis after invasive oro- 
dental procedures questionable. However, IE in this group of patients is 
associated with very high mortality, particularly in patients with fungal 
IE. In contrast, other series that include a larger proportion of non- 
cardiac solid organ transplant patients have shown that the pathogens 
are more frequently from the Staphylococcus spp. and the mortality 
seems to be similar to that of patients without solid organ 
transplant.106,107
3.3. Situations and procedures at risk
3.3.1. Dental procedures
Antibiotic prophylaxis is recommended in patients at high risk of IE under­
going at-risk dental procedures and is not currently recommended in other 
situations. At-risk dental procedures include dental extractions, oral sur­
gery procedures (including periodontal surgery, implant surgery, and oral 
biopsies), and dental procedures involving manipulation of the gingival or 
periapical region of the teeth (including scaling and root canal proce­
dures).49,108 The use of dental implants raises concerns about potential 
risk due to foreign material at the interface between the buccal cavity 
and blood, but available data remain very limited.109 So far there is no evi­
dence to contraindicate implants in all patients at risk and the indication 
should be discussed on an individual basis. Implant placement procedures, 
and invasive dental procedures on established implants, however, should 
be covered by antibiotic prophylaxis in those at high risk of IE. Once dental 
implants are placed in high-risk patients, professional dental hygiene and 
follow-up should be performed at least twice yearly under antibiotic cover, 
when indicated.
The main target for antibiotic prophylaxis is oral streptococci. 
Table 6 summarizes the main regimens of antibiotic prophylaxis recom­
mended before dental procedures. The risk of adverse fatal/non-fatal 
events appear to be extremely low for amoxicillin but high for clinda­
mycin (mainly related to Clostridioides difficile infections).63,110–112
Accordingly, this Task Force does not recommend the use of clindamy­
cin for antibiotic prophylaxis.
3.3.2. Non-dental procedures
No convincing evidence has been brought forward on the relationship 
between bacteraemia resulting from a non-dental procedure and risk of 
subsequent IE. However, observational studies reported that, com­
pared with patients with IE not undergoing an invasive procedure, 
Recommendation Table 1 — Recommendations for 
antibiotic prophylaxis in patients with cardiovascular 
diseases undergoing oro-dental procedures at increased 
risk for infective endocarditis
Recommendations
Classa
Levelb
General prevention measures are recommended in 
individuals at high and intermediate risk for IE.
I
C
Antibiotic prophylaxis is recommended in patients 
with previous IE.47,84,86
I
B
Antibiotic prophylaxis is recommended in patients 
with surgically implanted prosthetic valves and with 
any material used for surgical cardiac valve 
repair.47,87–89
I
C
Antibiotic prophylaxis is recommended in patients 
with transcatheter implanted aortic and pulmonary 
valvular prostheses.91–94
I
C
Antibiotic prophylaxis is recommended in patients 
with untreated cyanotic CHD, and patients treated 
with surgery or transcatheter procedures with 
post-operative palliative shunts, conduits, or other 
prostheses. After surgical repair, in the absence of 
residual defects or valve prostheses, antibiotic 
prophylaxis is recommended only for the first 6 
months after the procedure.8,47,97,101
I
C
Antibiotic prophylaxis is recommended in patients 
with ventricular assist devices.102
I
C
Antibiotic prophylaxis should be considered in 
patients with transcatheter mitral and tricuspid valve 
repair.95
IIa
C
Antibiotic prophylaxis may be considered in 
recipients of heart transplant.105–107
IIb
C
Antibiotic prophylaxis is not recommended in other 
patients at low risk for IE.11,51
III
C
© ESC 2023
CHD, congenital heart disease; IE, infective endocarditis. 
aClass of recommendation. 
bLevel of evidence.
Table 6 Prophylactic antibiotic regime for high-risk 
dental procedures
Situation
Antibiotic
Single-dose 30–60 min before 
procedure
Adults
Children
No allergy to 
penicillin or 
ampicillin
Amoxicillin
2 g orally
50 mg/kg orally up to 
maximum of 2 g
Ampicillin
2 g i.m. 
or i.v.
50 mg/kg i.m. or i.v. up 
to maximum of 2 g
Cefazolin or 
ceftriaxone
1 g i.m. 
or i.v.
50 mg/kg i.v. or i.m. up 
to maximum of 1 g
Allergy to 
penicillin or 
ampicillin
Cephalexina,b
2 g orally
50 mg/kg orally up to 
maximum of 2 g
Azithromycin or 
clarithromycin
500 mg 
orally
15 mg/kg orally up to 
maximum of 500 mg
Doxycycline
100 mg 
orally
<45 kg, 2.2 mg/kg orally 
>45 kg, 100 mg orally
Cefazolin or 
ceftriaxoneb
1 g i.m. 
or i.v.
50 mg/kg i.v. or i.m. up 
to maximum of 1 g
© ESC 2023
i.m., intramuscular; i.v., intravenous. 
aOr other first- or second-generation oral cephalosporin in equivalent adult or paediatric 
dosing. 
bCephalosporins should not be used in an individual with a history of anaphylaxis, 
angioedema, or urticarial with penicillin or ampicillin.
ESC Guidelines                                                                                                                                                                                          3961


<!-- PAGE 15 -->

### Page 15

several invasive non-dental medical procedures were associated with 
increased risk of IE, including cardiovascular interventions, skin proce­
dures and wound management, transfusion, dialysis, bone marrow 
puncture, and endoscopic procedures.6,11,51 For this reason, an aseptic 
operational environment should be ensured during all these proce­
dures to minimize the risk of IE. As previously indicated, it is very unlike­
ly that an RCT on antibiotic prophylaxis for IE will be performed in the 
foreseeable future. However, at-risk patients have longer survival due 
to the advent of newer medical and device-based medical therapies. 
In addition, the ageing general population with their accumulating num­
ber of co-morbidities has an increased risk of surgical therapy, if IE oc­
curs. For these reasons, this Task Force no longer felt that a class III 
recommendation for antibiotic prophylaxis in high-risk patients under­
going non-dental medical procedures (see Recommendation Table 2) 
was appropriate, despite the limitations of observational data used to 
support this class IIb recommendation.
3.3.3. Cardiac or vascular interventions
In all patients undergoing implantation of a prosthetic valve, any type of 
prosthetic graft/occluder device or CIED, peri-operative antibiotic 
prophylaxis is recommended due to the increased risk and adverse out­
come of an infection.6 The most frequent microorganisms underlying 
early (1 year after surgery) surgical PVE are coagulase-negative 
staphylococci (CoNS) and S. aureus. Pre-operative screening of nasal 
carriage for S. aureus is recommended before elective cardiac surgery 
or transcatheter valve implantation to treat carriers using local mupir­
ocin and chlorhexidine.113,114 Rapid identification techniques using gene 
amplification are useful to avoid delaying urgent surgery. Systematic lo­
cal treatment without screening is not recommended. It is strongly re­
commended that potential sources of dental sepsis should be 
eliminated at least 2 weeks before implantation of a prosthetic valve 
or other intracardiac or intravascular foreign material unless the latter 
procedure is urgent. For specific prophylactic measures in other cardiac 
and vascular interventions (i.e. CIED, transcatheter aortic valve implant­
ation [TAVI]), please see the Supplementary data online, Section S1.1.
3.4. Patient education
Preventing IE also depends on preventive measures other than antibiot­
ic prophylaxis. People at risk should be educated to maintain good den­
tal and skin hygiene, to look out for signs of infection and, when 
Education of high-risk patients to prevent infective endocarditis
Use dental floss daily
Brush teeth morning and evening
See your dentist for regular check-ups
Maintain good dental hygiene
If experiencing fever for no obvious reason,
contact your doctor, and discuss appropriate action based on your risk of endocarditis
Minimize risk of skin lesions
In case of lesions, observe for signs of infection (redness, swelling, tenderness, puss)
Avoid tattoos and piercings
Maintain good skin hygiene
Be mindful of infections
Do not self prescribe antibiotics
Show this card to your doctors before any interventions
Figure 2 Education of high-risk patients to prevent infective endocarditis.


<!-- PAGE 16 -->

### Page 16

experiencing fever of unknown origin, report to their physician that 
they are at risk, in which case clinicians should consider screening for 
IE before initiating antibiotics.
Use of non-medical language, visual aids, digital tools, repetition, and 
teach back methods all aid the patients’ comprehension and is encour­
aged.115 National cardiology societies should be encouraged to develop 
specific IE cards for patient awareness (Figure 2).
4. The Endocarditis Team
The importance of an Endocarditis Team in the diagnosis, management, 
and clinical outcomes of patients with IE has been demonstrated in sev­
eral observational studies.36–41,122–126 Establishing multidisciplinary 
endocarditis teams according to the European Society of Cardiology 
(ESC) and the American College of Cardiology/American Heart 
Association Guidelines4,127,128 has resulted in earlier and more accurate 
diagnosis of the primary disease and its complications,5,22,31,40,129 uni­
form antibiotic treatment,36,40,123 and optimized timing for surgical 
intervention.36,37,40,123 A variety of scenarios of patients presenting 
with 
IE 
justifies 
a 
multidisciplinary 
approach.5,25,27,28,130–135
Furthermore, the clinical presentation may vary significantly depending 
on the characteristics of the host and virulence of the microorganism. 
Accordingly, the concept of the Endocarditis Team needs to embrace a 
multidisciplinary approach that must adapt according to the patient’s 
clinical needs and the local epidemiology to ensure prompt diagnosis 
and treatment.
The members of the Endocarditis Team should include the specialists 
with direct involvement in the diagnostic and therapeutic processes 
(Table 7), and may vary depending on the type of centre. In the 
Recommendation Table 2 — Recommendations for 
infective endocarditis prevention in high-risk patients
Recommendations
Classa
Levelb
Antibiotic prophylaxis is recommended in dental 
extractions, oral surgery procedures, and 
procedures requiring manipulation of the gingival or 
periapical region of the teeth.11,49,51,108
I
B
Systemic antibiotic prophylaxis may be considered 
for high-riskc patients undergoing an invasive 
diagnostic or therapeutic procedure of the 
respiratory, gastrointestinal, genitourinary tract, skin, 
or musculoskeletal systems.6,11
IIb
C
© ESC 2023
aClass of recommendation. 
bLevel of evidence. 
cThis recommendation does not apply to patients with intermediate risk for IE or to the 
general population.
Recommendation Table 3 — Recommendations for 
infective endocarditis prevention in cardiac procedures
Recommendations
Classa
Levelb
Pre-operative screening for nasal carriage of S. aureus 
is recommended before elective cardiac surgery or 
transcatheter valve implantation to treat 
carriers.113,114
I
A
Peri-operative antibiotic prophylaxis is 
recommended before placement of a CIED.116–118
I
A
Optimal pre-procedural aseptic measures of the site 
of implantation is recommended to prevent CIED 
infections.119
I
B
Periprocedural antibiotic prophylaxis is 
recommended in patients undergoing surgical or 
transcatheter implantation of a prosthetic valve, 
intravascular prosthetic, or other foreign material.120
I
B
Surgical standard aseptic measures are 
recommended during the insertion and manipulation 
of catheters in the catheterization laboratory 
environment.
I
C
Elimination of potential sources of sepsis (including of 
dental origin) should be considered ≥2 weeks before 
implantation of a prosthetic valve or other 
intracardiac or intravascular foreign material, except 
in urgent procedures.
IIa
C
Continued
Antibiotic prophylaxis covering for common skin 
flora including Enterococcus spp. and S. aureus should 
be considered before TAVI and other transcatheter 
valvular procedures.121
IIa
C
Systematic skin or nasal decolonization without 
screening for S. aureus is not recommended.
III
C
© ESC 2023
CIED, cardiac implantable electronic device; TAVI, transcatheter aortic valve implantation. 
aClass of recommendation. 
bLevel of evidence.
Table 7 Members of the Endocarditis Team
Heart Valve Centre
Core members
• Cardiologists.
• Cardiac imaging experts.
• Cardiovascular surgeons.
• Infectious disease specialist (or internal medicine 
specialist with expertise in infectious diseases).
• Microbiologist.
• Specialist in outpatient parenteral antibiotic 
treatment.
Adjunct 
specialities
• Radiologist and nuclear medicine specialist.
• Pharmacologist.
• Neurologist and neurosurgeon.
• Nephrologist.
• Anaesthesiologists.
• Critical care.
• Multidisciplinary addiction medicine teams.
• Geriatricians.
• Social worker.
• Nurses.
• Pathologist.
© ESC 2023
ESC Guidelines                                                                                                                                                                                          3963


<!-- PAGE 17 -->

### Page 17

Heart Valve Centre, a centre having all diagnostic and therapeutic re­
sources to treat IE, the core members of the Endocarditis Team should 
include cardiologists, cardiovascular surgeons, infectious disease specia­
lists (or internal medicine specialists with expertise in infectious dis­
eases), and microbiologists. Furthermore, for specific clinical 
questions, cardiologists/surgeons with expertise in CIED extraction, 
HF, and CHD; pathologists; critical care specialists; cardiac anaesthesiol­
ogists; interventional cardiologists; neurologists and neurosurgeons; 
pharmacologists; radiologists and nuclear medicine specialists; 
nephrologists; geriatricians; and multidisciplinary addiction medicine 
teams (psychiatrists, nurses, and social work specialists providing coun­
selling) are crucial adjuncts that should be available onsite for consult­
ation. Specific subgroups of complex and high-risk patients are 
frequently assessed by the Endocarditis Team. The decision-making 
process may involve difficult decisions regarding continuation of ther­
apy, and legal counsel may therefore be required.
Cardiovascular imaging has achieved such an advanced sophistication 
in the diagnosis of IE that the cardiologists with expertise in 
N
Start empirical antibiotic treatment
Admission to a Heart Valve Centre
Admission to a Referring Centre
Adjust antibiotic treatment according to blood culture results
Patient with deﬁnite infective endocarditis 2023 ESC diagnostic criteria
Y
Endocarditis Team
Cardiologists
Cardiovascular surgeons
Infecious disease specialists
Microbiologists
Adjunct specialities
Radiologists/nuclear medicine specialists
Neurologists/
neurosurgeons
Intensive care specialists
Geriatricians
Nephrologists
Nurses
Addiction medicine teams
Establish indication and timing of cardiac surgery
Consultation with outpatient antibiotic therapy team
Frequent communication
Clinical, microbiological,
and imaging data sharing
Endocarditis Team
Cardiologists
Infectious disease specialists
Complicated clinical evolution
Unstable haemodynamic condition under pharmacological and/or respiratory support
Severe valvular regurgitation (clinical and echocardiographic criteria)
Prosthetic valve endocarditis with or without prosthetic valve dysfunction
Stroke (ischaemic or haemorrhagic) with definite or possible IE
Extravalvular complications (abscesses, fistulae, etc.)
Positive blood cultures >7 days under appropriate antibiotic therapy
Embolism
CIED-related infective endocarditis
Aggressive or difficult-to-treat microorganisms (S. aureus,
Gram-negative bacilli, fungi)
Figure 3 Management of patients with infective endocarditis: positioning of the Endocarditis Team. CIED, cardiovascular implanted electronic device; ESC, 
European Society of Cardiology.


<!-- PAGE 18 -->

### Page 18

multimodality imaging are key in the Endocarditis Team. In addition, 
radiology and nuclear medicine specialists with expertise on clinical car­
diovascular imaging should be available whenever indicated.22,31,129 The 
Endocarditis Team must meet on a frequent basis and work with stand­
ard operating procedures and the clinical governance arrangements de­
fined locally.128,136 Although the decision of timing is left to the 
discretion of the local team, a weekly meeting is to be considered.
In Referring Centres, i.e. those without a cardiovascular surgical 
team, the treating physician diagnosing IE should consult with a special­
ist in infectious diseases (or an internal medicine specialist with expert­
ise in infectious diseases) and the microbiologist.136 In addition, a 
cardiologist with expertise in valvular heart disease and cardiac imaging 
should be present to provide the initial and subsequent evaluations with 
echocardiography. Information of the strains of the isolated microor­
ganisms, usually kept for 7–15 days, should be provided to the Heart 
Valve Centre if requested.
Communication between Referring Centres and the Heart Valve 
Centres should be facilitated with digital solutions that enable reliable 
data sharing. Early referral to the Heart Valve Centre for further diag­
nostic testing and clinical management should be available when 
deemed necessary (Figure 3). When there is evidence of failure to re­
spond to the antibiotic therapy or there are complications related to 
valvular tissue destruction, the Referring Centre should consult the 
Heart Valve Centre. The Endocarditis Team of the Heart Valve 
Centre should share protocols with the physicians from the referring 
hospitals and should facilitate their continuing education.136
A critical aspect of the Endocarditis Team decision-making process is 
defining when a patient must be transferred to a Heart Valve Centre to 
expedite advanced diagnostics and therapy. The indications for transfer 
are comprehensive, to facilitate interhospital communication and avoid 
delaying therapy to improve prognosis.
5. Diagnosis
The diagnosis of IE is based on a clinical suspicion supported by consist­
ent microbiological data and the documentation of IE-related cardiac 
lesions by imaging techniques. Evidence of involvement of cardiac valves 
(native or prosthetic) or prosthetic intracardiac material is a major diag­
nostic criterion of IE. Echocardiography is the first-line diagnostic 
imaging technique. Other imaging modalities such as CT, nuclear im­
aging, and magnetic resonance imaging (MRI) are currently part of the 
diagnostic strategy of suspected IE, given their ability to provide key in­
formation to confirm IE diagnosis, to assess local IE complications as 
well as IE-related distant lesions, and to identify the original source of 
bacteraemia in patients who develop secondary IE.137 Beyond diagnosis 
of IE, imaging findings also have prognostic implications.
5.1. Clinical features
Infective endocarditis remains a diagnostic challenge due to its variable 
clinical presentation. In general, a diagnosis of IE should be considered in 
all patients with sepsis or fever of unknown origin in the presence of risk 
factors. Infective endocarditis may present as an acute, rapidly progres­
sive infection, but also as a subacute or chronic disease with low-grade, 
or even no fever, and non-specific symptoms that may mislead or con­
fuse initial assessment. Infective endocarditis can also present with a 
complication mimicking a wide range of medical conditions that may 
prompt evaluation of other diseases, such as rheumatological, neuro­
logical, and autoimmune disorders, or even malignancy, before reaching 
a diagnosis of IE. Therefore, high suspicion for IE is generally driven by 
fever and positive blood cultures in the absence of an alternative focus 
of infection, especially in patients with one or more risk factors. Early 
involvement of the Endocarditis Team to guide management is highly 
recommended.
The initial clinical assessment should include evaluation of cardiac and 
non-cardiac risk factors (Table 8), supportive clinical context, and phys­
ical examination findings including potential portals of entry. Physical 
examination may reveal a variety of clinical signs. However, the absence 
of clinical signs alone should not exclude IE since the overall sensitivity 
and specificity of the clinical signs are low.
In the European Infective Endocarditis Registry (EURO-ENDO), fe­
ver (77.7%), cardiac murmur (64.5%), and congestive HF (27.2%) were 
the most frequent clinical presentations.5 Embolic complications were 
detected in 25.3% of patients and cardiac conduction abnormalities 
were found in 11.5%. Some classical signs, such as peripheral stigmata, 
are less frequently observed, but may still be observed in severe infec­
tions caused by S. aureus and in cases of subacute endocarditis (mainly 
caused by Streptococcis spp.). However, vascular and immunological 
phenomena, such as splinter haemorrhages,138 Roth spots, and 
Recommendation Table 4 — Recommendations for the 
Endocarditis Team
Recommendations
Classa
Levelb
Diagnosis and management of patients with 
complicated IE are recommended to be performed 
at an early stage in a Heart Valve Centre, with 
immediate surgical facilities and an ‘Endocarditis 
Team’ to improve the outcomes.36–41,122,123,125,126
I
B
For patients with uncomplicated IE managed in a 
Referring Centre, early and regular communication 
between the local and the Heart Valve Centre 
endocarditis teams is recommended to improve the 
outcomes of the patients.36–41,122,123,125,126
I
B
© ESC 2023
IE, infective endocarditis. 
aClass of recommendation. 
bLevel of evidence.
Table 8 Cardiac and non-cardiac risk factors
Cardiac risk factors
Previous infective endocarditis
Valvular heart disease
Prosthetic heart valve
Central venous or arterial catheter
Transvenous cardiac implantable electronic device
Congenital heart disease
Non-cardiac risk factors
Central venous catheter
People who inject drugs
Immunosuppression
Recent dental or surgical procedures
Recent hospitalization
Haemodialysis
© ESC 2023
ESC Guidelines                                                                                                                                                                                          3965


<!-- PAGE 19 -->

### Page 19

glomerulonephritis, remain common. The main symptoms and signs 
observed in the EURO-ENDO registry are shown in the 
Supplementary data online, Table S1. Atypical presentation is common 
in elderly or immunocompromised patients.139–141 A high index of sus­
picion and low threshold for investigation are therefore essential to ex­
clude IE or avoid delays in diagnosis in these and other high-risk groups, 
such as those with CHD or prosthetic valves.142 It is important to in­
form those patients about the risk of IE who should be aware of com­
patible symptoms to ask for advice in referral centres.
5.2. Laboratory findings
Laboratory investigations and biomarkers typically yield non-specific re­
sults. A large number of potential biomarkers have been proposed, re­
flecting the complex pathophysiology of the pro- and anti-inflammatory 
processes, humoral and cellular reactions, and both circulatory and 
end-organ abnormalities involved in IE.143 The degree of anaemia, 
leucocytosis/leucopaenia, the number of immature white cell forms, 
concentrations of C-reactive protein and procalcitonin, erythrocyte 
sedimentation rate, and markers of end-organ dysfunction (serum lac­
tate, serum creatinine, bilirubin, thrombocytopaenia, cardiac troponin, 
and natriuretic brain peptides) can be used to estimate the severity of 
sepsis, but none is diagnostic of IE. C-reactive protein and procalcitonin 
are the most widely evaluated biomarkers in RCTs of antibiotic stew­
ardship. Furthermore, several of these biomarkers are included in 
scores used for risk stratification in critically ill patients. 
Unfortunately, no biomarker has sufficient accuracy for the diagnosis 
of sepsis or specificity for IE.144 Therefore, the main role of biomarkers 
is to facilitate initial risk stratification and monitor the response to anti­
biotic therapy.
5.3. Microbiological diagnosis
The aetiology of IE is described in the EURO-ENDO registry5 and the 
International Collaboration on Endocarditis-Prospective Cohort Study 
(ICE-PCS).145 In 2009, the ICE-PCS showed that the most frequent mi­
croorganisms causing IE were S. aureus (31%), followed by oral strepto­
cocci (17%), and CoNS (11%).145 Similar results were reported in the 
EURO-ENDO registry.5,145 Other registries have highlighted the 
increasing incidence of IE caused by E. faecalis and CoNS, particularly 
in the elderly.146–149 However, the results of these registries 
should be carefully interpreted due to inherent biases (type of partici­
pating centres, geographical differences, lack of complete granular data, 
etc.).
5.3.1. Blood culture-positive infective endocarditis
Positive blood cultures remain the cornerstone of IE diagnosis and pro­
vide live bacteria for both identification and susceptibility testing. At 
least three sets of blood cultures should be obtained at 30-minute in­
tervals prior to antibiotic therapy, each containing 10 mL of blood, 
and should be incubated in both aerobic and anaerobic atmo­
spheres.150,151 Sampling should be obtained from a peripheral vein ra­
ther than from a central venous catheter (because of the risk of 
contamination and misleading interpretation), using a meticulous sterile 
technique. In the absence of previous antimicrobial therapy, this is vir­
tually always sufficient to identify the usual causative microorganisms. 
The need for culture before antibiotic administration is self-evident. 
In IE, bacteraemia is almost constant and has two implications: (i) there 
is no rationale for delaying blood sampling to coincide with peaks of 
fever; and (ii) nearly all blood cultures are positive during bacteraemia. 
As a result, a single positive blood culture should be regarded cautiously 
for establishing IE diagnosis. The microbiology laboratory should be 
aware of the clinical suspicion of IE. Automated machines perform con­
tinuous monitoring of bacterial growth, which ensures quick provision 
of reports to physicians. When a positive blood culture is identified, 
presumptive identification is based on Gram staining. This information 
is immediately given to clinicians in order to adapt empirical antibiotic 
therapy. Complete identification is routinely achieved the same day 
or the following day with current methodology (e.g. matrix-assisted la­
ser 
desorption 
ionization 
time-of-flight 
mass 
spectrometry 
[MALDI-TOF MS]), but may require a longer time for fastidious or 
atypical organisms. Since there is a long delay between blood culture 
sampling and definitive identification of the organism responsible for 
the bacteraemia and antibiotic susceptibility testing, many improve­
ments have been proposed to speed up the process of detection and 
identification. One of the most recent procedures for rapid bacterial 
identification is based on peptide spectra obtained by MALDI-TOF 
MS.152 However, despite technical developments and the progress to­
ward rapid susceptibility testing using MALDI-TOF MS, the gold stand­
ard for susceptibility testing is still the determination of the minimal 
inhibitory concentrations (MICs) to select appropriate antibiotic ther­
apy, which needs to be performed following validated, standardized 
methodology.153
5.3.2. Blood culture-negative infective endocarditis
Blood culture-negative infective endocarditis (BCNIE) refers to IE in 
which no causative microorganism can be grown using the usual blood 
culture methods. The frequency of BCNIE as the cause of IE is highly 
variable and often poses considerable diagnostic and therapeutic dilem­
mas.154,155 Blood culture-negative IE most commonly arises as a conse­
quence of previous antibiotic administration, underlying the importance 
of performing blood cultures prior to antibiotic therapy, particularly in 
patients with known risk factors for IE. Withdrawal of antibiotics and 
repeating blood cultures may be required in stable patients with sub­
acute symptoms, no evidence of local or distant complications, and re­
ceiving a very short course of antibiotics. Blood culture-negative IE can 
also be caused by fungi or fastidious bacteria, notably obligatory intra­
cellular bacteria. Isolation of these microorganisms requires culturing 
on specialized media, and their growth is relatively slow. Depending 
on local epidemiology,156 systematic serological testing for Coxiella bur­
netii, Bartonella spp., Aspergillus spp., Mycoplasma pneumoniae, Brucella 
spp., and Legionella pneumophila should be proposed,157 followed by 
specific polymerase chain reaction (PCR) assays for Tropheryma whip­
plei, Bartonella spp., and fungi (Candida spp., Aspergillus spp.) from blood 
and the tissue (Table 9).158
In addition, 16S and 18S ribosomal ribonucleic acid (rRNA) sequen­
cing from tissue is routinely performed in most laboratories and may 
provide a microorganism diagnosis in BCNIE. For patients with pros­
thetic valve BCNIE, molecular imaging technique fluorescence in situ hy­
bridization combined with 16S rRNA-gene PCR and sequencing 
improved the conventional cultural diagnostic methods in 30% of 
cases.159 Next-generation sequencing of plasma microbial cell-free de­
oxyribonucleic acid (DNA) may facilitate a rapid diagnosis of IE in the 
future.160
When all microbiological assays are negative, the diagnosis of non- 
bacterial endocarditis should systematically be considered and assays


<!-- PAGE 20 -->

### Page 20

for antinuclear antibodies as well as antiphospholipid syndrome (APLs) 
(anticardiolipin 
antibodies 
[immunoglobulin 
(Ig)G] 
and 
anti-β2-glycoprotein 1 antibodies [IgG and IgM]) should be performed 
(although these antibodies may also be present in patients with proven 
IE).161,162 Pathological examination of resected tissue or embolic frag­
ments remains the gold standard for IE diagnosis. All tissue samples 
that are excised during surgical valve debridement/resection must be 
collected in a sterile container without fixative or culture medium. 
Samples should be sent to the pathology department and the micro­
biology laboratory for the identification of microorganisms. On histo­
logical examination of excised valve tissue, patterns, and degrees of 
inflammation will vary depending on the infecting organism. Stains for 
bacteria, mycobacteria, and fungi may identify the microorganisms, 
and organism-specific immunohistochemical stains can be very useful 
for the final diagnosis. Importantly, histopathological analysis may facili­
tate the diagnosis of non-infectious causes of endocarditis, such as neo­
plastic and autoimmune causes.160
5.3.3. Proposed strategy for a microbiological 
diagnostic algorithm in suspected infective 
endocarditis
A proposed diagnostic scheme is provided in Figure 4. When there is 
clinical suspicion of IE and blood cultures remain negative at 48 h, con­
sultation with the microbiologist is necessary.156,160 A suggested strat­
egy is the use of a diagnostic kit including blood cultures for the 
suspected microorganism and when negative, systematic serological 
testing for C. burnetii, Bartonella spp., Aspergillus spp., L. pneumophila, 
Brucella spp., and M. pneumoniae, as well as rheumatoid factor, sero­
logical tests for APLs (anticardiolipin [IgG] and anti-β2-glycoprotein 1 
[IgG and IgM]), antinuclear antibodies, and anti-pork antibodies. 
Serological testing should be performed taking into consideration the 
clinical characteristics of the patients (i.e. Aspergillus spp. in severe im­
munocompromised patients), the local epidemiology, and being aware 
of the specificity of the tests. In addition, tissue or prosthetic material 
obtained at surgery must be subjected to systematic culture, histologic­
al examination, and 16S or 18S rRNA sequencing aimed at document­
ing the presence of organisms.
5.4. Imaging techniques
Evidence of lesions characteristic of IE are major diagnostic criterion. 
Echocardiography is the first-line imaging technique to diagnose IE 
and to assess the structural and functional damage of cardiac struc­
tures. Echocardiographic findings have prognostic implications, and 
help to guide decision-making and patient follow-up while receiving 
antibiotic therapy and during the peri-operative and post-operative 
periods.163 In some clinical scenarios, other imaging modalities, such 
as CT, nuclear imaging, and MRI, are needed to confirm or exclude 
the diagnosis of IE, to characterize the extent of the cardiac lesions, 
and to diagnose extracardiac complications. They can also provide 
additional useful information for patient management.137 Each of 
these techniques has its diagnostic strengths and weaknesses (see 
Supplementary data online, Table S2). The use of an optimal imaging 
strategy depends on the availability of, and expertise in, each tech­
nique, but when indicated a multimodality imaging approach is essen­
tial for patients with suspected IE and should be strongly encouraged 
by the Endocarditis Team.21
5.4.1. Echocardiography
Transthoracic echocardiography (TTE) and transoesophageal echocar­
diography (TOE) are the first and key imaging techniques used to diag­
nose IE. Although echocardiography is widely accessible, significant 
variation in the use of TOE still exists.164 Three-dimensional TOE 
and intracardiac echocardiography have also been shown to be useful 
for the diagnosis of IE and its complications.165 However, the availability 
of intracardiac echocardiography is limited. Vegetation characteristics 
and size, perivalvular complications (abscess, pseudoaneurysm, new 
partial dehiscence of prosthetic valve), intracardiac fistula, and leaflet 
perforation are the main echocardiographic findings for the diagnosis 
and evaluation of local complications of IE (see Supplementary data 
online, Table S3). Importantly, vegetation size is a key metric that guides 
surgical indication, and vegetation size is defined as the maximal length 
of the vegetation.166 When evaluating IE on native or prosthetic valves, 
TTE had low sensitivity but good specificity as compared with TOE.166
TOE is helpful in a wide range of clinical scenarios, due to limitations of 
TTE to diagnose perivalvular complications, small vegetations, PVE, and 
vegetations associated with CIED. TOE is strongly recommended in pa­
tients with an inconclusive TTE, in patients with a negative TTE and a 
high suspicion of IE, as well as in patients with a positive TTE, in order 
to document local complications. Repeating TTE and/or TOE should be 
considered during follow-up of uncomplicated IE, in order to detect 
new silent complications and monitor vegetation size. The timing and 
mode (TTE or TOE) of repeated examination depend on the initial 
findings, type of microorganism, and initial response to therapy.
Table 9 Investigation of rare causes of blood culture- 
negative infective endocarditis
Pathogen
Diagnostic procedures
Brucella spp.
Serology, blood cultures, tissue culture, 
immunohistology, and 16S rRNA 
sequencing of tissue
C. burnetii
Serology (IgG phase l >1:800), tissue 
culture, immunohistology, and 16S rRNA 
sequencing of tissue
Bartonella spp.
Serology (IgG phase I >1:800), blood 
cultures, tissue culture, immunohistology, 
and 16S rRNA sequencing of tissue
T. whipplei
Histology and 16S rRNA sequencing of 
tissue
Mycoplasma spp.
Serology, tissue culture, immunohistology, 
and 16S rRNA sequencing of tissue
Legionella spp.
Serology, blood cultures, tissue culture, 
immunohistology, and 16S rRNA 
sequencing of tissue
Fungi
Serology, blood cultures, 18S rRNA 
sequencing of tissue
Mycobacteria (including 
Mycobacterium chimaera)
Specific blood cultures, 16S rRNA 
sequencing of tissue
© ESC 2023
Ig, immunoglobulin; rRNA, ribosomal ribonucleic acid.
ESC Guidelines                                                                                                                                                                                          3967


<!-- PAGE 21 -->

### Page 21

Echocardiographic imaging should be performed as soon as the IE 
diagnosis is suspected. The degree of valvular damage, the rate of 
peripheral embolic events, and the need for valve surgery increase 
with increasing time to initial echocardiographic assessment.167
Echocardiography should be repeated 5–7 days after an initial 
normal or inconclusive echocardiography, if the suspicion of IE re­
mains high, and in patients with diagnosed IE at high risk of compli­
cations 
(e.g. 
aggressive 
microorganisms, 
prosthetic 
valves).22,165,168,169
There is uncertainty regarding whether echocardiography should be 
systematically performed in patients with bloodstream infections due 
to different bacterial species, or if there are strategies (microbiological 
or imaging) that allow the identification of patients at higher risk of IE. 
Scoring systems have been developed to help in the appropriate 
indication to perform echocardiography when bacteraemia of different 
microorganisms 
occurs 
(see 
Supplementary 
data 
online, 
Table S4).60,170–173 The combination of microbiological parameters 
(type of microorganism and number of positive blood culture bottles) 
and cardiac-related risk factors (native valve disease, previous IE, pros­
thetic valve, and cardiac devices) may help identify the patients in whom 
echocardiography (TTE+TOE) is needed.19,174 Three risk scores were 
recently developed to identify patients at high risk of IE caused by S. aur­
eus, and those who should be evaluated with echocardiography (see 
Supplementary data online, Section S2.2.1).170–173,175–178 The cut-off 
values of the various scores are provided in Supplementary data 
online, Table S4.
N
N
N
N
N
Suspected IE
Y
Y
Y
Y
Blood cultures
Culture
Serologies
BCNIE
Identification by
MALDI-TOF MS
Microbiological identification
Antimicrobial susceptibility testing
Gram-positive and negative bacteria, fungi,
Mycobacterium spp.
Blood and vegetations PCRa
Antinuclear antibodiesb
Antiphospholipid antibodiesb
Anti-pork antibodiesb
Specific PCR
Antibiotic resistance and culture
C. burnetii
Bartonella spp.
Aspergillus spp.
L. pneumophila
Brucella spp.
M. pneumoniae
Y
Figure 4 Microbiological diagnostic algorithm in culture-positive and culture-negative infective endocarditis. BCNIE, blood cultures negative endocarditis; 
IE, infective endocarditis; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectrometry; PCR, polymerase chain reaction. 
aQualified microbiological laboratory. bImmunological laboratory.


<!-- PAGE 22 -->

### Page 22

5.4.2. Computed tomography
The indications for CT in patients with suspected or diagnosed IE 
include: 
(i) Diagnosis of IE and cardiac complications. Cardiac CT is more ac­
curate than TOE for diagnosing perivalvular and periprosthetic 
complications of IE (abscesses, pseudoaneurysms, and fistulae) 
and is recommended in both NVE and PVE if TOE is not conclusive 
or not feasible.33,168,169 In addition, cardiac CT can significantly 
influence 
subsequent 
surgical 
decision-making.20,185,186
Echocardiography continues to be superior for detecting valvular 
lesions, particularly small vegetations (<10 mm) which remain un­
derdiagnosed by CT, but also leaflet perforations and fistulae (see 
Supplementary data online, Table S3).35,168,169 Cardiac CT should 
be acquired according to the recommendations of cardiac CT 
guidelines to ensure high diagnostic accuracy, and can be per­
formed alone or in combination with PET.187
(ii) Detection of distant lesions and sources of bacteraemia. Whole-body 
and brain CT are useful for assessing IE systemic complications, includ­
ing septic emboli. The detection of distant lesions adds a minor diag­
nostic criterion leading to a more conclusive diagnosis of definite or 
rejected IE, and can be relevant for decision-making.188 CT angiog­
raphy can detect mycotic arterial aneurysms complicating IE in almost 
any site of the vascular tree,189,190 including the central nervous sys­
tem (CNS). Although MRI is superior to CT for diagnosing neuro­
logical complications,191 CT may be more feasible in an emergency 
setting and is an acceptable alternative for the detection of neurologic­
al complications, with a sensitivity of 90% and specificity of 86% in the 
detection of ischaemic and haemorrhagic lesions.192 Finally, CT can 
also detect the extracardiac sources of the bacteraemia, including 
early neoplastic lesions, that may be important for patient manage­
ment, and which need to be ideally addressed prior to undergoing 
heart valve surgery. However, CT does not replace the specific test 
indicated for the diagnosis of the extracardiac source of bacteraemia 
(i.e. colonoscopy in colon neoplasms).
(iii) Pre-operative assessment. Cardiac CT is a valuable alternative for 
non-invasive assessment of coronary artery disease (CAD) before 
cardiac surgery in patients with IE.193
(iv) Alternative diagnosis. In patients in whom IE is ruled out, or even in 
doubtful patients with possible IE, an alternative diagnosis can be 
reached by whole-body CT, as it can help to detect alternative in­
fectious foci. However, in these circumstances, an [18]FDG posi­
tron emission tomography/computed tomography (PET/CT) is 
the preferred imaging technique.194
5.4.3. Magnetic resonance imaging
The roles of MRI in the diagnostic work-up of IE include: 
(i) Diagnosis of IE and cardiac complications. The role of cardiac MRI to 
diagnose IE is limited by the low spatial resolution (as compared 
with cardiac CT) and the signal void generated by some prostheses 
impairing the assessment of prosthetic valve anatomy and 
function.195,196
(ii) Diagnosis of neurological IE-related complications. MRI has higher 
sensitivity than CT for the diagnosis of neurological lesions and, 
hence, increases the likelihood of detecting neurological complica­
tions in patients with IE. Patients with IE might present CNS lesions 
in up to 60–80% of cases,197 most of them corresponding to is­
chaemic lesions (50–80% of patients) that are often small and 
asymptomatic and do not impact on the decision-making.198
Other lesions that may influence the decision-making, such as par­
enchymal or subarachnoid haemorrhages, abscesses, or mycotic 
aneurysms, are found in <10% of patients.198–201 The systematic 
performance of brain MRI has shown to directly impact the 
Recommendation Table 5 — Recommendations for the 
role of echocardiography in infective endocarditis
Recommendations
Classa
Levelb
A. Diagnosis
TTE is recommended as the first-line imaging 
modality in suspected IE.166,179
I
B
TOE is recommended in all patients with clinical 
suspicion of IE and a negative or non-diagnostic 
TTE.166,178,179
I
B
TOE is recommended in patients with clinical 
suspicion of IE, when a prosthetic heart valve or an 
intracardiac device is present.166,178,179
I
B
Repeating TTE and/or TOE within 5–7 days is 
recommended in cases of initially negative or 
inconclusive examination when clinical suspicion of IE 
remains high.178
I
C
TOE is recommended in patients with suspected IE, 
even in cases with positive TTE, except in isolated 
right-sided native valve IE with good quality TTE 
examination and unequivocal echocardiographic 
findings.165,166,179
I
C
Performing an echocardiography should be 
considered in S. aureus, E. faecalis, and some 
Streptococcus spp. bacteraemia.19,149,174
IIa
B
B. Follow-up under medical therapy
Repeating TTE and/or TOE is recommended as soon 
as a new complication of IE is suspected (new 
murmur, embolism, persisting fever and bacteraemia, 
HF, abscess, AVB).165,166,179
I
B
TOE is recommended when patient is stable before 
switching from intravenous to oral antibiotic 
therapy.43,180
I
B
During follow-up of uncomplicated IE, repeat TTE and/ 
or TOE should be considered to detect new silent 
complications. The timing of repeat TTE and/or TOE 
depends on the initial findings, type of microorganism, 
and initial response to therapy.165,166,179
IIa
B
C. Intra-operative echocardiography
Intra-operative echocardiography is recommended 
in all cases of IE requiring surgery.181
I
C
D. Following completion of therapy
TTE and/or TOE are recommended at completion of 
antibiotic therapy for evaluation of cardiac and valve 
morphology and function in patients with IE who did 
not undergo heart valve surgery.182–184
I
C
© ESC 2023
AVB, atrioventricular block; HF, heart failure; IE, infective endocarditis; PVE, prosthetic 
valve endocarditis; TOE, transoesophageal echocardiography; TTE, transthoracic 
echocardiography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3969


<!-- PAGE 23 -->

### Page 23

diagnosis of IE, as it can add a minor diagnostic criterion in patients 
without neurological symptoms with non-definitive IE diagnosis. 
Brain MRI can reclassify 25% of patients with an initially inconclu­
sive diagnosis for IE to a more conclusive diagnosis, thereby leading 
to an earlier diagnosis.151 Cerebral microbleeds, found in 50–60% 
of patients with IE, are detected at gradient echo T2* se­
quences.200,202 Cerebral microbleeds should not be considered a 
minor criterion because there is no concordance with ischaemic 
lesions.203–205
(iii) Diagnosis of spine lesions. MRI is the diagnostic modality of choice 
of spondylodiscitis and vertebral osteomyelitis with a diagnostic ac­
curacy of 89–94%. MRI findings include vertebrae and disc oedema, 
paravertebral/epidural inflammation or abscess, bone erosion, and 
gadolinium enhancement of vertebrae and discs.32,206 It should be 
acknowledged that when MRI is performed too early, the rate of 
false-negative increases.207
5.4.4. Nuclear imaging positron emission 
tomography/computed tomography (angiography) 
and single photon emission tomography/computed 
tomography
Technical specifications of these imaging techniques are in the 
Supplementary data online, Section S2.2.2. The roles of nuclear imaging 
techniques in the diagnostic work-up of IE include: 
(i) Diagnosis of IE and cardiac complications. [18F]FDG-PET/CT and white 
blood cell (WBC) single photon emission computed tomography 
(SPECT)/CT are recommended in suspected PVE in cases of inconclu­
sive echocardiography. The most recent meta-analysis showed 86% 
sensitivity and 84% specificity for [18F]FDG-PET/CT in PVE.129
Additional evidence demonstrating the incremental diagnostic value 
of [18F]FDG-PET/CT and WBC SPECT/CT is summarized in the 
Supplementary data online, Section S2.2.2; Table S5.22,208–212
White blood cell SPECT/CT is an alternative nuclear imaging tech­
nique for the diagnosis of IE, when PET/CT is unavailable and in­
experienced centres. The sensitivity of WBC SPECT/CT has been 
reported as 64–90% and the specificity as 36–100%; diagnostic 
ability significantly increases with the presence of periprosthetic 
abscesses.213–215
99mTechnetium-hexamethylpropyleneamine oxime 
(99mTc-HMPAO)-SPECT/CT helped to reduce the number of misdiag­
nosed IE cases classified in the ‘possible IE’ category by the modified 
Duke criteria by 27%.216
In cases of NVE, the sensitivity of PET/CT and SPECT/CT is low 
(about 31%) but with a higher specificity (around 98%).211 In NVE, 
the diagnosis of IE cannot be excluded in the absence of abnormal 
[18F]FDG uptake.217 The more frequent presence of valve vegetations 
in comparison with paravalvular involvement in NVE compared with 
PVE leads to reduced inflammatory response and subsequently lower 
[18F]FDG and WBC uptake. The lower sensitivity of [18F]FDG-PET/ 
CT is offset by other strengths of the technique, such as its ability to 
identify septic emboli when suspected.211,218–220 Electrocardiogram 
(ECG)-gated PET may further improve the diagnostic accuracy.221
Combining PET/CT acquisition with a CT angiography (PET/CTA) al­
lows the detection of metabolic findings ([18F]FDG uptake distribution 
and intensity) and anatomical findings (IE-related lesions) within a single 
imaging procedure, resulting in the clinical clarification of indeterminate 
findings and change in the management of the patients.22,211 Such inves­
tigations may be particularly helpful in complex settings, such as patients 
with CHD222,223 and/or aortic grafts.22,224
(ii) Detection of distant lesions and sources of bacteraemia. 
Whole-body [18F]FDG-PET/CT imaging is particularly useful in 
patients with a suspicion or proven IE to identify distant lesions, 
mycotic aneurysms, and the portal of entry of the infection.225,226
Septic emboli are typically located in the spleen, lungs (in right- 
sided IE), and kidneys, and metastatic infections in the interverte­
bral discs and/or the vertebral bone (spondylodiscitis) as well as 
in muscles and joints (septic arthritis) and liver.211,227,228 [18F] 
FDG-PET/CT is less suited to detect cerebral septic embolism 
and mycotic aneurysms of intracerebral arteries due to the high 
physiological uptake of [18F]FDG in the brain.
(iii) Monitoring response to antimicrobial treatment with [18F] 
FDG-PET/CT in patients with established IE and indication for sur­
gery but who cannot be operated on due to unacceptable high risk 
and remain with long-term suppressive antibiotic treat­
ment.137,184,229–236
Recommendation Table 6 — Recommendations for the 
role of computed tomography, nuclear imaging, and 
magnetic resonance in infective endocarditis
Recommendations
Classa
Levelb
Cardiac CTA is recommended in patients with 
possible NVE to detect valvular lesions and confirm 
the diagnosis of IE.33,168,169
I
B
[18F]FDG-PET/CT(A) and cardiac CTA are 
recommended in possible PVE to detect valvular 
lesions and confirm the diagnosis of 
IE.22,129,209,210,237–239
I
B
Cardiac CTA is recommended in NVE and PVE to 
diagnose paravalvular or periprosthetic 
complications if echocardiography is 
inconclusive.20,168,169,185,186
I
B
Brain and whole-body imaging (CT, [18F]FDG-PET/ 
CT, and/or MRI) are recommended in symptomaticc 
patients with NVE and PVE to detect peripheral 
lesions or add minor diagnostic criteria.22,197– 
200,210,213,240,241
I
B
WBC SPECT/CT should be considered in patients 
with high clinical suspicion of PVE when 
echocardiography is negative or inconclusive and 
when PET/CT is unavailable.213–216
IIa
C
[18F]FDG-PET/CT(A) may be considered in possible 
CIED-related IE to confirm the diagnosis of 
IE.22,129,209,210,237,238
IIb
B
Brain and whole-body imaging (CT, [18F]FDG-PET/ 
CT, and MRI) in NVE and PVE may be considered for 
screening of peripheral lesions in asymptomatic 
patients.188,197–201
IIb
B
© ESC 2023
[18F]FDG-PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed 
tomography; CAD, coronary artery disease; CT, computed tomography; CTA, 
computed tomography angiography; IE, infective endocarditis; MRI, magnetic resonance 
imaging; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; WBC 
SPECT/CT, white blood cell single photon emission tomography/computed tomography. 
aClass of recommendation. 
bLevel of evidence. 
cSymptomatic: symptoms suggesting septic embolic complications.


<!-- PAGE 24 -->

### Page 24

5.5. Diagnostic criteria
Since 2000, clinical, microbiological, and imaging findings have been inte­
grated in the modified Duke criteria (see Supplementary data online, 
Table S6), which have demonstrated an overall sensitivity of 80% for 
IE.151 However, the clinical presentation of IE can be highly variable 
and some major limitations of the modified Duke criteria have become 
clear, particularly when prosthetic material is present (PVE, aortic grafts, 
cardiac devices, CHD). In these situations, echocardiography can be 
normal or inconclusive in up to 30% of cases despite the presence of 
IE.242–244 Therefore, the 2015 ESC diagnostic criteria introduced a 
multimodality 
imaging 
approach 
(echocardiography, 
cardiac/ 
whole-body CT, cerebral MRI, [18F]FDG-PET/CT, and WBC SPECT/ 
CT) to improve the diagnostic yield. This new approach has shown to 
be superior over the traditional diagnostic criteria.36–41,122,123,125,126,212
5.5.1. Modifications for the diagnosis of infective 
endocarditis
The current 2023 ESC Guidelines for the management of endocarditis 
introduce the following modifications for IE diagnosis: 
(i) Changes to the major and minor diagnostic criteria (Table 10).
Table 10 Definitions of the 2023 European Society of Cardiology modified diagnostic criteria of infective endocarditis
Major criteria
(i) Blood cultures positive for IE 
(a) Typical microorganisms consistent with IE from two separate blood cultures: 
Oral streptococci, Streptococcus gallolyticus (formerly S. bovis), HACEK group, S. aureus, E. faecalis
(b) Microorganisms consistent with IE from continuously positive blood cultures: 
• ≥2 positive blood cultures of blood samples drawn >12 h apart.
• All of 3 or a majority of ≥4 separate cultures of blood (with first and last samples drawn ≥1 h apart).
(c) Single positive blood culture for C. burnetii or phase I IgG antibody titre >1:800.
(ii) Imaging positive for IE: 
Valvular, perivalvular/periprosthetic and foreign material anatomic and metabolic lesions characteristic of IE detected by any of the following imaging techniques: 
• Echocardiography (TTE and TOE).
• Cardiac CT.
• [18F]-FDG-PET/CT(A).
• WBC SPECT/CT.
Minor criteria
(i) Predisposing conditions (i.e. predisposing heart condition at high or intermediate risk of IE or PWIDs)a
(ii) Fever defined as temperature >38°C
(iii) Embolic vascular dissemination (including those asymptomatic detected by imaging only): 
• Major systemic and pulmonary emboli/infarcts and abscesses.
• Haematogenous osteoarticular septic complications (i.e. spondylodiscitis).
• Mycotic aneurysms.
• Intracranial ischaemic/haemorrhagic lesions.
• Conjunctival haemorrhages.
• Janeway’s lesions.
(IV) Immunological phenomena: 
• Glomerulonephritis.
• Osler nodes and Roth spots.
• Rheumatoid factor.
(V) Microbiological evidence: 
• Positive blood culture but does not meet a major criterion as noted above.
• Serological evidence of active infection with organism consistent with IE.
IE Classification (at admission and during follow-up)
Definite: 
• 2 major criteria.
• 1 major criterion and at least 3 minor criteria.
• 5 minor criteria.
Possible: 
• 1 major criterion and 1 or 2 minor criteria.
• 3–4 minor criteria.
Rejected: 
• Does not meet criteria for definite or possible at admission with or without a firm alternative diagnosis.
© ESC 2023
[18F]-FDG-PET/CT, 18F-fluorodeoxyglucose positron emission tomography; CT(A), computed tomography (angiography); HACEK, Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, 
and Kingella; IE, infective endocarditis; Ig, immunoglobulin; PWID, people who inject drugs; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT/CT, 
white blood cell single photon emission tomography/computed tomography. 
aFor detailed explanation of predisposing conditions, please see Section 3.
ESC Guidelines                                                                                                                                                                                          3971


<!-- PAGE 25 -->

### Page 25

(ii) Specific diagnostic algorithms to support decision-making, especially 
in the recommended sequence of imaging techniques (Figures 5–7).
(iii) CIED-related IE is considered a right-sided endocarditis for diag­
nostic purposes and is included in the diagnostic algorithms, but 
its definitions and recommendations for management can be 
found in Section 12 and are in accordance with the specific 
European Heart Rhythm Association (EHRA) consensus on 
CIED infections.130
Repeat blood cultures if negative or doubtful
Repeat TTE/TOE within 5–7  days
Cardiac CTA to diagnose valvular lesions
Add minor criteria:  brain or whole-body imaging (MRI, CT, PET/CT,  WBC SPECT)
to detect distant lesions
Suspected paravalvular complications and TOE inconclusive
Cardiac CTA
(Class I)
No symptoms suggesting extracardiac complications
Brain and whole-body imaging
(CT, [18F]FDG-PET/CT, and/or MRI)
(Class IIb)
Symptoms suggesting extracardiac complications
Brain and whole-body imaging
(CT, [18F]FDG-PET/CT, and/or MRI)
(Class I)
Suspected native valve IE
ESC 2023 DIAGNOSTIC CRITERIA after IE
Baseline assessment and initial classification:
clinical presentation + blood cultures + TTE + TOEa
(Class I)
POSSIBLE
REJECTED
DEFINITE
(Class I)
(Class IIa)
Figure 5 European Society of Cardiology 2023 algorithm for diagnosis of native valve infective endocarditis. [18F]FDG, 18F-fluorodeoxyglucose; CT, com­
puted tomography; CTA, computed tomography angiography; ESC, European Society of Cardiology; IE, infective endocarditis; MRI, magnetic resonance im­
aging; NVE, native valve endocarditis; PET, photon emission tomography; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; 
WBC SPECT, white blood cell single photon emission tomography. aTOE for diagnosis and to detect perivalvular complications in all cases (unless right-sided 
NVE when TTE is good quality and conclusive).


<!-- PAGE 26 -->

### Page 26

The reasons to justify the changes in the diagnostic criteria include:
5.5.1.1. Major criteria – microbiology
Enteroccus faecalis should be acknowledged as a typical endocarditis 
bacterium, regardless of the place of acquisition or the source of 
infection. Currently, the modified Duke criteria fail to identify 30% of 
E. faecalis definite IE. Using data from a prospective study of 344 pa­
tients with E. faecalis bacteraemia evaluated with echocardiography, 
Dahl et al. demonstrated that designating E. faecalis as a ‘typical’ endo­
carditis pathogen significantly improved the sensitivity to correctly iden­
tify definite IE, from 70% to 96%.245
5.5.1.2. Major criteria – imaging
(i) Diagnosis based on the presence of lesions characteristics of IE. 
Anatomic lesions and increased [18F]FDG uptake or WBC accu­
mulation can be depicted by nuclear imaging techniques and add 
Repeat blood cultures if negative or doubtful
Repeat TTE/TOE within 5–7  days
Cardiac CTA or [18]FDG-PET/CT(A) to diagnose valvular lesions
WBC SPECT
Add minor criteria:  brain or whole-body imaging (MRI, CT, PET/CT,  WBC SPECT)
to detect distant lesions
Suspected paravalvular complications and TOE inconclusive
Cardiac CTA
(Class I)
No symptoms suggesting extracardiac complications
Brain and whole-body imaging
(CT, [18F]FDG-PET/CT, and/or MRI)
(Class IIb)
Symptoms suggesting extracardiac complications
Brain and whole-body imaging
(CT, [18F]FDG-PET/CT, and/or MRI)
(Class I)
Suspected prosthetic valve IE
ESC 2023 DIAGNOSTIC CRITERIA after IE
Baseline assessment and initial classification:
clinical presentation + blood cultures + TTE + TOEa
(Class I)
POSSIBLE
REJECTED
DEFINITE
(Class I)
(Class IIa)
Figure 6 European Society of Cardiology 2023 algorithm for diagnosis of prosthetic valve infective endocarditis. [18F]FDG, 18F-fluorodeoxyglucose; CT, com­
puted tomography; CTA, computed tomography angiography; ESC, European Society of Cardiology; IE, infective endocarditis; MRI, magnetic resonance imaging; 
PET, positron emission tomography; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT, white blood cell single photon 
emission tomography. aTOE for diagnosis and to detect perivalvular complications in all cases (unless right-sided NVE when TTE is good quality and conclusive).
ESC Guidelines                                                                                                                                                                                          3973


<!-- PAGE 27 -->

### Page 27

a major diagnostic criterion. Definitions of the anatomic and meta­
bolic features of the infective lesions can be found in the 
Supplementary data online, Table S5.
(ii) Abnormal prosthetic or periprosthetic uptake (intense focal or 
heterogeneous) detected by [18F]FDG-PET/CT or WBC 
SPECT/CT should be considered a major criterion for PVE, irre­
spective of the interval from surgery (see Supplementary data 
online, Figure S1). Published data support that intense focal or 
heterogeneous patterns is associated with a final diagnosis of in­
fection, while post-operative inflammatory changes can be per­
sistent more than 3 months after surgery, as noted in the 
previous guidelines. However, these inflammatory changes can 
be differentiated from infection even after recent valve implant­
ation.246 Therefore, a consensus of experts has concluded that 
the need for a time interval prior to investigation is questionable, 
but accurate imaging interpretation by proper interpretation cri­
teria is mandatory.233,236
5.5.1.3. Minor criteria
Distant IE-related lesions include all lesions that can result from embolic 
events and from haematogenous seeding of bacteria. These lesions can 
be suspected due to specific symptoms or can be incidentally detected 
on imaging techniques. Spondylodiscitis is the most frequent osteoarti­
cular infective complication in patients with IE.247,248
5.5.1.4. Microbiological criteria
Molecular biology (16S/18S rRNA PCR sequencing) in cardiac tissue or 
embolic material has increased the diagnostic performance of IE with 
negative blood culture. The sensitivity ranges between 41% and 96% 
and the specificity is very high, ranging between 90% and 100%.249
Repeat blood cultures if negative or doubtful
Repeat TTE/TOE within 5–7 days
PET/CT(A) to detect pocket infection +/-
pulmonary embolism
Add minor criteria: thoracic CT to detect septic pulmonary embolism/infarction
PET/CT(A) to detect lead infection
(Class IIa)
(Class IIb)
(Class I)
Suspected CIED-associated IE
ESC 2023 DIAGNOSTIC CRITERIA after IE
Baseline assessment and initial classification:
clinical presentation + blood cultures + TTE + TOE
(Class I)
POSSIBLE
REJECTED
DEFINITE
Figure 7 European Society of Cardiology 2023 algorithm for diagnosis of cardiac device-related infective endocarditis. CIED, cardiovascular implanted 
electronic device; CT, computed tomography; CTA, computed tomography angiography; ESC, European Society of Cardiology; IE, infective endocarditis; 
PET, positron emission tomography; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT, white blood cell single 
photon emission tomography.


<!-- PAGE 28 -->

### Page 28

5.5.1.5. Infective endocarditis classification
Infective endocarditis classification has been added to the 2023 ESC cri­
teria. Possible IE cases include the combination of 1 major and 1 or 2 
minor criteria. Infective endocarditis classification should be applied 
by the Endocarditis Team at admission and later at follow-up, taking 
into account the complete clinical, microbiology, imaging, and surgical 
information to establish the final diagnosis.
It is important to acknowledge that these new criteria should be pro­
spectively validated.
5.5.2. The new 2023 European Society of Cardiology 
diagnostic algorithms
The diagnosis of IE is based on clinical suspicion, blood cultures, and im­
aging findings. Echocardiography is usually the first imaging technique to 
diagnose IE, although the use of other techniques, either for the diagno­
sis of cardiac involvement (cardiac CT, [18F]FDG-PET/CT, or WBC 
SPECT/CT), or for the diagnosis of distant lesions (cerebral MRI, whole- 
body CT, and/or PET/CT), is encouraged. In the presence of prosthetic 
valves and CIED, echocardiography is particularly limited and the afore­
mentioned imaging techniques are strongly recommended. Adapted 
diagnostic algorithms for suspected IE in NVE, PVE, and CIED are dis­
played in Figures 5–7, respectively.
6. Prognostic assessment at 
admission
The in-hospital mortality rate of patients with IE has remained largely 
unchanged over the past two decades, ranging from 15% to 
30%.5,145,250,251 Several patient characteristics, often occurring simul­
taneously, have been shown to confer an increased risk of death in 
IE. The rapid identification of patients at the highest risk may offer 
the opportunity to change the course of the disease (i.e. with urgent 
or emergency surgery) and improve prognosis. Predictors of poor out­
come on admission of patients with IE are specified in the 
Supplementary data online, Section S3.1; Table S7.
7. Antimicrobial therapy: principles 
and methods
7.1. General principles
Successful treatment of IE relies on microbial eradication by antimicro­
bial drugs. Surgery contributes by removing infected material. 
Bactericidal regimens are more effective than bacteriostatic therapy, 
both in animal experiments and in humans.252–254 Aminoglycosides sy­
nergize with cell wall inhibitors (i.e. beta-lactams and glycopeptides) for 
bactericidal activity and are useful for shortening the duration of ther­
apy (e.g. oral streptococci) and eradicating problematic organisms. 
However, the side effects of aminoglycosides should be taken into con­
sideration and currently the combination of ampicillin with ceftriaxone 
has demonstrated effective in treating IE caused by E. faecalis irrespect­
ive of the presence of high-level aminoglycoside resistance (HLAR) and 
minimizing the risk of nephrotoxicity.255,256
One major hindrance to drug-induced killing is bacterial antibiotic 
tolerance. Tolerant microbes are not resistant (i.e. they are still suscep­
tible to growth inhibition by the drug) but escape drug-induced killing 
and 
may 
resume 
growth 
after 
treatment 
discontinuation. 
Slow-growing and dormant microbes display phenotypic tolerance 
towards most antimicrobials (except rifampin to some extent). They 
are present in vegetations and biofilms (complex communities of bac­
teria residing within an exopolysaccharide matrix that adheres to a sur­
face, e.g. in PVE),257 and justify the need for prolonged therapy to fully 
sterilize infected heart valves. Some bacteria carry mutations rendering 
them tolerant during both active growth and stationary (dormant) 
phases.258,259 Bactericidal drug combinations are preferred to mono­
therapy against tolerant organisms (e.g. the combination of ampicillin 
and ceftriaxone in IE caused by E. faecalis).
Drug treatment of PVE should last longer (≥6 weeks) than that of 
NVE (2–6 weeks) but is otherwise similar. In staphylococcal PVE, the 
regimen should include rifampin whenever the strain is susceptible, 
even if some recent data have shown no differences in outcomes be­
tween patients with PVE treated with rifampin vs. those treated 
without.260,261
In NVE needing valve replacement by a prosthesis during antibiotic 
therapy, the post-operative antibiotic regimen should be that recom­
mended for NVE, not for PVE. In both NVE and PVE, the duration of 
treatment is based on the first day of effective antibiotic therapy (nega­
tive blood culture in the case of initial positive blood culture), not on the 
day of surgery. A new full course of treatment should only start if valve 
cultures are positive.
Finally, 
there 
are 
important 
considerations 
in 
these 
recommendations: 
(i) Only published antibiotic efficacy data from clinical trials and cohort 
studies in patients with IE (or bacteraemia if there are no IE data) 
have been considered in these guidelines. Data from experimental 
IE models have not been taken into account. A recent systematic 
review evaluating the existing evidence about clinical benefits and 
harms of different antibiotic regimens used to treat patients with 
IE has shown that there is limited and low- to very low-quality evi­
dence to make strong conclusions on the comparative effects of dif­
ferent antibiotic regimens on cure rates or other relevant clinical 
outcomes and, therefore, there is not enough evidence to support 
or reject any regimen of antibiotic therapy for the treatment of 
IE.262,263
(ii) These guidelines have adopted the MIC breakpoints included in the 
2022 EUCAST clinical breakpoint tables.42 The EUCAST break­
points are used to categorize results into three susceptibility 
categories: 
• Susceptible, standard dosing regimen: a microorganism is cate­
gorized as such, when there is a high likelihood of therapeutic 
success using a standard dosing regimen of the agent.
• Susceptible, increased exposure: a microorganism is categorized 
as such when there is a high likelihood of therapeutic success be­
cause exposure to the agent is increased by adjusting the dosing 
regimen or by its concentration at the site of infection.
• Resistant: a microorganism is categorized as such when there is a 
high likelihood of therapeutic failure even when there is in­
creased exposure.
The term exposure is defined as a function of how the mode of ad­
ministration, dose, dosing interval, infusion time, as well as distribution 
and excretion of the antimicrobial agent, will influence the infecting or­
ganism at the site of infection. The local laboratories are responsible for 
the use of appropriate methods and interpretative criteria and quality 
control of the test results (MIC) while the clinicians are responsible 
for adjusting the level of exposure by modifying the dosing strategy 
ESC Guidelines                                                                                                                                                                                          3975


<!-- PAGE 29 -->

### Page 29

(individual dose, frequency of dosing, mode of administration [oral or 
intravenous (i.v.)]).42
(iii) Oral antimicrobial therapy. The POET trial has changed the para­
digm of i.v. antibiotic treatment for IE.43 For more than 60 years it 
had been considered that antibiotics should always be given intra­
venously. The POET trial has shown that after an initial phase of 
i.v. treatment, up to 20% of patients could complete the treatment 
by oral antibiotic therapy (see Section 7.13.1).43 Therefore, as indi­
cated in Figure 8, the antibiotic treatment of IE has two phases. 
The first phase can last up to 2 weeks of hospital i.v. treatment using 
combinations of rapidly bactericidal antibiotics to destroy planktonic 
bacteria.257 In this initial phase, cardiac surgery should be performed 
if indicated, infected foreign bodies should be removed, and cardiac 
as well as extracardiac abscesses should be drained. After this peri­
od, clinically stable patients can end the antibiotic treatment at home 
with i.v. (OPAT) or oral antibiotic regimens for up to 6 weeks in or­
der to eliminate the dormant (resting) bacteria and prevent relapses.
(iv) Aminoglycosides are not recommended in staphylococcal NVE be­
cause their clinical benefits have not been demonstrated, but they 
can increase renal toxicity.255,264 When they are indicated in other 
conditions (e.g. resistant oral streptococci),265 aminoglycosides should 
be given for no longer than 2 weeks to reduce nephrotoxicity.266
(v) Rifampin should be used only in foreign body infections such as PVE after 
3–5 days of effective antibiotic therapy, once the bacteraemia has been 
cleared. The rationale supporting this recommendation is based on the 
likely antagonistic effect of the antibiotic combinations with rifampin 
against planktonic/replicating bacteria,267 and the synergy seen against 
dormant bacteria within the biofilms and prevention of rifampin- 
resistant variants.268New evidence based on a small, retrospective study 
has questioned this approach and needs further validation.260
(vi) Daptomycin has been recommended for treating staphylococcal 
and enterococcal endocarditis.269 When daptomycin is indicated, 
it must be given at high doses (10 mg/kg once daily)270 and 
combined with a second antibiotic (beta-lactams or fosfomycin in 
beta-lactam allergic patients) to increase activity and avoid the de­
velopment of resistance.271 It should be noted the use of fosfomycin 
is associated with increased risk of acute HF and renal failure due to 
the high load of sodium while the use of daptomycin has been asso­
ciated with eosinophilic syndromes in up to 15% of patients.272,273
Phases of antibiotic treatment of infective endocarditis
Complicated cases: continue inpatient i.v. treatmenta
From Day 10 post-treatment initiation and/or 7 days post-surgery:
consider OPAT or oral antibiotic treatment in stable patients
Inpatient treatment i.v. rapid bactericidal combinations
Removal of infected cardiac devices
0
Week
Early critical phase
Continuation phase with resting bacteria
1
2
4-6
+
+
Cardiac surgery, if 
indicated
Draining of abscesses
10
Day
Perform TOE before therapy switch
(Class I)
Figure 8 Phases of antibiotic treatment for infective endocarditis in relation to outpatient parenteral antibiotic therapy and partial oral endocarditis treat­
ment. i.v., intravenous: OPAT, outpatient parenteral antibiotic treatment; TOE, transoesophageal echocardiography. aCriteria for switching to OPAT or par­
tial oral treatment of endocarditis are given in the Supplementary data online, Table S8.


<!-- PAGE 30 -->

### Page 30

(vii) The antibiotic regimens need to adapt to the local circumstances 
and the availability of antibiotics.
(viii) Data on the efficacy of long-term antibiotic suppressive therapy in pa­
tients with IE who do not undergo cardiac surgery are limited to small 
and heterogeneous series with various antibiotic regimens.184,274 In a 
small series of Gram-positive bloodstream infections and IE, dalba­
vancin (500 mg weekly or 1000 mg biweekly regimens) has been 
shown effective.274,275 Relapses are not infrequent.184
7.2. Penicillin-susceptible oral streptococci 
and Streptococcus gallolyticus group
Oral streptococci include the groups mitis, sanguinis, anginosus, salivar­
ius, downei, and mutans (see Supplementary data online, Figure S2).276
The remaining streptococci isolated outside of the oral cavity are clas­
sified into either the Streptococcus gallolyticus (former bovis) or pyogen­
ic groups. Recommended regimens against susceptible (susceptible 
standard dosing regimen and increased exposure) streptococci are 
summarized in Recommendation Table 7.4,277–279 The cure rate is ex­
pected to be >95%. In uncomplicated cases of NVE, short-term 2-week 
therapy can be administered by combining penicillin or ceftriaxone with 
gentamicin or netilmicin.280,281 Gentamicin and netilmicin can be given 
once daily in patients with IE due to susceptible streptococci and nor­
mal renal function. When outpatient antibiotic therapy is feasible, cef­
triaxone alone or combined with gentamicin or netilmicin given once a 
day is particularly convenient.280–282 In patients with documented al­
lergy to penicillin, desensitization is recommended. If desensitization 
cannot be performed, patients allergic to beta-lactam should receive 
cephalosporins (in non-anaphylactic reaction) or vancomycin, keeping 
in mind that a beta-lactam is superior to glycopeptides. Teicoplanin 
has been proposed as an alternative,4 starting with loading doses 
(6 mg/kg/12 h for 3 days) and followed by 6–10 mg/kg/day. Loading is 
critical because the drug is highly bound (≥98%) to serum proteins 
and penetrates slowly into vegetations.283 However, only limited retro­
spective studies have assessed its efficacy in streptococcal IE.284 After 
10–14 days of therapy, OPAT or outpatient oral antibiotic therapy 
should be considered.
7.3. Oral streptococci and 
Streptococcus gallolyticus group 
susceptible, increased exposure or 
resistant to penicillin
The incidence of these resistant streptococci is increasing. Large strain 
collections have reported >30% of resistant S. mitis and Streptococcus 
oralis.285
Retrospective series provide the evidence for the recommendations 
on antibiotic treatment of IE caused by penicillin-resistant oral strepto­
cocci and S. gallolyticus. Compiling four of them, 47 of 60 patients (78%) 
were treated with penicillin or ceftriaxone, mostly combined with ami­
noglycosides.285–290 In penicillin-resistant cases, aminoglycoside treat­
ment must be given for ≥2 weeks and short-term therapy regimens 
are not recommended. There is very limited experience with daptomy­
cin in IE caused by resistant isolates.265,291 After 10–14 days of therapy, 
OPAT or outpatient oral antibiotic therapy should be considered if clin­
ically stable (see Section 7.13).
Recommendation Table 7 — Recommendations for antibiotic treatment of infective endocarditis due to oral strepto­
cocci and Streptococcus gallolyticus group
Recommendations
Classa
Levelb
Penicillin-susceptible oral streptococci and Streptococcus gallolyticus group
Standard treatment: 4-week duration in NVE or 6-week duration in PVE
In patients with IE due to oral streptococci and S. gallolyticus group, penicillin G, amoxicillin, or ceftriaxone are recommended for 4 
(in NVE) or 6 weeks (in PVE), using the following doses:277,278
I
B
Adult antibiotic dosage and route
Penicillin G
12–18 millionc U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Paediatric antibiotic dosage and route
Penicillin G
200 000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg/day i.v. in 1 dose
Standard treatment: 2-week duration (not applicable to PVE)
2-week treatment with penicillin G, amoxicillin, ceftriaxone combined with gentamicin is recommended only for the treatment of 
non-complicated NVE due to oral streptococci and S. gallolyticus in patients with normal renal function using the following 
doses:277,278
I
B
Adult antibiotic dosage and route
Penicillin G
12–18 millionc U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dosed
Continued
ESC Guidelines                                                                                                                                                                                          3977


<!-- PAGE 31 -->

### Page 31

Paediatric antibiotic dosage and route
Penicillin G
200 000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. in 1 dose
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dose or 3 equally divided dosesd
Allergy to beta-lactams
In patients allergic to beta-lactams and with IE due to oral streptococci and S. gallolyticus, vancomycin for 4 weeks in NVE or for 6 
weeks in PVE is recommended using the following doses:292
I
C
Adult antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 dosese
Paediatric antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 or 3 equally divided dosese
Oral streptococci and Streptococcus gallolyticus group susceptible, increased exposure or resistant to penicillin
In patients with NVE due to oral streptococci and S. gallolyticus, penicillin G, amoxicillin, or ceftriaxone for 4 weeks in combination 
with gentamicin for 2 weeks is recommended using the following doses:285–290
I
B
Adult antibiotic dosage and route
Penicillin G
24 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dosed
In patients with PVE due to oral streptococci and S. gallolyticus, penicillin G, amoxicillin, or ceftriaxone for 6 weeks combined with 
gentamicin for 2 weeks is recommended using the following doses:285–290
I
B
Adult antibiotic dosage and route
Penicillin G
24 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dosed
Allergy to beta-lactams
In patients with NVE due to oral streptococci and S. gallolyticus and who are allergic to beta-lactams, vancomycin for 4 weeks is 
recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 dosese
Paediatric antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 dosese
In patients with PVE due to oral streptococci and S. gallolyticus and who are allergic to beta-lactams, vancomycin for 6 weeks 
combined with gentamicin for 2 weeks is recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 dosese
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dosed
Paediatric antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 dosese
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dosed
© ESC 2023
IE, infective endocarditis; i.m., intramuscular; i.v., intravenous; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; U, units. 
aClass of recommendation. 
bLevel of evidence. 
cThe starting recommended doses are the lower doses which can be scalable to the highest doses. 
dMaximum doses 240 mg/day. High doses are associated with increased risk of nephrotoxicity. Renal function and serum gentamicin concentrations should be monitored once a week. When 
given in a single daily dose, pre-dose (trough) concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum concentrations should be ∼10–12 mg/L. 
eSerum vancomycin concentrations should achieve 10–15 mg/L at pre-dose (trough) level, although some experts recommend to increase the dose of vancomycin to 45–60 mg/kg/day i.v. in 2 
or 3 divided doses to reach serum trough vancomycin levels (Cmin) of 15–20 mg/L as in staphylococcal endocarditis. However, vancomycin dose should not exceed 2 g/day unless serum levels 
are monitored and can be adjusted to obtain a peak plasma concentration of 30–45 μg/mL 1 h after completion of the i.v. infusion of the antibiotic.


<!-- PAGE 32 -->

### Page 32

7.4. Streptococcus pneumoniae, 
β-haemolytic streptococci  
(groups A, B, C, and G)
Infective endocarditis due to Streptococcus pneumoniae has become 
rare. It is associated with meningitis and pneumonia in up to 30% of 
cases,293–296 which requires special consideration in cases with penicil­
lin resistance. Treatment of penicillin-susceptible strains is similar to 
that of oral streptococci (see Recommendation Table 7), except for 
the use of short-term 2-week therapy, which has not been thoroughly 
investigated. The same holds true for penicillin-susceptible increased 
exposure or resistant strains without meningitis, although for resistant 
strains some authors recommend high doses of cephalosporins (e.g. 
cefotaxime or ceftriaxone) or vancomycin.295 In cases with meningitis, 
penicillin must be avoided because of its poor penetration into the 
cerebrospinal fluid, and should be replaced with ceftriaxone or cefotax­
ime alone, or in association with vancomycin according to the antibiotic 
susceptibility pattern.297,298 After 10–14 days of therapy and when 
meningitis is not associated, OPAT or outpatient oral antibiotic therapy 
should be considered if clinically stable (see Section 7.13).
Infective endocarditis due to group A, B, C, or G streptococci, includ­
ing the Streptococcus anginosus group (S. constellatus, S. anginosus, and S. 
intermedius) is relatively rare.299,300 Group A streptococci are uniformly 
susceptible to beta-lactams, whereas other serogroups may display 
some degree of resistance. Infective endocarditis due to group B 
streptococci was once associated with the peripartum period, but it 
now occurs in all adults, especially the elderly. Groups B, C, and G 
streptococci and S. anginosus induce abscesses that require adjunctive 
surgery.300 Mortality from group B PVE is very high and cardiac surgery 
is recommended.301 Antibiotic treatment is similar to that of oral 
streptococci (see Recommendation Table 7), except that short-term 
(2 weeks) therapy is not recommended and gentamicin should be given 
for 2 weeks.
7.5. Granulicatella and Abiotrophia 
(formerly nutritionally variant 
streptococci)
Granulicatella and Abiotrophia induce IE with a prolonged course and are 
associated with large vegetations (>10 mm), and consequently with 
high rates of complications and valve replacement (around 
50%).302,303 This is possibly due to delayed diagnosis and treatment. 
Antibiotic recommendations include penicillin G, ceftriaxone, or vanco­
mycin for 6 weeks, combined with an aminoglycoside for at least the 
first 2 weeks in case of PVE (for doses, please see Recommendation 
Table 7).302–304
7.6. Staphylococcus aureus and 
coagulase-negative staphylococci
Staphylococcus aureus is usually responsible for acute and destructive 
IE,305 whereas CoNS can induce more protracted valve infec­
tions.306,307 Of note, the addition of an aminoglycoside in staphylococ­
cal NVE is no longer recommended because it increases renal 
toxicity.264,308 Short-term (2-week) and oral treatments have been 
proposed for uncomplicated right-sided native valve methicillin- 
susceptible S. aureus (MSSA) IE (see also Section 12.4.2), but these regi­
mens cannot be applied to left-sided IE. For penicillin-allergic patients 
with MSSA IE, penicillin desensitization can be attempted in stable pa­
tients or cefazolin can be used since vancomycin is inferior to beta- 
lactams.309 If beta-lactams cannot be given, where available, daptomycin 
should be chosen and given in combination with another effective anti­
staphylococcal drug to increase activity and avoid the development of 
resistance.310
Staphylococcus lugdunensis is mostly methicillin- 
susceptible and can be treated with cloxacillin.
Staphylococcus aureus PVE carries a very high risk of mortality 
(>45%),305,312,313 and often requires early valve replacement. Other 
differences in comparison with NVE include the overall duration of ther­
apy, the use of aminoglycosides, and the addition of rifampin after 3–5 
days of effective antibiotic therapy once the bacteraemia has been 
cleared.264,314–318 The rationale supporting this recommendation is based 
on the antagonistic effect of the antibiotic combinations with rifampin 
against planktonic/replicating bacteria as has been demonstrated in foreign 
body infection models and clinically in prosthetic orthopaedic and vascular 
infections.319 However, a recent study has shown that the addition of ami­
noglycosides to a regimen containing vancomycin or cloxacillin plus rifam­
picin in S. aureus PVE was not associated with a better outcome.320 In 
addition, the risk of nephrotoxicity associated with the use of aminoglyco­
sides should be taken into consideration. Adding rifampin to the treatment 
of staphylococcal PVE is standard practice despite the weak evi­
dence.261,321 The potential side effects and drug interactions of rifampin 
should also be considered. In patients with PVE who are allergic to penicil­
lin, daptomycin can be given combined with ceftaroline or fosfomycin or 
with gentamicin (for 2 weeks) plus rifampin for at least 6 weeks. After 
10–14 days of therapy, OPAT or outpatient oral antibiotic therapy should 
be considered if clinically stable (see Section 7.13).
7.7. Methicillin-resistant staphylococci
Methicillin-resistant S. aureus (MRSA) produces low-affinity penicillin- 
binding proteins (PBPs), which confer cross-resistance to most beta- 
lactams. Methicillin-resistant S. aureus is usually resistant to multiple 
antibiotics, leaving vancomycin, daptomycin, ceftaroline, and dalbavan­
cin to treat severe infections.322–324 However, it should be noted 
that subpopulations susceptible with increased exposure and resistant 
to vancomycin have emerged worldwide and are associated with IE 
treatment failures.325–328 The prevalence of MRSA causing IE that is 
susceptible with increased exposure or resistant to vancomycin ranges 
between 19% and 34%. In addition, among patients with IE caused by 
MRSA, those isolates with a population analysis profile MIC ≥4 mg/L 
were associated with treatment failure defined by persistent bacteriae­
mia for ≥7 days or MRSA-attributable mortality.325 Nephrotoxicity is 
of concern when using trough monitoring of levels of vancomycin as 
a surrogate marker of the area under the curve relative to the MIC 
(AUC/MIC). Therefore, it is recommended to use a target of AUC/ 
MIC between 400 and 600 mg*h/L (assuming an MIC of 1 mg/L) that 
should be achieved with 48 h of therapy.329 When the MIC is >1 mg/ 
L, the probability of achieving an AUC/MIC ≥400 is unlikely. In that clin­
ical scenario, changing therapy should be considered due to the high risk 
of nephrotoxicity with higher doses of vancomycin. Daptomycin is a li­
popeptide antibiotic approved for S. aureus bacteraemia and right-sided 
IE.330 Cohort studies of S. aureus and CoNS IE have shown that dapto­
mycin is at least as effective as vancomycin,327,328 and, in two cohort 
studies of MRSA bacteraemia with high vancomycin MICs (>1 mg/ 
L),331,332 daptomycin was associated with better outcomes (including 
survival) compared with vancomycin. Importantly, daptomycin needs 
to be administered in appropriate doses and combined with other anti­
biotics to avoid further resistance in patients with IE.330,333 Therefore, 
daptomycin should be given at high doses (10 mg/kg), and most experts 
recommend its combination with beta-lactams334 or fosfomycin335
(beta-lactams [and probably fosfomycin] increase membrane 
ESC Guidelines                                                                                                                                                                                          3979


<!-- PAGE 33 -->

### Page 33

daptomycin binding by decreasing the positive surface charge) for NVE, 
and with gentamicin and rifampin for PVE.326–328 However, in a rando­
mized trial including 352 patients with MRSA bacteraemia, daptomycin 
or vancomycin combined with i.v. flucloxacillin, cloxacillin, or cefazolin 
did not result in a significant reduction of the primary composite end­
point of mortality, persistent bacteraemia, relapse, or treatment failure 
as compared with daptomycin or vancomycin alone.328 The study was 
stopped prematurely before recruiting the target number of patients 
(n = 440) due to increased incidence of acute kidney injury in the 
combination therapy arm and, therefore, the results should be inter­
preted with caution.
Other alternatives include fosfomycin plus imipenem,336 ceftaroline,337
quinupristin–dalfopristin with or without beta-lactams,338,339 beta-lactams 
plus oxazolidinones (linezolid),340 beta-lactams plus vancomycin,341 and 
high doses of trimethoprim/sulfamethoxazole and clindamycin.342,343
These clinical and therapeutic scenarios warrant collaborative manage­
ment with the Endocarditis Team including an infectious disease specialist, 
since the evidence is based on very small populations.
Recommendation Table 8 — Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus 
spp.
Recommendations
Classa
Levelb
IE caused by methicillin-susceptible staphylococci
In patients with NVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin is recommended for 4–6 weeks using 
the following doses:264,314,316–318
I
B
Adult antibiotic dosage and route
(Flu)cloxacillinc
12 g/day i.v. in 4–6 doses
Cefazoline
6 g/day i.v. in 3 doses
Paediatric antibiotic dosage and route
(Flu)cloxacillinc
200–300 mg/kg/day i.v. in 4–6 equally divided doses
Cefazoline
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
In patients with PVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin with rifampin for at least 6 weeks and 
gentamicin for 2 weeks is recommended using the following doses:264,314,316–318,320
I
B
Adult antibiotic dosage and route
(Flu)cloxacillinc
12 g/day i.v. in 4–6 doses
Cefazolin
6 g/day i.v. in 3 doses
Rifampin
900 mg/day i.v. or orally in 3 equally divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
(Flu)cloxacillinc
200–300 mg/kg/day i.v. in 4–6 equally divided doses
Cefazolin
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Allergy to beta-lactams
In patients with NVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin for 4–6 weeks is 
recommended using the following doses:322–327
I
B
Adult antibiotic dosage and route
Cefazoline
6 g/day i.v. in 3 doses
Paediatric antibiotic dosage and route
Cefazoline
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
In patients with PVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin combined with rifampin for 
at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:344
I
B
Adult antibiotic dosage and route
Cefazoline
6 g/day i.v. in 3 doses
Rifampin
900 mg/day i.v. or orally in 3 equally divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
Cefazoline
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Continued


<!-- PAGE 34 -->

### Page 34

In patients with NVE due to methicillin-susceptible staphylococci who are allergic to penicillin, daptomycin combined with 
ceftaroline or fosfomycin may be considered.322–327
IIb
C
Adult antibiotic dosage and route
Daptomycin
10 mg/kg/day i.v. in 1 dose
Ceftarolinef 
OR 
Fosfomycing
1800 mg/day i.v. in 3 doses 
OR 
8–12 g/day i.v. in 4 doses
In patients with PVE due to methicillin-susceptible staphylococci who are allergic to penicillin, daptomycin combined with 
ceftaroline or fosfomycin or gentamicin with rifampin for at least 6 weeks and gentamicin for 2 weeks may be considered using the 
following doses:344
IIb
C
Adult antibiotic dosage and route
Daptomycin
10 mg/kg/day i.v. in 1 dose
Ceftarolinef 
OR 
Fosfomycing
1800 mg/day i.v. in 3 doses 
OR 
8–12 g/day i.v. in 4 doses
Rifampin
900 mg/day i.v. or orally in 3 equally divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
IE caused by methicillin-resistant staphylococci
In patients with NVE due to methicillin-resistant staphylococci, vancomycin is recommended for 4–6 weeks using the following 
doses:345
I
B
Adult antibiotic dosage and route
Vancomycinh
30–60 mg/kg/day i.v. in 2–3 doses
Paediatric antibiotic dosage and route
Vancomycinh
30 mg/kg/day i.v. in 2–3 equally divided doses
In patients with PVE due to methicillin-resistant staphylococci, vancomycin with rifampin for at least 6 weeks and gentamicin for 
2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Vancomycinh
30–60 mg/kg/day i.v. in 2–3 doses
Rifampin
900–1200 mg/day i.v. or orally in 2 or 3 divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
Vancomycinh
30 mg/kg/day i.v. in 2–3 equally divided doses
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
In patients with NVE due to methicillin-resistant staphylococci, daptomycin combined with cloxacillin, ceftaroline or fosfomycin may 
be considered using the following doses:335,345–349
IIb
C
Adult antibiotic dosage and route
Daptomycin
10 mg/kg/day i.v. in 1 dose
Cloxacillinc 
OR 
Ceftarolinef 
OR 
Fosfomycing
12 g/day i.v. in 6 doses 
OR 
1800 mg/day i.v. in 3 doses 
OR 
8–12 g/day i.v. in 4 doses
© ESC 2023
IE, infective endocarditis; i.m., intramuscular; i.v., intravenous; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; U, units. 
aClass of recommendation. 
bLevel of evidence. 
cCloxacillin is not recommended if the patient has penicillin allergy. 
dMaximum doses 240 mg/day. High doses are associated with increased risk of nephrotoxicity. Renal function and serum gentamicin concentrations should be monitored once a week. When 
given in a single daily dose, pre-dose (trough) concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum concentrations should be ∼10–12 mg/L. 
eCefazolin can replace cloxacillin only in patients with non–immediate-type hypersensitivity reactions to penicillin. 
fHigh doses of ceftaroline may be associated with risk of leucopaenia after 2 weeks. Ceftaroline can replace cloxacillin only in patients with non–immediate-type hypersensitivity reactions to 
penicillin. 
gIn patients with heart failure, the high load of sodium associated with the use of fosfomycin can lead to acute heart failure. 
hSerum vancomycin concentrations should achieve 10–15 mg/L at pre-dose (trough) level, although some experts recommend to increase the dose of vancomycin to 45–60 mg/kg/day i.v. in 2 
or 3 divided doses to reach serum trough vancomycin levels (Cmin) of 15–20 mg/L as in staphylococcal endocarditis. However, vancomycin dose should not exceed 2 g/d unless serum levels 
are monitored and can be adjusted to obtain a peak plasma concentration of 30–45 μg/mL 1 h after completion of the i.v. infusion of the antibiotic.
ESC Guidelines                                                                                                                                                                                          3981


<!-- PAGE 35 -->

### Page 35

7.8. Enterococcus spp.
Enterococcal IE is primarily caused by E. faecalis (90% of cases) and less 
often by Enterococcus faecium (5% of cases), or other species.350
Enterococcal IE poses two major problems. First, enterococci are highly 
resistant to antibiotic-induced killing, and eradication requires pro­
longed administration (up to 6 weeks) of synergistic bactericidal com­
binations of two cell wall inhibitors (ampicillin plus ceftriaxone, which 
synergize by inhibiting complementary PBPs), or one cell wall inhibitor 
with aminoglycosides.351–353 Second, they may be resistant to multiple 
drugs, including aminoglycosides (HLAR), beta-lactams (via PBP 5 modi­
fication and sometimes beta-lactamases), and vancomycin.351–357
Penicillin-susceptible strains are treated with penicillin G or ampicillin 
(or amoxicillin) combined with gentamicin. However, ampicillin (or 
amoxicillin) is preferred since the MIC is two to four times lower than 
that of penicillin G. Gentamicin resistance is frequent in both E. faecalis 
and E. faecium (up to 75%).358,359 An aminoglycoside MIC >128 mg/L 
(HLAR) is associated with the loss of bactericidal synergism with cell 
wall inhibitors, and aminoglycosides should not be used in such conditions.
There have been two important advances in recent years. First, in sev­
eral cohort studies of E. faecalis IE including hundreds of cases, it was ob­
served that ampicillin plus ceftriaxone is as effective as ampicillin plus 
gentamicin for non-HLAR E. faecalis IE. The combination of ampicillin 
plus ceftriaxone was also associated with a beneficial safety profile, 
due to the lack of nephrotoxicity.355,360,361 Therefore, this is the com­
bination of choice for treating NVE and PVE caused by HLAR E. faecalis. 
This double beta-lactam therapy is not effective against E. faecium and 
the experience in the treatment of other enterococcal species is very 
limited. Second, the total daily dose of gentamicin can be given in a single 
daily dose instead of the 2 or 3 divided doses previously recommended, 
and the length of the treatment with gentamicin for non-HLAR E. faeca­
lis IE may be safely shortened from 4–6 weeks to 2 weeks, reducing the 
rates of nephrotoxicity to very low levels.266,362,363 After 10–14 days of 
therapy, OPAT or outpatient oral antibiotic therapy should be consid­
ered if the patient is clinically stable (see Section 7.13).364–367
Beta-lactam or vancomycin resistance is mainly observed in E. fae­
cium. Since dual resistance is rare, beta-lactam might be used against 
vancomycin-resistant strains and vice versa. Varying results have been 
reported with quinupristin–dalfopristin (not active against E. faecalis), 
linezolid, 
daptomycin, 
teicoplanin, 
and 
tigecycline.353,365,368
Daptomycin 10–12 mg/kg/24 h, always combined with beta-lactams 
(ampicillin, ertapenem, or ceftaroline) or fosfomycin in order to 
prevent the development of daptomycin resistance, is the best 
option for treating multidrug- and vancomycin-resistant enterococcal 
IE.369
Recommendation Table 9 — Recommendations for antibiotic treatment of infective endocarditis due to Enterococcus spp.
Recommendations
Classa
Levelb
Beta-lactam and gentamicin-susceptible strains
In patients with NVE due to non-HLAR Enterococcus spp., the combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks 
or with gentamicin for 2 weeks is recommended using the following doses:355,360,361
I
B
Adult antibiotic dosage and route
Amoxicillin
12 g/day i.v. in 4–6 doses
Ampicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. in 2 doses
Gentamicinc
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. in 2 doses
Gentamicinc
3 mg/kg/day i.v. or i.m. in 3 equally divided doses
In patients with PVE and patients with complicated NVE or >3 months of symptoms due to non-HLAR Enterococcus spp., the 
combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks or with gentamicin for 2 weeks is recommended using the 
following doses:355,360,361
I
B
Adult antibiotic dosage and route
Amoxicillin
12 g/day i.v. in 4–6 doses
Ampicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. in 2 doses
Gentamicinc
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg/day i.v. in 2 doses
Gentamicinc
3 mg/kg/day i.v. or i.m. in 3 equally divided doses
Continued


<!-- PAGE 36 -->

### Page 36

7.9. Gram-negative bacteria
7.9.1. Haemophilus, Aggregatibacter, Cardiobacterium, 
Eikenella, and Kingella-related species
Haemophilus, Aggregatibacter (previously Actinobacillus), Cardiobacterium, 
Eikenella, and Kingella (HACEK) Gram-negative bacilli are fastidious organ­
isms that require special investigations when they are the suspected cause 
of IE (see also Section 5). Because they grow slowly, standard MIC tests may 
be difficult to interpret. Some HACEK group bacilli produce beta- 
lactamases, and therefore ampicillin is no longer the first-line option. 
Conversely, they are susceptible to ceftriaxone, other third-generation ce­
phalosporins, and fluoroquinolones. The standard treatment is ceftriaxone 
2 g/day for 4 weeks in NVE and for 6 weeks in PVE. If they do not produce 
beta-lactamase, ampicillin (12 g/day i.v. in 4 or 6 doses) for 4–6 weeks plus 
gentamicin (3 mg/kg/day divided into 2 or 3 doses) for 2 weeks is an 
High-level aminoglycoside resistanced
In patients with NVE or PVE due to HLAR Enterococcus spp., the combination of ampicillin or amoxicillin and ceftriaxone for 6 weeks 
is recommended using the following doses:355,360,361
I
B
Adult antibiotic dosage and route
Ampicillin
12 g/day i.v. in 4–6 doses
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. or i.m. in 2 doses
Paediatric antibiotic dosage and route
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. or i.m. in 2 doses
Beta-lactam resistant Enterococcus spp. (E. faecium)e
In patients with IE due to beta-lactam resistant Enterococcus spp. (E. faecium), vancomycin for 6 weeks combined with gentamicin for 
2 weeks is recommended using the following doses:358,359,369
I
C
Adult antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2–3 equally divided doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Vancomycin-resistant Enterococcus spp.f
In patients with IE due to vancomycin-resistant Enterococcus spp., daptomycin combined with beta-lactams (ampicillin, ertapenem, or 
ceftaroline) or fosfomycin is recommended using the following doses:369
I
C
Adult antibiotic dosage and route
Daptomycin
10–12 mg/kg/day i.v. in 1 dose
Ampicillin
12 g/day i.v. in 4–6 doses
Fosfomycin
12 g/day i.v. in 4 doses
Ceftaroline
1800 mg/day i.v. in 3 doses
Ertapenemg
2 g/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Daptomycin
10–12 mg/kg/day i.v. in 1 dose (age-adjusted)
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to a maximum of 12 g/day
Fosfomycin
2–3 g/day i.v. in 1 dose
Ceftaroline
24–36 mg/kg/day in 3 doses
Ertapenemg
1 g/day i.v. or i.m. in 1 dose [if younger than 12 years, 15 mg/kg/dose (to a maximum of 500 mg) twice daily]
© ESC 2023
HLAR, high-level aminoglycoside resistance; IE, Infective endocarditis; i.m., intramuscular; i.v., intravenous; NVE, native valve endocarditis; PBP, Penicillin-binding protein; PVE, prosthetic valve endocarditis. 
aClass of recommendation. 
bLevel of evidence. 
cMaximum doses 240 mg/day. High doses are associated with increased risk of nephrotoxicity. Renal function and serum gentamicin concentrations should be monitored once a week. When given in a single 
daily dose, pre-dose (trough) concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum concentrations should be ∼10–12 mg/L. 
dHigh-level resistance to gentamicin: if susceptible to streptomycin, replace gentamicin with streptomycin 15 mg/kg/day in two equally divided doses. 
eBeta-lactam resistance: (i) if due to beta-lactamase production, replace ampicillin with ampicillin–sulbactam or amoxicillin with amoxicillin–clavulanate; (ii) if due to PBP5 alteration, use vancomycin-based 
regimens. 
fMultiresistance to aminoglycosides, beta-lactams and vancomycin: suggested alternatives are (i) daptomycin 10 mg/kg/day plus either ampicillin 200 mg/kg/day i.v. in four to six doses, ertapenem (2 g/day i.v.), 
ceftaroline (600 mg/8 h i.v.), or fosfomycin (3 g/6 h i.v.); (ii) linezolid 2 × 600 mg/day i.v. or orally for ≥8 weeks (monitor haematological toxicity); (iii) quinupristin–dalfopristin 3 × 7.5 mg/kg/day for ≥8 weeks. 
Quinupristin–dalfopristin is not active against E. faecalis; (iv) for other combinations (daptomycin plus ertapenem or ceftaroline or fosfomycin), consult infectious disease specialists. 
gHigh doses of ertapenem are associated with seizures.
ESC Guidelines                                                                                                                                                                                          3983


<!-- PAGE 37 -->

### Page 37

option.370 Ciprofloxacin (400 mg every 8–12 h i.v. or 750 mg every 12 h 
orally) is a less well-validated alternative.370–373
7.9.2. Non-Haemophilus, Aggregatibacter, 
Cardiobacterium, Eikenella, and Kingella species
The ICE cohort reported non-HACEK Gram-negative bacteria in 49 of 
2761 (1.8%) IE cases.279,374 Recommended treatment is early surgery 
plus prolonged (6 weeks) therapy with bactericidal combinations of 
beta-lactams and aminoglycosides, sometimes with additional quino­
lones or cotrimoxazole.375,376 In vitro bactericidal tests and monitoring 
of serum antibiotic concentrations may be helpful. Because of their rar­
ity and severity, these conditions should be discussed by the 
Endocarditis Team.
7.10. Blood culture-negative infective 
endocarditis
The main causes of BCNIE are summarized in Section 5.3.2.377,378
Treatment options are summarized in Table 11.379–383 Treatment of 
Whipple’s IE remains highly empirical. Successes have been reported 
with long-term therapy (>1 year).384 In cases of CNS involvement, 
sulfadiazine 1.5 g/6 h orally must be added to doxycycline. An alterna­
tive therapy is ceftriaxone (2 g/24 h i.v.) for 2–4 weeks or penicillin G (2 
million U/4 h) and streptomycin (1 g/24 h) i.v. for 2–4 weeks followed 
by cotrimoxazole (800 mg/12 h) orally. Trimethoprim is not active 
against T. whipplei. Consultation with the Endocarditis Team, including 
an infectious disease specialist, is recommended.
7.11. Fungi
Fungi are most frequently observed in PVE and in IE affecting PWID or 
immunocompromised patients.386 Candida and Aspergillus spp. predom­
inate, the latter resulting in BCNIE.387,388 Mortality is very high (>50%), 
and treatment necessitates combined antifungal administration and with a 
low threshold for surgery.278,387,388 Antifungal therapy for Candida IE in­
cludes an echinocandin at high doses or liposomal amphotericin B (or other 
lipid formulations) with or without flucytosine. for Aspergillus IE, voricon­
azole is the drug of choice. Some experts recommend the addition of an 
echinocandin or amphotericin B.278,387–390 Suppressive long-term treat­
ment with oral azoles (fluconazole and voriconazole) is recommended, 
sometimes lifelong.278,388,389 Consultation with the Endocarditis Team in­
cluding an infectious disease specialist is recommended.
7.12. Empirical therapy
Treatment of IE should be started promptly. Three sets of blood cultures 
should be drawn at 30-minute intervals before initiation of antibiotics.391
The initial choice of empirical treatment depends on several 
considerations: 
(i) Previous antibiotic therapy.
(ii) IE in a native valve or a prosthesis (and if so, when surgery was per­
formed [early vs. late PVE]).
(iii) The place of the infection (community, nosocomial, or non- 
nosocomial healthcare-associated IE) and knowledge of the local 
epidemiology, especially for antibiotic resistance and specific genu­
ine culture-negative pathogens.
(iv) Cloxacillin/cefazolin administration is associated with lower mortality 
rates than other beta-lactams, including amoxicillin/clavulanic acid or 
ampicillin/sulbactam,392 and vancomycin for empirically treating 
MSSA bacteraemia/endocarditis.309,393 However, recently amoxicil­
lin/clavulanic acid or ampicillin/sulbactam might be an effective empir­
ical treatment for MSSA bacteraemia when de-escalated to cloxacillin 
or cefazolin within 96 h from the index blood culture.394
Native valve endocarditis and late PVE regimens should cover 
staphylococci, streptococci, and enterococci. If the patient was receiv­
ing antibiotic therapy, the empirical therapy should include different 
antibiotics. CoNS should be empirically covered in PVE but not in 
NVE. Early PVE or healthcare-associated IE regimens should cover 
methicillin-resistant 
staphylococci, 
enterococci 
and, 
ideally, 
non-HACEK Gram-negative pathogens. Once the pathogen is identi­
fied (usually within 24 h), the antibiotic treatment must be adapted 
to its antimicrobial susceptibility pattern. It should be emphasized 
that the empirical treatment should be changed to targeted therapy 
once the organism is identified within 24–48 h.
Table 11 Antibiotic treatment of blood culture- 
negative infective endocarditis
Pathogens
Proposed therapya
Treatment 
outcome
Brucella spp.
Doxycycline (200 mg/24 h) 
plus cotrimoxazole (960 mg/ 
12 h) plus rifampin (300– 
600 mg/24 h) for ≥3–6 
monthsb orally
Treatment success defined 
as an antibody titre <1:60. 
Some authors recommend 
adding gentamicin for the 
first 3 weeks
C. burnetii (Q 
fever agent)
Doxycycline (200 mg/24 h) 
plus hydroxychloroquine (200– 
600 mg/24 h)c orally (>18 
months of treatment)
Treatment success defined 
as anti-phase I IgG titre 
<1:400, and IgA and IgM 
titres <1:50
Bartonella spp.d
Doxycycline 100 mg/12 h 
orally for 4 weeks plus 
gentamicin (3 mg/24 h) i.v. for 2 
weeks
Treatment success 
expected in ≥90%
Legionella spp.
Levofloxacin (500 mg/12 h) i.v. 
or orally for ≥6 weeks or 
clarithromycin (500 mg/12 h) 
i.v. for 2 weeks, then orally for 4 
weeks plus rifampin (300– 
1200 mg/24 h)
Optimal treatment 
unknown
Mycoplasma spp.
Levofloxacin (500 mg/12 h) i.v. 
or orally for ≥6 monthse
Optimal treatment 
unknown
T. whipplei 
(Whipple’s 
disease agent)f
Doxycycline (200 mg/24 h) 
plus hydroxychloroquine (200– 
600 mg/24 h)c orally for ≥18 
months
Long-term treatment, 
optimal duration unknown
© ESC 2023
IE, infective endocarditis; Ig, immunoglobulin; i.v., intravenous. 
Adapted from Brouqui et al.383
aOwing to the lack of large series, the optimal duration of treatment of IE due to these 
pathogens is unknown. The presented durations are based on selected case reports. 
Consultation with an infectious disease specialist is recommended. 
bAddition of streptomycin (15 mg/kg/24 h in 2 doses) for the first few weeks is optional. 
cDoxycycline plus hydroxychloroquine (with monitoring of serum hydroxychloroquine 
levels) is significantly superior to doxycycline.385
dSeveral therapeutic regimens have been reported, including ampicillin or amoxicillin, (12 g/ 
24 h i.v.) or cephalosporins (ceftriaxone 2 g/24 h i.v.) combined with aminoglycosides 
(gentamicin or netilmicin).381 Dosages are as for streptococcal and enterococcal IE.379,380
eNewer fluoroquinolones (levofloxacin, moxifloxacin) are more potent than ciprofloxacin 
against intracellular pathogens such as Mycoplasma spp., Legionella spp., and Chlamydia spp. 
fTreatment of Whipple’s IE remains highly empirical. In the case of central nervous system 
involvement, sulfadiazine 1.5 g/6 h orally must be added to doxycycline. An alternative 
therapy is ceftriaxone (2 g/24 h i.v.) for 2–4 weeks or penicillin G (2 million U/4 h) and 
streptomycin (1 g/24 h) i.v. for 2–4 weeks followed by cotrimoxazole (800 mg/12 h) 
orally. Trimethoprim is not active against T. whipplei. Successes have been reported with 
long-term therapy (1 year).


<!-- PAGE 38 -->

### Page 38

7.13. Outpatient parenteral or oral 
antibiotic therapy for infective 
endocarditis
Outpatient parenteral antibiotic treatment or step-down outpatient oral 
antibiotic treatment is used to consolidate antimicrobial therapy once crit­
ical infection-related complications are under control (e.g. perivalvular ab­
scesses, acute HF, septic emboli, and stroke) and the patient is clinically 
stable.43,396–399 When feasible, early hospital discharge and OPAT helps 
to alleviate the effects of infection and prolonged hospitalization especially 
in the elderly.400 In the initial phase of IE treatment, standard i.v. treatment 
is administered according to recommendations for specific microorgan­
isms. Once the clinical condition of the patient is stable, OPAT or step- 
down outpatient oral antibiotic treatment is a safe alternative to in-hospital 
i.v. treatment in selected patients.43,399 Patients may reach such stability at 
various points in their disease course but, when criteria for stability are 
reached, the patient may then be switched to OPAT or alternatively to 
an oral therapy at hospital discharge. The OPAT regime consists of the 
same antibiotic combinations administered in the acute phase if possible. 
The 5-year outcomes from the POET trial showed continued effectiveness 
of oral antibiotic therapy as compared with i.v. antibiotic therapy for IE in 
selected patients.401 Hence, clinical stability will then differentiate IE 
courses into two phases: 
(i) Critical phase where at least 10 days of i.v. treatment is required: at 
this time point, OPAT has a restricted indication.
(ii) Continuation phase (beyond 10 days of therapy and 7 days 
post-surgery), where OPAT/step-down oral therapy may be feasible.
Supplementary data online, Table S8 summarizes the salient ques­
tions to address when considering OPAT/step-down oral therapy for IE.
Recommendation Table 10 — Recommendations for 
antibiotic regimens for initial empirical treatment of 
infective endocarditis (before pathogen identification)a
Recommendations
Classb
Levelc
In patients with community-acquired NVE or late 
PVE (≥12 months post-surgery), ampicillin in 
combination with ceftriaxone or with (flu)cloxacillin 
and gentamicin should be considered using the 
following doses:255
IIa
C
Adult antibiotic dosage and route
Ampicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. or i.m. in 2 doses
(Flu)cloxacillin
12 g/day i.v. in 4–6 doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Ampicillin
200–300 mg/kg/day i.v. in 4–6 
doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. or i.m. in 1 dose
(Flu)cloxacillin
200–300 mg/kg/day i.v. in 4–6 
equally divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 3 equally 
divided doses
In patients with early PVE (<12 months 
post-surgery) or nosocomial and non-nosocomial 
healthcare-associated IE, vancomycin or daptomycin 
combined with gentamicin and rifampin may be 
considered using the following doses:395
IIb
C
Adult antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 doses
Daptomycin
10 mg/kg/day i.v. in 1 dose
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dose
Rifampin
900–1200 mg i.v. or orally in 2 or 
3 doses
Paediatric antibiotic dosage and route
Vancomycine
40 mg/kg/day i.v. in 2–3 equally 
divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 3 equally 
divided doses
Rifampin
20 mg/kg/day i.v. or orally in 3 
equally divided doses up to 
maximum of 900 mg/day
Allergy to beta-lactams
In patients with community-acquired NVE or late 
PVE (≥12 months post-surgery) who are allergic to 
penicillin, cefazolin, or vancomycin in combination 
with gentamicin may be considered using the 
following doses:
IIb
C
Adult antibiotic dosage and route
Cefazolin
6 g/day i.v. in 3 doses
Vancomycine
30 mg/kg/day i.v. in 2 doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dose
Continued
Paediatric antibiotic dosage and route
Cefazolin
100 mg/kg/d i.v. in 3–4 doses, up 
to maximum of 6 g/day
Vancomycine
40 mg/kg/day i.v. in 2–3 equally 
divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 3 equally 
divided doses
© ESC 2023
BCNIE, blood culture-negative infective endocarditis; IE, infective endocarditis; i.m., 
intramuscular; i.v., intravenous; NVE, native valve endocarditis; PVE, prosthetic valve 
endocarditis. 
aIf initial blood cultures are negative and there is no clinical response, BCNIE aetiology (see 
Section 7.10) and the extension of the antibiotic spectrum to blood culture-negative 
pathogens should be considered. If cardiac surgery is indicated, molecular diagnosis can 
be performed. 
bClass of recommendation. 
cLevel of evidence. 
dMaximum doses 240 mg/day. High doses are associated with increased risk of 
nephrotoxicity. Renal function and serum gentamicin concentrations should be 
monitored once a week. When given in a single daily dose, pre-dose (trough) 
concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum 
concentrations should be ∼10–12 mg/L. 
eSerum vancomycin concentrations should achieve 10–15 mg/L at pre-dose (trough) 
level, although some experts recommend to increase the dose of vancomycin to 
45–60 mg/kg/day i.v. in 2 or 3 divided doses to reach serum trough vancomycin levels 
(Cmin) of 15–20 mg/L as in staphylococcal endocarditis. However, vancomycin dose 
should not exceed 2 g/d unless serum levels are monitored and can be adjusted to 
obtain a peak plasma concentration of 30–45 μg/mL 1 h after completion of the i.v. 
infusion of the antibiotic.
ESC Guidelines                                                                                                                                                                                          3985


<!-- PAGE 39 -->

### Page 39

In addition to the patient being medically stable, general considerations 
for suitability for OPAT include assessment of the patient’s home environ­
ment and self-care capabilities. Adherence to treatment and follow-up vis­
its are also crucial for a beneficial outcome of outpatient treatment and the 
healthcare provider–patient relationship is important for ensuring proper 
and continued treatment and maintenance of infection control.
7.13.1. Parenteral and oral step-down antibiotic 
treatment
Stability criteria are essential and timing in the clinical planning the pa­
tient’s course, especially TOE, becomes key (Figure 9). Stability criteria 
include blood samples, clinical parameters, and TOE.43
OPAT has been shown to be a safe treatment in IE for stable patients 
who are suitable for home treatment.
The patient, and preferably also a caregiver, should be educated care­
fully in the disease and how to monitor/observe for signs of infection, 
including daily temperature and other signs of disease progression or 
complications. In addition, regular post-discharge evaluation is required 
(nurse once per day, responsible physician 1–3 times per week). For pa­
tients receiving OPAT, regular i.v. catheter inspection and care by a 
healthcare professional should be provided. If the patient is not suffi­
ciently able to self-monitor, and has no close caregivers, added surveil­
lance is required by involved staff and home treatment should generally 
be carefully considered in such cases.
Certain combinations of two oral antibiotics should be used for oral 
step-down treatment (see Supplementary data online, Table S9).
7.13.2. Other considerations for outpatient oral or 
parenteral antimicrobial therapy
In the OPAT programme, patients continue with the same antibiotics 
that are administered in the acute phase in once-daily regimens, or 
with infusion pumps if antibiotics should be administered intermittently, 
N
N
N
N
Definite infective endocarditis
Y
Y
Y
Y
Patient not suitable for oral antibiotic treatment
The patient may be shifted from i.v. to oral antibiotics (two-drug strategy)
Blood cultures with either
S. aureus, streptococci, CoNS, or E. faecalis
Other indication for continued i.v. antibiotics?
or BMI >40 or faulty gastrointestinal uptake
Perform TOE:
New surgical indication?
Infection control?
Satisfying response to treatment: no fever >2 days,
CRP <25% of max measured value or <20 mg/L
and leukocytes <15 x 109/L
Treated with relevant i.v. antibiotics ≥10 days and ≥7 days after valve surgery
Continue i.v. antibiotics
Figure 9 Flowchart to assess clinical stability based on the Partial Oral Treatment of Endocarditis trial. BMI, body mass index; CoNS, coagulase-negative 
staphylococci; CRP, C-reactive protein; i.v., intravenous; TOE, transoesophageal echocardiography. Adapted with permission from Iversen et al.43


<!-- PAGE 40 -->

### Page 40

or in continuous infusion. Dalbavancin is a glycopeptide antibiotic with a 
very long half-life that can be administered weekly. There is previous 
positive experience in sensitive Gram-positive IE, although the most ef­
fective administration schedule is not clear.274,402 The recommended 
prescription is 1.5 g as a loading dose followed by 0.5–1 g weekly until 
completing 6 weeks of antibiotic treatment.
Although the evidence is weak, another option (in addition to the 
combinations listed in the Supplementary data online, Table S9) for 
staphylococcal IE is the combination of i.v. cotrimoxazole (sulfameth­
oxazole 4800 mg/day and trimethoprim 960 mg/day in 4–6 doses) 
plus i.v. clindamycin (1800 mg/day in 3 doses) during the first week fol­
lowed by only oral cotrimoxazole for 5 weeks.343
8. Indications for surgery and 
management of main infective 
endocarditis complications
Infective endocarditis is associated with certain risks and complications 
that can only be controlled with surgical intervention. Despite the risks 
of surgery in these patients, current evidence suggests that surgical 
treatment may generate a survival advantage of up to 20% in the first 
year.403,404 There are three main reasons to undergo surgery in the set­
ting of acute IE: HF, uncontrolled infection, and prevention of septic 
embolization (in particular, to the CNS) (Figure 10).
A significant proportion of surgical procedures for IE are performed 
on an urgent basis. The Task Force has defined urgent surgery as that 
requiring intervention within 3–5 days, although unnecessary delays 
should be avoided once the indication for urgent surgery is established. 
Some cases require emergency surgery (within 24 h), irrespective of 
the pre-operative duration of antibiotic treatment. A third group re­
quires surgery non-urgently, i.e. within the same hospital admission. 
In cases where the infective component can be completely healed 
with antibiotic treatment alone, both timing and indications for treat­
ment of residual valve dysfunction follow the conventional guidelines 
for valve treatment.128
8.1. Pre-operative risk assessment
The risk of surgical therapy during the active phase of IE can be signifi­
cant. It is heavily influenced by pre-existing co-morbidities and current 
organ function, but should not be limited by one risk factor alone (e.g. 
age or liver function).405,406 The decision to operate should therefore 
be made by the Endocarditis Team (see Section 4),167 considering ur­
gency of the patient’s clinical condition, peri-operative risk, the poten­
tial to recover from the infection, and the patient’s associated 
long-term prognosis.403,404
There are several scoring systems that predict mortality after general 
(i.e. non-IE) cardiac surgery and which are in routine clinical use.407,408
Other scoring systems were designed specifically for the setting of IE in­
cluding the AEPEI (Association for the Study and Prevention of Infective 
Endocarditis Study) score, the STS (Society of Thoracic Surgeons) IE score, 
the PALSUSE (prosthetic valve, age ≥70, large intracardiac destruction, 
Staphylococcus spp., urgent surgery, sex [female], EuroSCORE ≥10) score, 
the de Feo score, and the ANCLA (anaemia, NYHA [New York Heart 
Association] class IV, critical state, large intracardiac destruction, surgery 
of thoracic aorta) score, among others.256,409–414 Some of these scoring 
systems are web-based and free of charge (e.g. the AEPEI risk calculator 
https://www.endocardite.org/index.php/calculateurs/score-de- 
mortalite-post-chirurgie-aepei). Such scoring systems have been devel­
oped based on retrospective data and their performance is vari­
able.250,256,415–417 In addition, none of these scoring systems are used in 
daily clinical routine. Therefore, prospective surgical scoring systems 
with better precision need to be developed, particularly for determining 
operative futility in prohibitively high-risk patients.
A significant proportion of patients with clear indications for surgery 
for IE may have multiple risk factors or other reasons that lead to sur­
gery not being performed, and these patients have the worst progno­
sis.184,403 Conversely, high-risk but salvageable patients may not be 
offered life-saving operations on the basis of perceived unacceptable 
risk, and this is especially true in the elderly (see Section 12.2). The com­
plex decision of not offering surgery when indicated should therefore 
be made in the setting of an Endocarditis Team with experienced sur­
gical input.418 Determining when operative management for a specific 
patient is futile requires compassionate multidisciplinary insight along 
with consideration of the patient’s and family’s wills (see Section 13.2).
8.2. Heart failure
8.2.1. Heart failure in infective endocarditis
Heart failure is the most frequent complication of IE and the main indi­
cation for urgent and emergency surgery for IE.419 The prevalence of 
HF with left-sided IE is variable and inconsistently defined between re­
ported series, ranging between 19% and 73%.420–425 Clinical symptoms 
Recommendation Table 11 — Recommendations for 
outpatient antibiotic treatment of infective endocarditis
Recommendations
Classa
Levelb
Outpatient parenteral or oral antibiotic treatment 
should be considered in patients with left-sided IE 
caused by Streptococcus spp., E. faecalis, S. aureus, or 
CoNS who were receiving appropriate i.v. antibiotic 
treatment for at least 10 days (or at least 7 days after 
cardiac surgery), are clinically stable, and who do not 
show signs of abscess formation or valve 
abnormalities requiring surgery on TOE.43,401
IIa
A
Outpatient parenteral antibiotic treatment is not 
recommended in patients with IE caused by highly 
difficult-to-treat microorganisms,c liver cirrhosis 
(Child-Pugh B or C), severe cerebral nervous system 
emboli, untreated large extracardiac abscesses, heart 
valve complications, or other severe conditions 
requiring surgery, severe post-surgical complications, 
and PWID-related IE.
III
C
© ESC 2023
CoNS, coagulase-negative staphylococci; IE, infective endocarditis; i.v., intravenous; TOE, 
transoesophageal echocardiography; PWID, people who inject drugs. 
aClass of recommendation. 
bLevel of evidence. 
cHighly difficult-to-treat microorganism: microorganisms requiring i.v. antibiotic 
combinations that cannot be administered by means of outpatient parenteral antibiotic 
treatment or that require strict monitoring of drug levels either in blood or in other 
fluids owing to their potential toxicity or narrow therapeutic index (e.g. MRSA or 
vancomycin-resistant enterococci also resistant to alternative drugs such as daptomycin 
and linezolid, multidrug- or extensively drug-resistant Gram-negative rods, highly 
penicillin-resistant oral streptococci, fungi other than Candida).
ESC Guidelines                                                                                                                                                                                          3987


<!-- PAGE 41 -->

### Page 41

Heart failure
Emergency surgery
(Class I)
Uncontrolled infection
High risk of embolism or established embolism
Cardiogenic shock or pulmonary oedema
Local complications
(abscess, false aneurysm,
fistula, enlarging vegetation)
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Poor haemodynamic tolerance
Persistent positive blood culturesa
Vegetation ≥10 mm and other reason for surgeryb
N
Non-urgent surgery
(Class I)
N
N
Resistant bacteriac or fungi
N
N
Vegetation ≥10 mm and no evidence of embolus
N
Antibiotic therapy and continued observation
N
Surgical timing for patient with left-sided infective endocarditis
Y
Urgent surgery
(Class I)
Y
Urgent surgery
(Class I)
Y
Urgent surgery
(Class I)
Y
Urgent surgery
(Class IIa)
Y
Urgent or non-urgent surgery
(Class I)d
Y
PVE caused by S. aureus or non-HACEK
Gram-negative bacilli
N
Non-urgent surgery
(Class I)
N
Urgent surgery
(Class IIa)
Y
Urgent surgery
(Class I)
Y
Urgent surgery
(Class IIb)
Y
Figure 10 Proposed surgical timing for infective endocarditis. HACEK, Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, and Kingella; PVE, prosthet­
ic valve endocarditis. Surgery timing: emergency, within 24 h. Urgent, within 3–5 days. Non-urgent, within same hospital admission. aDespite appropriate 
antibiotic therapy for >1 week and control of septic embolic foci. bE.g. patients with significant valvular dysfunction that is, or is not, a direct result of endo­
carditis process. cS. aureus (methicillin resistant and non-methicillin resistant), vancomycin-resistant enterococci, non-HACEK Gram-negative bacteria and 
fungi. dUrgent for S. aureus, non-urgent for others.


<!-- PAGE 42 -->

### Page 42

are mainly caused by congestion and may vary from mild dyspnoea to 
severe and rapidly worsening dyspnoea, orthopnoea, pulmonary oe­
dema, and cardiogenic shock. Factors associated with increased risk 
of HF complicating the course of IE include older age, presence of 
NVE with aortic valve involvement, and high comorbidity.420–425
Leaflet perforation and rupture, as well as mitral chordal rupture, 
lead to new severe valvular regurgitation or worsening of pre-existent 
valvular regurgitation and subsequent acute HF. Other less common 
causes of HF include intracardiac fistulae, interference of the vegetation 
mass with leaflet opening and closure, or myocardial infarction from ve­
getations embolizing into the coronary arteries. Patients with right- 
sided IE complicated by HF present with symptoms of right heart con­
gestion, as discussed in Section 12.6.
New-onset HF is the predominant clinical presentation in IE patients, 
whereas worsening of pre-existing HF is less frequent. Cardiogenic 
shock can be the first presentation in up to 5% of cases, of which half 
of such patients develop cardiogenic shock within 72 h of admission 
for IE.424 On imaging tests, patients with IE complicated by HF present 
more frequently with lower left ventricular ejection fraction, larger 
vegetation size, perivalvular abscesses, pseudoaneurysms, and valvular 
regurgitation secondary to leaflet perforation or rupture.420–425
Heart failure complicating IE is independently associated with poor 
in-hospital and 1-year survival, and surgical treatment is the only effect­
ive treatment that is associated with improved survival.420,421,424,426–430
Even though in-hospital mortality rates increase with the severity of HF 
presentation, the survival benefit of surgical treatment vs. medical ther­
apy is more pronounced among patients with NYHA functional class 
III–IV symptoms.420 TTE provides important information on the sever­
ity of the haemodynamic consequences of valve dysfunction. New on­
set of elevated filling pressures, pulmonary hypertension, and/or 
pericardial effusion may lead to urgent or emergency recommendation 
for surgery.163 Biomarkers such as B-type natriuretic peptide and 
troponin have been associated with poor prognosis in IE.431,432
Patients who are discharged after treatment of IE require subsequent 
follow-up (see Section 11). Heart failure is more likely to develop during 
follow-up in IE patients who are discharged with valvular regurgitation 
than in those without regurgitation, particularly if mitral regurgitation is 
present.433
8.2.2. Indications and timing of surgery in the 
presence of heart failure in infective endocarditis
Timing of surgical intervention in patients with IE (Figure 10) compli­
cated by HF should be decided by the Endocarditis Team, although sur­
gery should not be delayed by Endocarditis Team discussions in patients 
requiring emergency operations. The presence of HF leads to recom­
mendation for surgery in the majority of patients and is the principal in­
dication for urgent surgery in IE patients.429,434 Emergency surgery 
should be performed in patients with new-onset NYHA class IV HF 
symptoms, pulmonary oedema, and/or cardiogenic shock, irrespective 
of the status of infection or length of antibiotic treatment and when 
considered non-futile intervention. Urgent surgery is indicated in pa­
tients with milder forms of HF (NYHA class II–III) and severe valve re­
gurgitation or echocardiographic signs of haemodynamic compromise 
(elevated end-diastolic left ventricular pressure, high left atrial pressure, 
or moderate and severe pulmonary hypertension), or large vegetations. 
In patients without haemodynamic compromise, i.v. antibiotic therapy 
and strict clinical and echocardiographic observation are first indicated, 
and surgery can be temporarily delayed. However, it should be 
emphasized that early surgery is a good option for patients with surgical 
indications and low risk of surgery.403,404
8.3. Uncontrolled infection
Uncontrolled infection is one of the most common complications of IE 
and is the second most frequent indication for surgery.5 Uncontrolled 
infection is considered to be present when there is: (i) persistent infec­
tion or sepsis despite antibiotic therapy; (ii) signs of local infection that 
do not respond to antibiotic therapy; or (iii) infection with resistant or 
very virulent organisms.
8.3.1. Septic shock and persistent infection
Septic shock, defined as vasopressor requirement to maintain a mean 
arterial pressure of 65 mmHg or greater and serum lactate level greater 
than 2 mmol/L in the absence of hypovolaemia,435 is a highly lethal com­
plication of IE and occurs in ∼5–10% of patients.425,436 Risk factors for 
septic shock include S. aureus and Gram-negative bacteria, persistent 
bacteraemia, nosocomial acquisition, acute renal failure, diabetes melli­
tus, CNS emboli, and large vegetations.147,436 Surgery is associated with 
a significant reduction in early and 1-year mortality for patients with IE 
and septic shock.425,436 Urgent surgery is therefore recommended in 
patients with IE and persistent sepsis or septic shock despite adequate 
antibiotic therapy, in which surgery is non-futile.
The definition of persistent infection is somewhat arbitrary and con­
sists of fever and persistent positive cultures after 7 days of appropriate 
antibiotic treatment. It has been demonstrated that persistent blood 
cultures 48–72 h after initiation of antibiotics are an independent risk 
factor for hospital mortality.437 In many cases of persistent infection, 
antibiotics alone are insufficient to eradicate the infection. Surgery is 
therefore indicated for persistent infection when extracardiac ab­
scesses (splenic, vertebral, cerebral, or renal) and other potential causes 
of positive cultures and fever (infected lines and embolic complications) 
have been excluded. Persistent fever may also be caused as an adverse 
reaction to antibiotics.438
8.3.2. Locally uncontrolled infection
Signs of locally uncontrolled infection include increasing vegetation size, 
abscess formation, the creation of pseudoaneurysms and/or fistulae, 
and new atrioventricular block (AVB). The incidence of perivalvular ex­
tension ranges from 10% to 30% in NVE with higher incidences found in 
patients with PVE.5,439 Perivalvular complications and abscess forma­
tion are more frequent in aortic valve than mitral valve IE, and may 
be higher in patients with bicuspid vs. tricuspid aortic valves.440 In aortic 
valve IE, perivalvular extension occurs most frequently in the 
mitral-aortic intervalvular fibrosa,441 whereas perivalvular abscesses 
are usually located posteriorly or laterally in mitral valve IE.442
Persistent fever and infection, new AVB, chest pain, new heart murmur, 
recurrent embolism, or HF may indicate perivalvular extension. The 
diagnosis should be confirmed by TOE, which is more sensitive and spe­
cific than TTE.443 However, mitral annular calcification may obscure 
small regions of mitral perivalvular extension, particularly in the poster­
ior aspects of the mitral annulus. Cardiac CT has been shown to be an 
accurate alternative imaging procedure for the evaluation of perivalvu­
lar extension of infection, and PET/CT imaging may be particularly help­
ful in cases of PVE (see Section 5.4.4.
ESC Guidelines                                                                                                                                                                                          3989


<!-- PAGE 43 -->

### Page 43

##### 8.3.3 Indications and timing of surgery in the presence

of uncontrolled infection
Surgery should be considered for uncontrolled infection when antibiot­
ic therapy is ineffective and extracardiac sources are ruled out. Reports 
in the literature demonstrate that surgery for uncontrolled infection in 
IE has the potential to improve 1-year survival by 15–20%.403,429,444
8.3.3.1. Persistent infection
Uncontrolled infection is present in the form of persistent infection 
when blood cultures remain positive for >1 week or persistent sepsis 
despite appropriate antimicrobial therapy and when other causes of 
bacteraemia have been excluded. Not performing surgery for uncon­
trolled infection is associated with significantly increased mortality.444
8.3.3.2. Locally uncontrolled infection
Uncontrolled infection is also present if signs of local progression, i.e. 
increasing vegetation size or perivalvular involvement, are observed 
during follow-up imaging.5,420,421,445,446 Surgery should be performed 
urgently (within 3–5 days) in such cases. Rarely, when there are no 
other reasons for surgery and fever is easily controlled with antibiotics, 
small abscesses or pseudoaneurysms can be treated conservatively un­
der close clinical and echocardiographic follow-up.429,444
8.3.3.3. Infection with resistant or virulent organisms
Microorganisms causing endocarditis that are unlikely to be controlled 
with current antimicrobial therapy include fungi,447,448 multiresistant 
bacteria (e.g. MRSA or vancomycin-resistant enterococci) and, in rare 
cases, non-HACEK Gram-negative bacteria. S. aureus should also be in­
cluded in this group due to its fast progression and ability to cause local 
tissue destruction and abscess formation,5,449 specifically, if a favourable 
early response to antibiotics is not achieved.305,312,449 The presence of 
these organisms should lead to discussions within the Endocarditis 
Team and urgent surgery.385,450
8.4. Prevention of systemic embolism
8.4.1. Incidence of embolic events in infective 
endocarditis
Embolic events are frequent and potentially life-threatening complica­
tions of IE related to the migration of cardiac vegetations.451,452 The 
brain and spleen are the most frequent sites of embolism for left-sided 
IE, while pulmonary embolism is frequent in right-sided and pacemaker 
lead IE (see Section 12). Stroke may be the first clinical manifestation of 
IE, and is a severe complication that is associated with increased mor­
bidity and mortality.451,453,454 Embolic events may be clinically silent in 
up to 50% of patients with IE.198 Emboli affecting the splenic or cerebral 
circulation are frequently asymptomatic, and are diagnosed by non- 
invasive imaging.197,200 Although whole-body CT imaging (i.e. chest, 
abdomen, and pelvis) is frequently performed during the work-up for 
surgery, diagnosis and management of patients is infrequently altered 
as a result of these investigations.194 However, cerebral CT may affect 
clinical decision-making and outcomes when surgery is considered.452
Embolic risk in IE is high, with 20–50% of patients being af­
fected.452,455 The highest incidence of embolic strokes can be observed 
in the days around the initial diagnosis of IE,456 and embolic events are 
often what leads to the initial diagnosis of IE. Embolic risk is highest the 
day after therapy initiation, and is 10–20 times higher on the day before 
and after the start of antibiotic treatment compared with 2 weeks be­
fore and after.456 Thus, embolic events occurring after the initiation of 
antibiotic therapy continuously drop in incidence within the first 2 
weeks of antibiotic treatment.429,455–457 The benefits of surgery to pre­
vent embolism may therefore be greatest during the early stages of 
therapy, when embolic risk is at its highest.
8.4.2. Predicting the risk of embolism
Predicting the risks of embolization is important for decision-making in 
IE. Echocardiography plays a key role in identifying potentially embolic 
structures in the heart,429,455,456,458 although predicting the time point 
of embolization remains difficult. Several factors are associated with in­
creased risk of embolism including the size and mobility of vegeta­
tions,455,456,458–460 the location of the vegetation on the mitral 
valve,455 the increasing or decreasing size of the vegetation under anti­
biotic therapy,455 particular microorganisms (especially S. aureus,455
S. gallolyticus,461 and Candida spp.450), previous embolism,455 multivalv­
ular involvement,458 and biological markers.462 Among these, the size 
and mobility of the vegetations are the most important independent 
predictors of new embolic events.459,460,463 A recent study, however, 
demonstrated that vegetation size was predictive of worse outcomes 
only when present with other indications for surgery (i.e. HF or uncon­
trolled infection).464 Staphylococcal endocarditis is also a risk factor for 
embolization,465–468 which is particularly important because the inci­
dence of S. aureus IE is increasing.78,469 Risk of neurological complica­
tions is particularly high in patients with very large vegetations 
(>30 mm in length).451
Additional factors may need to be taken into account and it may be 
helpful to use an embolic risk calculator.470 S. aureus infection, previous 
embolism, vegetation length, age, diabetes, and the presence of atrial 
fibrillation have been identified as specific risk factors for embolism.470
8.4.3. Indications and timing of surgery to prevent 
embolism in infective endocarditis
Surgical removal of potentially embolic material from the heart may 
prevent new or additional embolic events. Given the imminent risk 
and high rates of embolization in patients with mobile and large vegeta­
tions,5,451,455–457,460,471 surgery should be considered urgently (within 
3–5 days) in such patients. A prospective randomized trial in young, 
low-risk patients assessed the effects of early surgery in patients with 
large vegetations and streptococcal IE.471 Although there was no differ­
ence in all-cause mortality at 6 months between the early surgery and 
conventional treatment groups, the risk of embolization was significant­
ly reduced with early surgery. Non-randomized observational analyses 
including patients at higher risk also suggest that early surgery may be 
beneficial in patients with a high likelihood of embolization,428,459,472,473
and that initial conservative treatment is associated with increased mor­
tality.474,475 However, prosthetic dehiscence has also been associated 
with early surgery in patients with S. aureus IE.429 Individualized 
decision-making is required to balance the risk of surgery, which is 
also influenced by pre-operative neurological events or other 
co-morbidities.5,453
The main indications and the timing of surgery to prevent embolism 
based on the currently available literature are given in Recommendation 
Table 12 and Figure 10.


<!-- PAGE 44 -->

### Page 44

### 9 Other complications of infective

endocarditis
9.1. Neurological complications
Neurological manifestations may occur before or after the diagnosis of 
IE is established and recurrent events can also take place later in the 
course of IE.451 The possibility of IE should be considered in patients 
who present with stroke, meningitis, or brain abscess. Unexplained fe­
ver accompanying a stroke in a patient with valvular disease should trig­
ger the suspicion of IE with blood cultures taken prior to empirical 
antibiotic therapy.
Symptomatic cerebrovascular complications occur in up to 35% of pa­
tients with IE,145,198,451,452 whereas silent cerebrovascular complications 
(including ischaemia and microhaemorrhage) occur in up to 80% of pa­
tients.200,204,403 Clinical presentation is variable, but ischaemic stroke and 
transient ischaemic attack are the most common presentations.479
Other manifestations include haemorrhage (intracerebral, subarachnoid), 
meningitis, brain abscess, encephalopathy, and infectious aneurysms. Focal 
neurological symptoms are present in ∼40% of affected patients, and non- 
focal presentations occur in approximately one-third.
S. aureus IE is more frequently associated with neurological compli­
cations compared with IE caused by other microorganisms. 
Vegetation size and mobility also correlate with embolic risk.
Neurological complications are associated with excess mortality, as 
well as long-term morbidity, particularly in the case of stroke.480
Prompt diagnosis of IE and early initiation of the antibiotic therapy are 
pivotal to preventing neurological complications. Early cardiac surgery 
in high-risk patients is key to preventing embolization of vegeta­
tions.471,481 In contrast, antithrombotic/thrombolytic medical therapies 
are not beneficial.481–483
Mechanical thrombectomy may be considered within time limits in 
selected cases.484 If mechanical thrombectomy is performed, the re­
trieved embolic material must be sent off for pathological and microbio­
logical 
analyses. 
Neurosurgery 
or 
endovascular 
therapy 
is 
recommended for large infective aneurysms, especially when a continu­
ous growth, despite optimal antibiotic therapy or ruptured intracranial 
infective aneurysms, is observed.485
The use of anticoagulation in patients with left-sided IE does not 
seem to have an effect on the risk of stroke, cerebrovascular haemor­
rhage, or mortality at 10 weeks and, therefore, continuation of 
anticoagulation in patients with left-sided IE and with a pre-existing in­
dication for the use of anticoagulants is recommended in the absence of 
other contraindications.486 Substitution from oral anticoagulation to 
heparin in such patients is generally preferred in case of cerebral bleed­
ing or indication for early surgery.
Following a neurological event, the indication for cardiac surgery must 
be balanced against the peri-operative risk and post-operative prognosis 
of the patient. Randomized studies are impractical and cohort studies suf­
fer from bias that can only be partially compensated for by statistical meth­
ods. The majority of publications demonstrate lower risk of secondary 
haemorrhagic conversion of uncomplicated ischaemic lesions than the 
risk of recurrent embolism under antibiotic treatment. Therefore, the 
available evidence supports early surgery in such patients (see Section 10.4).
Recommendation Table 13 summarizes the recommended manage­
ment of neurological complications in IE; considerations for cardiac sur­
gery after neurological complications are discussed in Section 10.4.
Recommendation Table 12 — Recommendations for 
the main indications of surgery in infective endocarditis 
(native 
valve 
endocarditis 
and 
prosthetic 
valve 
endocarditis)a
Recommendations
Classb
Levelc
(i) Heart failure
Emergencyd surgery is recommended in aortic or 
mitral NVE or PVE with severe acute regurgitation, 
obstruction, or fistula causing refractory pulmonary 
oedema or cardiogenic shock.420,423,424,429,476,477
I
B
Urgentd surgery is recommended in aortic or mitral 
NVE or PVE with severe acute regurgitation or 
obstruction causing symptoms of HF or 
echocardiographic signs of poor haemodynamic 
tolerance.5,420–422,429
I
B
(ii) Uncontrolled infection
Urgentd surgery is recommended in locally 
uncontrolled infection (abscess, false aneurysm, 
fistula, enlarging vegetation, prosthetic dehiscence, 
new AVB).5,420,421,429,445
I
B
Urgentd or non-urgent surgery is recommended in IE 
caused by fungi or multiresistant organisms according 
to the haemodynamic condition of the patient.420
I
C
Urgentd surgery should be considered in IE with 
persistently positive blood cultures >1 week or 
persistent sepsis despite appropriate antibiotic 
therapy and adequate control of metastatic 
foci.436,437
IIa
B
Urgentd surgery should be considered in PVE caused 
by S. aureus or non-HACEK Gram-negative 
bacteria5,385,449
IIa
C
(iii) Prevention of embolism
Urgentd surgery is recommended in aortic or mitral 
NVE or PVE with persistent vegetations ≥10 mm 
after one or more embolic episodes despite 
appropriate antibiotic therapy.451,455,457,471,478
I
B
Urgentd surgery is recommended in IE with 
vegetation ≥10 mm and other indications for 
surgery.5,460,465,466,471,478
I
C
Urgentd surgery may be considered in aortic or 
mitral IE with vegetation ≥10 mm and without 
severe valve dysfunction or without clinical evidence 
of embolism and low surgical risk.460,463,465,473,478
IIb
B
© ESC 2023
AVB, atrioventricular block; HACEK, Haemophilus, Aggregatibacter, Cardiobacterium, 
Eikenella, Kingella; HF, heart failure; IE, infective endocarditis; NVE, native valve 
endocarditis; PVE, prosthetic valve endocarditis. 
aFor right-sided endocarditis, please refer to Section 12. 
bClass of recommendation. 
cLevel of evidence. 
dEmergency, within 24 h. Urgent, within 3–5 days. Non-urgent, within same hospital 
admission.
ESC Guidelines                                                                                                                                                                                          3991


<!-- PAGE 45 -->

### Page 45

9.1.1. The role of cerebral imaging in infective 
endocarditis
Cerebral imaging is mandatory when neurological complications of IE 
are suspected. Evaluation should include MRI with and without gadolin­
ium, or CT with and without contrast if MRI is not possible.487 Vascular 
imaging should not be performed routinely, and CTA or magnetic res­
onance angiography (MRA) is probably sufficient for screening when in­
fective aneurysm is suspected. Catheter angiography should be 
performed in patients in whom an infective aneurysm was diagnosed 
on CTA or MRA, in patients with an acute brain haemorrhage, or if 
the suspicion of aneurysm remains despite negative non-invasive tech­
niques, and if mechanical thrombectomy is considered.488
In patients without neurological symptoms, cerebral MRI often de­
tects ‘silent’ lesions such as microbleeds.204 The lack of association 
with parenchymal haemorrhage and the absence of post-operative 
neurological complications in patients with microbleeds suggest that 
microbleeds should not postpone surgery when indicated.489
9.2. Infective aneurysms
An infective (mycotic) aneurysm is a rare but potentially devastating com­
plication of IE. Infective cerebral aneurysms may be asymptomatic, cause 
headaches, seizures, or focal symptoms, and may progress to a potentially 
lethal rupture. They are associated with subarachnoid, intracerebral, and 
intracranial haemorrhage,201
particularly when the patient is 
anticoagulated. The true incidence of infective cerebral aneurysms may 
be underdiagnosed as vascular imaging modalities are not systematically 
performed in asymptomatic patients. In 168 patients who underwent 
cerebral angiography with a diagnosis of IE or infected left ventricular assist 
device were retrospectively reviewed and infective aneurysms were pre­
sent in 9% of patients.488 Another series using CTA identified infective an­
eurysms in up to 32% of patients with left-sided IE.492
Digital subtraction angiography (DSA) remains the gold standard 
diagnostic test for the detection of infective aneurysms.487 The sensitiv­
ity of CTA and MRA progressively increases with the size of the aneur­
ysm. In a large study including 142 patients, the sensitivity for detection 
of infective aneurysms smaller than 5 mm was 57% for CTA and 35% 
for MRA, compared with respective 94% and 86% sensitivities for the 
detection of aneurysms of 5 mm or larger.493 Compared with the sen­
sitivity of DSA, the sensitivities of CTA and MRA for detecting infective 
aneurysms are inferior.488,490 Therefore, in patients with IE and high 
suspicion of infective aneurysms in whom CTA or MRA are negative, 
DSA may be considered.490,494
Treatment options of infective cerebral aneurysms consist of anti­
biotic treatment with or without endovascular or surgical therapy, al­
though evidence is limited to case reports and retrospective 
studies.495–498 Therefore, management should be discussed among 
the members of the Endocarditis Team and tailored to individual clinical 
situations. Shi et al.496 reported that in patients with unruptured infect­
ive cerebral aneurysms, antibiotic treatment may have similar outcomes 
to invasive treatment. However, interventional treatment should be 
considered in cases of ruptured infective aneurysms or unruptured in­
fective aneurysms that do not respond to antibiotic therapy.485,495
Endovascular therapy is highly successful and associated with low 
morbidity compared with microsurgical and medical manage­
ment.487,499 A systematic review including 499 patients with infective 
cerebral aneurysms reported a 36% rate of aneurysm rupture.495
Endovascular surgical and conservative therapies were performed in 
an approximately equal number of patients. Among patients undergo­
ing valve surgery in this series, only 15% underwent cardiac surgery be­
fore aneurysm treatment whereas 85% underwent cardiac surgery 
after aneurysm treatment.495
Urgency of cardiac surgery plays a pivotal role in decision-making re­
garding the type of invasive treatment. Compared with neurosurgical 
clipping that requires a craniotomy and often at least 2-week delay 
prior to procedure, cardiovascular surgery can be performed on the 
same day as endovascular treatment.485,487,496,499 Finally, endovascular 
treatment of infective cerebral aneurysms prior to heart valve surgery 
may be considered, even if no rupture is documented.499
9.3. Splenic complications
Splenic complications associated with IE range from asymptomatic in­
farction500 and abscess formation501 through to splenic rupture and 
cardiovascular collapse.502 Splenic infarcts are common (∼20% of pa­
tients in the EURO-ENDO registry) and very often asymptomatic.5
Up to 5% of splenic infarcts can progress to abscess formation.503
Persistent or recurrent fever, abdominal pain, and persistent bacter­
aemia are suggestive for the presence of such complications. Patients 
with suspected splenic complications should be evaluated with ultra­
sound, abdominal CT, MRI, or PET/CT.504
Treatment of splenic complications includes conservative medical 
therapy with appropriate antibiotics for splenic infarction or for 
antibiotic-responsive abscesses, although antibiotic penetration may 
be poor in these circumstances. When an abscess is large, splenectomy 
may be considered, but the timing of splenectomy in relation to heart 
valve surgery needs careful assessment.505 Splenectomy and heart valve 
surgery are seldom performed in the same operative episode.506
Splenectomy is usually performed prior to valve surgery due to con­
cerns of dissemination and reinfection of the heart valve. 
Recommendation Table 13 — Recommendations for 
the treatment of neurological complications of infective 
endocarditis
Recommendations
Classa
Levelb
Brain CT or MRA is recommended in patients with IE 
and suspected infective cerebral aneurysms.490
I
B
Neurosurgery or endovascular therapy is 
recommended for large aneurysms, those with 
continuous growth despite optimal antibiotic 
therapy, and ruptured intracranial infective cerebral 
aneurysms.485
I
C
If non-invasive techniques are negative and the 
suspicion of infective aneurysm remains, invasive 
angiography should be considered.488
IIa
B
In embolic stroke, mechanical thrombectomy may be 
considered if the expertise is available in a timely 
manner.484
IIb
C
Thrombolytic therapy is not recommended in 
embolic stroke due to IE.481,491
III
C
© ESC 2023
CT, computed tomography; IE, infective endocarditis; MRA, magnetic resonance 
angiography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 46 -->

### Page 46

Nevertheless, one case series reported that it is safe to address the 
splenic abscess with splenectomy after valve repair.502 Alternatives to 
open splenectomy, i.e. percutaneous drainage507 and/or laparoscopic 
surgery,508 may be considered in patients with high surgical risk. 
After splenectomy, vaccination against encapsulated microorganisms 
(S. pneumoniae, N. meningitis, and Haemophilus spp.) is recommended.
9.4. Myocarditis and pericarditis
The actual prevalence of acute myocarditis in the setting of IE is un­
known. Myocarditis will usually present in the form of acute HF and/ 
or ventricular arrhythmias indicating myocardial involvement in the in­
flammatory process most likely mediated by an immune mechanism. 
Differential diagnosis and exclusion of other potential complications 
are best assessed using echocardiography and cardiac MRI.509–511
Pericarditis is an infrequent complication of IE. In one retrospective 
series of 95 patients with aortic valve IE, 19% developed pericarditis 
usually related to ring abscess formation. The same authors also de­
scribed a 12% rate of pericarditis associated with mitral valve 
IE.512,513 The pathophysiological mechanisms most commonly involved 
in IE-related pericarditis are the extension of inflammation from an in­
fective aneurysm of the aortic root or valve ring abscess, an embolus in 
an extramural coronary artery, or the rupture of an infective aneurysm. 
In a recent large series of NVE, pericardial effusion was observed in 
7.8% of patients and was associated with a higher risk of HF during ad­
mission. After adjusting for possible confounders, patients did not have 
a higher rate of surgery, and the presence of pericardial effusion was not 
associated with a higher in-hospital or 1-year mortality.513
9.5. Heart rhythm and conduction 
disturbances
Due to the critical anatomical relationship between heart valves and the 
conduction system, AVB may complicate the clinical presentation of IE. 
The atrioventricular node (AVN) and His bundle lie in close proximity 
to the insertion of the septal leaflet of the tricuspid valve, the aortic 
root (below the non-coronary and right coronary cusps), and the mitral 
annulus.514 A paravalvular abscess of these valves, especially of the aor­
tic valve, may lead to AVB, and new electrocardiographic AVN conduc­
tion abnormalities are indicative of a paravalvular extension of the 
infection. In the EURO-ENDO registry, conduction abnormalities 
were observed at diagnosis in 11.5% of patients, including first-degree 
AVB in 8.1%, second-degree AVB in 0.6%, and third-degree AVB in 
2.8% of cases.5 New-onset AVB caused by local extension of IE (i.e. ab­
scess) is an indication for urgent cardiac surgery.
Atrioventricular block may not only occur as a complication of para­
valvular extension of the infection, but it may also develop as a conse­
quence of valve surgery. In a series of 444 patients who survived cardiac 
surgery for IE,515 12.8% of patients required pacemaker implantation 
for AVB. Multivariable analysis identified that prolonged pre-operative 
PR and QRS intervals, S. aureus infection, presence of aortic root ab­
scess, tricuspid valve involvement, and prior valvular surgery were inde­
pendently associated with the need for post-operative pacemaker 
implantation.
Pacemaker implantation should be considered in patients with sur­
gery for valvular endocarditis and complete AVB if one or more of 
these risk factors is present.515
9.6. Musculoskeletal manifestations
9.6.1. Osteoarticular infective endocarditis-related 
infections
Metastatic bone or joint IE-related lesions are relatively frequent due to 
the spread of the pathogen through the bloodstream and its subse­
quent tissue implantation. Although these lesions are considered an 
IE-related distal lesion or complication because infected valves are a 
continuous source of bacteraemia, it is often impossible to determine 
whether the primary infection is the valve or the osteoarticular infec­
tion. Overall, the incidence of osteoarticular infection among patients 
with IE is 6–8%, including bones, joints, and vertebral discs.5,145,247,516
The prevalence of spondylodiscitis ranges from 2% to 10% in patients 
with IE, including symptomatic and asymptomatic cases,248,517 while 
series of spontaneous spondylodiscitis have reported co-existing IE in 
up to 20–30% of patients.518–520 In general, the rate of IE is 10 times 
higher in patients with known spondylodiscitis. Therefore, in patients 
with a definite diagnosis of pyogenic spondylodiscitis and positive blood 
cultures, TTE/TOE is recommended to rule out IE.521
The most frequent microorganisms associated with spondylodiscitis 
are S. aureus, followed by Streptococcus spp., CoNS, and Enterococcus 
spp.247,248,305,517–523
The most common symptom of spondylodiscitis is back pain, al­
though only 4% of patients with IE and back pain have spondylodisci­
tis.32,522 An MRI should be performed to accurately diagnose 
spondylodiscitis. Computed tomography can detect indirect signs of 
spondylodiscitis: loss of disc height, erosion/destruction of the end­
plates and vertebral bodies, and paravertebral soft tissue phlegmonous 
changes or abscess.206 Whole-body [18F]FDG-PET/CT can also iden­
tify spondylodiscitis.30,32,524 Indeed, spondylodiscitis is frequently de­
tected as an incidental finding when PET/CT is performed for the 
diagnosis of PVE. Imaging techniques can also be helpful in guiding biop­
sies to obtain material for cultures in cases of suspected IE with negative 
blood cultures.206
Antibiotic treatment adapted to the antimicrobial susceptibility pat­
tern is appropriate for most cases of spondylodiscitis. The outcome is 
usually favourable with the 4- to 6-week IE treatment course. 
Prolonged therapy is necessary in patients with IE caused by 
difficult-to-treat microorganisms, such as S. aureus or Candida spp., or 
in those with epidural or perivertebral abscesses.523,525 In patients 
with neurological deficits or severe spinal instability, the indication for 
Recommendation Table 14 — Recommendations for 
pacemaker implantation in patients with complete 
atrioventricular block and infective endocarditis
Recommendations
Classa
Levelb
Immediate epicardial pacemaker implantation should 
be considered in patients undergoing surgery for 
valvular IE and complete AVB if one of the following 
predictors of persistent AVB is present: 
pre-operative conduction abnormality, S. aureus 
infection, aortic root abscess, tricuspid valve 
involvement, or previous valvular surgery.515
IIa
C
© ESC 2023
AVB, atrioventricular block; IE, infective endocarditis. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3993


<!-- PAGE 47 -->

### Page 47

surgical spinal treatment should be considered.526 In patients with ur­
gent indication for cardiac surgery, the presence of these lesions 
does not contraindicate the cardiac intervention. Spondylodiscitis 
does not appear to worsen the prognosis of patients with IE but delay­
ing the diagnosis of IE in patients with spondylodiscitis is associated with 
poor prognosis.248,517–520
9.6.2. Rheumatological manifestations
The pathogenesis of rheumatological manifestations and musculoskeletal 
symptoms in IE is not well established. The probable immunological- 
inflammatory aetiology of this clinical presentation is supported by a var­
iety of antibodies and laboratory markers, the sterility of the synovial fluid, 
and the rapid resolution without sequelae.527 Myalgia and back pain are re­
ported in 12–15% of cases. Arthralgia occurs in ∼10% of patients, some­
times sequentially affecting several joints. Slightly less often are symptoms 
of peripheral arthritis preferentially involving the major and proximal joints 
at the lower extremities.5,145,182,516
Sacroiliitis is less frequently observed (1% of cases) as well as poly­
myalgia rheumatic-like syndrome with pain and morning stiffness of 
the shoulders and hips, proximal muscle weakness (0.9% of cases), 
and cutaneous leucocytoclastic vasculitis (purpuric skin lesions, 3.6% 
of cases).182,527,528 Rheumatological manifestations and musculoskel­
etal symptoms show rapid and complete resolution with antibiotics 
and their presence does not impact on the prognosis of IE.182,529
9.7. Acute renal failure
Acute renal failure is a common complication of IE and is associated 
with increased morbidity and mortality as well as significant increase 
in length and cost of hospitalization.5,531–534 Additionally, renal failure 
is an independent predictor of poor outcome after cardiac surgery.417
However, acute renal failure should not be a reason to delay cardiac 
surgery. The EURO-ENDO registry reported that in patients with IE, 
acute renal failure was the second most common complication with 
an incidence of almost 18%.5 Some single-centre studies that specifically 
reported on the incidence of acute renal failure (using standardized cri­
teria) in patients with IE reported that any degree of acute renal failure 
from mild to severe might be observed in 40–69% of cases.532,535,536
Severe renal failure requiring haemodialysis has been reported in 6% 
of patients with IE and it is associated with a very high risk of mortality 
(40%).537
Several factors may be responsible for the onset or worsening of re­
nal dysfunction: (i) immune complex and vasculitic glomerulonephritis; 
(ii) renal infarction due to septic emboli;538,539 (iii) haemodynamic im­
pairment in patients with HF; (iv) antibiotic and other drug toxicity 
(notably related to aminoglycosides, vancomycin, nafcillin, amoxicillin, 
oxacillin, concomitant use of non-steroidal anti-inflammatories, and/ 
or high dose loop diuretics); and (v) nephrotoxicity of contrast agents 
used for diagnostic imaging techniques.417,531,534,535,537,540
To reduce the incidence of acute renal failure, nephrotoxic antibio­
tics should be avoided if possible or, if not possible, serum levels (ami­
noglycosides and vancomycin) as well as creatinine should be closely 
monitored, and the optimal dose of medication should be periodically 
re-evaluated and discussed with the Endocarditis Team and a pharma­
cologist.536 Loop diuretics should also be used cautiously and other po­
tentially nephrotoxic drugs, such as non-steroidal anti-inflammatories, 
should be avoided.536 Similarly, the use of nephrotoxic contrast agents 
for diagnostic imaging techniques should be carefully evaluated and 
avoided when possible.
In patients with IE and a reduced glomerular filtration rate, contrast 
enhanced abdominal ultrasound or MRI are reasonable tests to diag­
nose embolization as cause of renal function impairment.541
10. Surgical therapy: principles and 
methods
Surgery has been demonstrated to be an independent predictor of sur­
vival in many retrospective studies of IE patients under various clinical 
conditions and offers a potential curative therapy to select patient 
groups.5,250,403,404,421,436 Optimal management of such patients may 
lead to lower peri-operative complication rates and further potential 
benefits of surgical therapy.
10.1. Pre-operative and peri-operative 
management
10.1.1. Coronary angiography
When cardiac surgery becomes necessary in IE, assessment of coronary 
anatomy is recommended (see Recommendation Table 16). Classically, 
pre-operative coronary angiography is recommended for men >40 
years, post-menopausal women, and in those with one or more cardio­
vascular risk factors or history of CAD.128 The presence of aortic valve 
vegetations may preclude invasive coronary angiography due to the risk 
of iatrogenic embolization.542,543 However, some studies have demon­
strated the safety of performing invasive coronary angiography in the 
presence of aortic valve vegetations, particularly in patients without 
very large and mobile vegetations.193,544 Alternatively, coronary CTA 
can be used to rule out significant coronary obstructions. 
Furthermore, surgery may need to be conducted without detailed in­
formation on coronary anatomy in certain clinical conditions, particu­
larly emergencies. Of note, a recent study questioned the need for 
coronary artery bypass grafting of non-critical lesions at the time of sur­
gery for IE and suggested that such concomitant intervention may have 
a negative impact on peri-operative outcomes.545
Recommendation Table 15 — Recommendations for 
patients with musculoskeletal manifestations of infect­
ive endocarditis
Recommendations
Classa
Levelb
MRI or PET/CT is recommended in patients with 
suspected spondylodiscitis and vertebral 
osteomyelitis complicating IE.30,32,206,524
I
C
TTE/TOE is recommended to rule out IE in patients 
with spondylodiscitis and/or septic arthritis with 
positive blood cultures for typical IE 
microorganisms.247,248,517–521,523
I
C
More than 6-week antibiotic therapy should be 
considered in patients with osteoarticular IE-related 
lesions caused by difficult-to-treat microorganisms, 
such as S. aureus or Candida spp., and/or complicated 
with severe vertebral destruction or 
abscesses.523,525,530
IIa
C
© ESC 2023
IE, infective endocarditis; MRI, magnetic resonance imaging; PET/CT, positron emission 
tomography/computed tomography, TOE, transoesophageal echocardiography; TTE, 
transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 48 -->

### Page 48

10.1.2. Extracardiac infection
Extracardiac foci may be treated prior to valve surgery, during the valve 
operation, or post-operatively, dependent on the urgency of cardiac 
surgery. Regardless of the timing of intervention, infective foci need 
to be eradicated before completion of antibiotic therapy in order to 
avoid cardiac valve reinfection.
10.1.3. Intra-operative echocardiography
Intra-operative TOE provides contemporaneous assessment of the ex­
tent of infection prior to valve repair/replacement. Extent of infection, 
stability of known vegetations, re-assessment of previously uninvolved 
heart valves, and biventricular function are routinely performed with 
intra-operative TOE. Intra-operative TOE post-surgical repair is man­
datory to determine the immediate result and establish a baseline for 
follow-up comparisons.547
10.2. Other intra-operative considerations
Specific peri-operative management considerations are necessary in all 
IE patients undergoing valve surgery, particularly in those following 
stroke (see Section 10.3). Pre-operative antibiotic therapy must be con­
tinued intra-operatively, and doses may need to be repeated in case of 
prolonged operations or major bleeding. Although the pharmacokinet­
ics of antibiotic therapy is altered during cardio-pulmonary bypass 
(CPB), adjustment of doses is rarely required.548 In general, ongoing 
IE antibiotic treatment offers appropriate surgical site infection prophy­
laxis. However, when the antibiotic treatment for IE does not fully cov­
er normal surgical prophylactic treatment, conventional prophylaxis 
should be added. Intra-operative bleeding management is often compli­
cated by marked coagulopathy in patients with IE, particularly those 
undergoing surgery during persistent sepsis. The management of hypo­
tension and vasoplaegia is particularly challenging in patients presenting 
with septic shock, and accompanying vasoplaegia tends to worsen sig­
nificantly during CPB. Norepinephrine is frequently used as first-line 
therapy for septic shock, followed by vasopressin or terlipressin in cases 
of resistant vasoplaegia.549 Methylene blue may be used as a rescue 
agent in patients who are unresponsive to these measures, but mortal­
ity rates are high for such patients.550
Retrospective studies have suggested that the use of haemoadsor­
bent filters during CPB may decrease the negative effects associated 
with cytokine cascade activation.551 A recent RCT of haemoadsorption 
during cardiac surgery in IE patients, however, failed to demonstrate 
any beneficial effects with regards to adverse events or end-organ 
function.552
10.3. Surgical approach and techniques
Surgery for IE aims to remove infected structures followed by re- 
establishment of anatomy and haemodynamic function. With regards 
to the involved heart valve(s), repair or replacement is carried out 
based on the extent of destruction, acuity of disease, and patient char­
acteristics.553 Appropriate collection and labelling of tissue samples for 
pathological, microbiological, and molecular biological analyses are ne­
cessary to help guide antibiotic treatment.
Aortic valve replacement is usually required for aortic IE. Aortic valve 
repair is very uncommon in the acute situation but may be performed 
for isolated aortic regurgitation after healed endocarditis. In mitral IE, leaf­
let perforations with preserved free margin and chordae tendinae may be 
treated with patch repair, particularly in the setting of subacute or healed 
IE. Although mitral valve repair is feasible in more complex mitral IE involv­
ing the annuli, the leaflet free edge, and/or chordae, evidence showing the 
feasibility and durability of such repair techniques is scarce.554,555 A large 
registry on mitral repair vs. replacement in IE was limited by the lack of in­
formation on severity of IE, different patient group profiles, and significantly 
higher incidence of staphylococcal endocarditis in the mitral valve replace­
ment group.556Therefore, it cannot be concluded that mitral valve repair is 
superior to replacement due to the high probability of selection bias. Valve 
preservation in acute IE should only be attempted if a durable repair is an­
ticipated and complete eradication of infected tissue can be achieved. 
However, valve repair may be necessary in children, where valve replace­
ment options are more limited.
Invasion of the aortic annuli may create shallow defects (very limited 
abscess or small pseudoaneurysms) that are still amenable to conven­
tional valve replacement surgery. When disease progresses into an ex­
tensive aortic root abscess or periannular destruction, aortic root 
replacement is usually required. In experienced centres, the use of allo­
grafts has been preferred as they have the advantage of adapting to ir­
regular surfaces and provide haemostatic advantages with very good 
haemodynamic function and low thrombo-embolic risk, and can be 
used to repair concomitant lesions of the anterior mitral valve leaf­
let.557,558 Additionally, allografts and stentless bioprostheses can be 
beneficial in small aortic roots and are associated with low reinfection 
rates. However, experience is generally limited to single-centre case 
series and there is no clear evidence of superiority of one valve substi­
tute over the other.559 In very selected patients and children in particu­
lar, the Ross operation (pulmonary valve autotransplantation) may be 
considered for aortic root IE.128
The use of patches to cover abscess cavities and prevent extensive 
resection and reconstruction is discouraged in aortic root IE as it 
may be associated with recurrences, periprosthetic leaks, and pseudoa­
neurysm formation. After exclusion from the circulation, abscess and 
pseudoaneurysm cavities are left to drain into the pericardial cavity.
When periannular infection of the aortic root extends into the inter­
valvular fibrosa body, complex surgical reconstructions are required and 
are frequently the only option to achieve patient survival. The reported 
Recommendation Table 16 — Recommendations for 
pre-operative coronary anatomy assessment in patients 
requiring surgery for infective endocarditis
Recommendations
Classa
Levelb
In haemodynamically stable patients with aortic valve 
vegetations who require cardiac surgery and are high 
risk for CAD, a high-resolution multislice coronary 
CTA is recommended.185,546
I
B
Invasive coronary angiography is recommended in 
patients requiring heart surgery who are high risk for 
CAD, in the absence of aortic valve vegetations.
I
C
In emergency situations, valvular surgery without 
pre-operative coronary anatomy assessment 
regardless of CAD risk should be considered.543,545
IIa
C
Invasive coronary angiography may be considered 
despite the presence of aortic valve vegetations in 
selected patients with known CAD or at high risk of 
significant obstructive CAD.193,543,544
IIb
C
© ESC 2023
CAD, coronary artery disease, CTA, computed tomography angiography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3995


<!-- PAGE 49 -->

### Page 49

pooled peri-operative survival rate of such surgical technique is 84%.560
Even more extensive repairs may be required for cases involving the in­
tervalvular fibrosa, central fibrous body, and mitral valve, with or without 
fistulation to the right-side chambers. These operations are technically 
complex and require a surgeon who is very experienced in IE, which 
may not be available in every cardiovascular surgery department.
Exceptionally, heart transplantation has been utilized for carefully se­
lected patients without other surgical options.561
10.3.1. Choice of valve prosthesis
Many patient characteristics are taken into account when deciding the 
type of valve prosthesis to implant in a given patient with IE. The studies 
published to date evaluating various valve prostheses in the setting of IE, 
however, suffer from numerous biases.90,559,562–566
Beyond the patient characteristics that apply in the non-IE setting,128
valve selection in IE is influenced by the presence of recent stroke, risk 
of new-onset bleeding, complexity of expected post-operative course, 
Haemorrhagic
Ischaemic
Meaningful recovery possible with acceptable residual quality of life
Severely decreased level of consciousnessa
Neurology and/or neurosurgery assessment and discussion with the Endocarditis Team
(Class I)
N
Cardiogenic shock
Type of stroke
N
N
Infective endocarditis with stroke
Y
Y
Uncontrolled infection, heart failure or high-risk of recurrent embolization
N
Frequent follow-up and assessment,
delay surgery 4 weeks, if possible
Y
Y
Favourable brain bleed featuresb
Conservative or palliative care
N
Continued non-surgical management
Urgent surgery
(Class I)
Y
Emergency surgery
(Class I)
Figure 11 Surgery for infective endocarditis following stroke. NIHSS, National Institutes of Health Stroke Scale Score. Surgery timing: emergency, within 
24 h. Urgent, within 48–72 h. Non-urgent, within same hospital admission. aGlasgow Coma Scale ≤4 or NIHSS >18. bIntracranial haemorrhage volume 
<30 mL or NIHSS <12.


<!-- PAGE 50 -->

### Page 50

and the ability of the patient to participate in decision-making, especially 
for emergency surgery (Table 12). In the absence of specific 
contraindications for a particular valve substitute, patient preferences 
should determine the final decision.
10.4. Timing of surgery after ischaemic and 
haemorrhagic stroke
There is a general trend of offering early surgery in IE in light of the im­
proved operative outcomes and survival benefits observed with operative 
management.451,567 For patients who have suffered a neurological injury, 
however, the optimal timing of surgery remains to be defined.568 There 
are no RCTs specifically assessing this clinically relevant issue and contem­
porary evidence arises from observational studies.415,454,473,569,570
Neurological exacerbation may occur during surgery or early post- 
operatively due to the altered physiology conditions during and imme­
diately after cardiac repair.571 Several peri-operative variables should be 
addressed in order to lower the risk of neurological deterioration and 
haemorrhagic transformation post-stroke (see Supplementary data 
online, Table S10).
The risk of neurological exacerbation during surgery needs to be ba­
lanced against that of delaying a cardiac operation. When haemo­
dynamic disturbances are present, surgery should be pursued 
without 
delay 
(see 
Figure 
11
and 
Recommendation 
Table 17).451,468,473,567,568,570–578 A more common situation occurs 
when surgery is considered for the prevention of recurrent embolism 
after stroke, due to the presence of large vegetations (>10 mm). In pa­
tients that have suffered a transient ischaemic attack, the risk of surgery 
is usually low and surgery should be performed without delay. For 
patients with ischaemic stroke, multiple observational data exist sup­
porting a non-delayed (urgent) intervention, unless the neurological 
status is poor (i.e. coma or extensive damage leading to poor functional 
prognosis).573,578 Involvement of an expert neurology/neurosurgical 
specialist will help in risk assessment discussions.
The risk of post-operative haemorrhagic conversion after pre- 
operative stroke is reported in the range of 2–7%.453,579 Remarkably, 
bleeding transformation after cardiac surgery can also occur in patients 
with silent pre-operative cerebral embolisms, with similar frequency as 
in patients with overt neurological deficits. Unfortunately, these events 
cannot currently be accurately predicted prior to surgery. When haem­
orrhagic transformation occurs, it is associated with high mortality 
(40%) and may require rescue neurointerventional or neurosurgical 
treatment to control bleeding or allow cerebral decompression by 
means of craniectomy.577,580
Several retrospective studies report benefits of early surgery (with­
in 2 weeks) after haemorrhagic stroke without further compromising 
neurological outcomes.574,581,582 Decisions should be taken on a 
case-by-case basis by the Endocarditis Team, including a neurologist, 
and should be adapted to the mechanism of intracranial haemorrhage 
and its severity including intracranial haemorrhage volume measure­
ment and National Institutes of Health Stroke Scale Score (NIHSS) 
score (see Figure 11).495 In patients in whom surgery is delayed, re­
peat CT or MRI imaging should be performed 1–2 weeks following 
intracranial haemorrhage (or earlier in the case of clinical deterior­
ation) in order to assess stability of the cerebral finding and potential­
ly re-assess timing of surgery. The timing of surgery after intracranial 
haemorrhage is controversial and an area where further evidence is 
urgently required.
10.5. Post-operative complications
Post-operative management of patients with IE may be challenging due 
to pre-operative multiorgan involvement and often complex surgical 
procedures. The risk of in-hospital mortality associated with IE surgery 
remains high (10–20%), particularly in patients >75 years of age, usually 
due to co-morbidities and complications of IE. Further research should 
focus on methods to lower surgical mortality.
The most frequent serious post-operative complications are coagu­
lopathy requiring extensive use of blood products and clotting factors, 
re-exploration of the thorax due to bleeding/tamponade, haemodialy­
sis, stroke, or cerebral haemorrhagic transformation of prior cerebro­
vascular lesions, low cardiac output syndrome, respiratory 
complications and tracheostomy, prolonged hospital stay, and need 
for a permanent pacemaker.515,585,586 When mortality occurs, the 
cause of death is often multifactorial. Post-mortem examination is help­
ful for determining the cause of death, further understanding of disease 
process, teaching purposes at academic environments, and quality 
control.
Recommendation Table 17 — Indications and timing of 
cardiac surgery after neurological complications in active 
infective endocarditis
Recommendations
Classa
Levelb
After a transient ischaemic attack, cardiac surgery, if 
indicated, is recommended without delay.454,468
I
B
After a stroke, surgery is recommended without any 
delay in the presence of HF, uncontrolled infection, 
abscess, or persistent high embolic risk, as long as 
coma is absent and the presence of cerebral 
haemorrhage has been excluded by cranial CT or 
MRI.451,468,473,567,568,570–578
I
B
Following intracranial haemorrhage, delaying cardiac 
surgery >1 month, if possible, with frequent 
re-assessment of the patient’s clinical condition and 
imaging should be considered.571
IIa
C
In patients with intracranial haemorrhage and 
unstable clinical status due to HF, uncontrolled 
infection or persistent high embolic risk, urgent or 
emergency surgery should be considered weighing 
the likelihood of a meaningful neurological 
outcome.199,581–584
IIa
C
© ESC 2023
CT, computed tomography; HF, heart failure; MRI, magnetic resonance imaging. 
aClass of recommendation. 
bLevel of evidence.
Table 12 Features favouring a non-mechanical valve 
substitute in the setting of surgery for acute infective 
endocarditis
Early surgery after a recent ischaemic stroke
Evidence of intracranial bleeding
Woman of childbearing age
High likelihood of prolonged mechanical circulatory support
Advanced age or frailty
Poor or unknown medical compliance
Expected complicated and prolonged post-operative course
Patient preference
© ESC 2023
ESC Guidelines                                                                                                                                                                                          3997


<!-- PAGE 51 -->

### Page 51

10.6. Management of antithrombotic 
therapy after surgery
The management of antithrombotic therapy early after surgery for IE 
may need to be altered when compared with non-IE clinical scenarios 
(see also Section 12.10).128 This is mainly due to known increased risk of 
intracranial haemorrhage after cerebral embolism. Restrictive or tai­
lored use of antiplatelet and antithrombotic agents after surgery are 
key to avoid further complications,203,587 which is more feasible in pa­
tients who received bioprosthetic valve prostheses or valve repair op­
erations than after mechanical valve replacement surgery.
11. Outcome after discharge: 
follow-up and long-term prognosis
Following in-hospital treatment, patients should be followed-up for the 
occurrence of main post-discharge complications, including recurrence 
of infection, HF, need for valve surgery or additional intervention, 
stroke, need for renal replacement therapy, psychological complica­
tions, and death.86,588,589
11.1. Recurrences: relapses and 
reinfections
The risk of recurrence (which includes relapses and reinfections) among 
survivors of IE varies significantly between studies, ranging from 2% to 
9% in more contemporary analyses.86,589–595 However, it has been shown 
that reinfections have worse outcomes as compared with relapses.592
Figure 12 illustrates the diagnostic paths to differentiate relapse from 
reinfection.596
Conceptually, relapse refers to a repeat episode of IE caused by the 
same microorganism and represents a failure of treatment due to insuf­
ficient duration of initial treatment, sub-optimal choice of initial antibio­
tics, or a persistent focus of infection.592 Conversely, reinfection is 
related to patients’ clinical and immunological profiles, describes an in­
fection caused by a different microorganism usually more than 6 
months after the initial episode,4,596 and is associated with worse out­
come.592 The differentiation between relapse and reinfection needs to 
be interpreted with caution, however, as a long time period from initial 
infection suggests reinfection even in the presence of the same strain. 
Contemporary data report low rates of relapse,86 most probably re­
flecting improved management of these patients. Relapse should be 
treated with i.v. antibiotics for an additional 4–6 weeks, depending on 
the causative microorganism and its antibiotic susceptibility, and cardiac 
surgery should be considered. It is also important to consider that anti­
biotic resistance may develop over time. Factors associated with an in­
creased rate of relapse are listed in Table 13.588,595,597
In surgically managed NVE, the risk of IE recurrence is no different 
when comparing valve replacement and valve repair.84,598 Several pre­
vious studies have also reported no difference regarding the risk of re­
current IE between types of valve implanted.599–601 However, the most 
recent Danish registry study reports increased risk of IE recurrence as­
sociated with biological vs. mechanical prostheses.84
Partial oral vs. i.v. antibiotic treatment of IE, as well as OPAT vs. 
hospital-based antibiotic treatment in select stable patients, is not asso­
ciated with an increased risk of recurrent IE.43,396,399,602 Notably, re­
sidual vegetation after treatment for IE also did not show increased 
association with recurrence of IE,602 although this result should be in­
terpreted with caution. Patients with relapse or reinfection IE should 
be managed as indicated in Sections 7 and 8 (if complicated IE).
Same species isolated
Reinfection
Relapse
Same strain
Stored isolate from prior infective endocarditis
Use molecular methods/
strain typing
New episode <6 months from prior infective endocarditis
N
N
N
N
Storage of isolates following infective endocarditis episode
New episode of infective endocarditis
Y
Y
Y
Y
Figure 12 Algorithm differentiating relapse from reinfection. Reproduced with permission from Chu et al.596


<!-- PAGE 52 -->

### Page 52

11.2. First year follow-up
Patients discharged after the first episode of IE should remain under 
close surveillance for potential long-term complications. A partnership 
between cardiologists, infectious disease specialists, cardiac surgeons, 
general practitioners, and dentists is encouraged to improve patient 
care and reinforce prophylaxis measures. In medically treated patients, 
residual valve dysfunction may worsen, or structural valve deterioration 
may progress, despite bacteriological cure. To monitor the risk of de­
velopment of secondary HF, an initial clinical evaluation and baseline 
TTE should be performed at the completion of antimicrobial therapy 
and repeated if a change in the clinical condition occurs.
Clinical re-assessment should be performed one or more times in 
the first year and yearly thereafter depending on the individual risk pro­
file. The need for late valve surgery is relatively low, ranging from 3% to 
11%.27,588,592 Blood testing for inflammatory markers (i.e. WBC, 
C-reactive protein, procalcitonin) should be performed early after fin­
ishing antimicrobial treatment and repeated thereafter when clinically 
indicated.592 Due to the increased risk of relapse for virulent microor­
ganisms, blood cultures are encouraged within the first week after fin­
ishing treatment.
The early period after discharge might be challenged by slow physical 
and mental recovery.603,604 Patients’ and families’ concerns should be 
addressed during follow-up. Supporting the family may indirectly sup­
port the patient during recovery and reduce the psychological burden. 
Cardiac rehabilitation, including physical exercise training and patient 
education, may be beneficial, and has been shown to be safe and feasible 
in stable patients at a minimum of 2 weeks after surgery for left-sided 
IE.605 Physical training should start as early as possible and can be 
adapted 
post-sternotomy 
with 
isolated 
lower-limb 
training. 
Adherence is improved if the delay to training is minimized, and rebuild­
ing muscle mass and reducing frailty should be a priority.
Patients, and their caregivers, should be informed of their risk of IE 
recurrence and be educated on preventive measures and self- 
monitoring. In particular, patients should be educated that new onset 
of fever, chills, or other signs of infection mandate immediate evalu­
ation, including procurement of blood cultures before empirical use 
of antibiotics, and that contact with the Heart Valve Centre is manda­
tory in case of suspected recurrent IE. Good oral health maintenance, 
preventive dentistry, and advice about skin hygiene, including advice on 
tattoos and skin piercing, are mandatory. Deficiencies in dental surveil­
lance contribute to the continuous gradual increase in the incidence of 
IE, which underlines the need for repeating the principles of IE preven­
tion at each follow-up visit. In PWID patients, follow-up care should in­
clude a strategy for addiction treatment, involve relevant addiction 
specialists before hospital discharge, and possibly including medication 
for opioid-use disorder.606,607
11.3. Long-term prognosis
Contemporary long-term survival rates after the completion of IE 
treatment are estimated to be ∼85–90% and 70–80% at 1 and 5 years, 
respectively.589,592–594,610,611 Impact of referral bias, however, should 
be taken into consideration.612 The main predictors of long-term 
mortality are age, co-morbidities, PWID, double valve infection, recur­
rences of IE, and HF, especially when cardiac surgery cannot be per­
formed.588,589,592,593,613 Compared with an age- and sex-matched 
general population, patients that survived a first episode of IE have sig­
nificantly worse survival when suffering relapses or reinfections.589,614
This excess mortality is especially high within the first few years after 
hospital discharge and can be explained by late complications such as 
HF, risk of recurrences, and higher patient vulnerability.589,611 In fact, 
most recurrences of IE and late cardiac surgeries occurred during this 
period of time.589,592,611
12. Management of specific 
situations
12.1. Prosthetic valve endocarditis
Prosthetic valve endocarditis is the most severe form of IE and occurs in 
1–6% of patients with valve prostheses,615 with an incidence of 
0.3–1.2% per patient-year.5,420,616,617 PVE accounts for 20–30% of all 
cases of IE,618 and may be more common after biological than after 
mechanical valve replacement surgery.619,620 PVE was observed in 
21% of cases of IE in a French survey,618 in 26% of cases in the Euro 
Heart Survey,419 and in 20% of cases in the ICE-PCS.621 Real-world 
Table 13 Factors associated with an increased rate of 
relapse of infective endocarditis
Inadequate antibiotic treatment (i.e. agent, dose, duration)
Resistant microorganisms (i.e. Brucella spp., Legionella spp., Chlamydia 
spp., Mycoplasma spp., Mycobacterium spp., Bartonella spp., C. Burnetii, 
fungi)
Infective endocarditis caused by S. aureus and Enterococcus spp.
Polymicrobial infection in people who inject drugs
Periannular extension
Prosthetic valve endocarditis
Persistent metastatic foci of infection (abscesses)
Resistance to conventional antibiotic regimens
Positive valve culture
Persistence of fever at the 7th post-operative day
Chronic kidney disease, especially on dialysis
High-risk behaviour, inability to adhere to medical treatment
Poor oral hygiene
© ESC 2023
Recommendation Table 18 — Recommendations for 
post-discharge follow-up
Recommendations
Classa
Levelb
Patient education on the risk of recurrence and 
preventive measures, with emphasis on dental health, 
and based on the individual risk profile, is 
recommended during follow-up.608
I
C
Addiction treatment for patients following 
PWID-related IE is recommended.606,607
I
C
Cardiac rehabilitation including physical exercise 
training should be considered in clinically stable 
patients based on an individual assessment.605,609
IIa
C
Psychosocial support may be considered to be 
integrated in follow-up care, including screening for 
anxiety and depression, and referral to relevant 
psychological treatment.605,609
IIb
C
© ESC 2023
IE, infective endocarditis; PWID, persons who inject drugs. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3999


<!-- PAGE 53 -->

### Page 53

observational studies demonstrated stable rates of IE, but a remarkable 
increase in PVE between 1998 and 2013.80 Recently, a further increase 
in PVE cases (31%) was observed in the EURO-ENDO registry.5 PVE is 
still associated with difficulties in diagnosis, determination of the opti­
mal therapeutic strategy, and poor prognosis.
12.1.1. Definition and pathophysiology
A distinction is commonly made between early PVE and late PVE based 
on the time since valve surgery, because of significant differences in the 
microbiological profiles between these two groups.622 However, the 
time to IE onset is prognostically less important than the connection 
of IE to the peri-operative period or to specific pathogens. Prosthetic 
valve endocarditis with an onset in the peri-operative period involves 
mainly S. aureus, Staphylococcus epidermidis, or nosocomial microorgan­
isms, such as Gram-negative pathogens or fungi. Late PVE more com­
monly mimics the pattern of NVE, which is mostly represented by 
streptococcal and staphylococcal infections.623 S. aureus is more com­
monly observed in patients with mechanical valves, while alpha- 
haemolytic streptococci, enterococci, and CoNS are more common 
in patients with bioprosthetic valves.624 PVE due to Mycobacterium chi­
maera is an uncommon form of nosocomial infection that can result 
from contaminated CPB heater-cooler systems. Such infections pre­
sent many months after the index operation and can therefore be chal­
lenging to identify, and are associated with high mortality.625
The pathogenesis of PVE differs according to both the type of con­
tamination and the type of prosthetic valve (see Supplementary data 
online, Section S6.1).
12.1.2. Diagnosis
Diagnosis is more difficult in PVE than in NVE. Clinical presentation is 
frequently atypical, particularly in the early post-operative period, in 
which fever and inflammatory syndromes are common in the absence 
of macroscopic alterations of the prosthesis on cardiac imaging. 
However, persistent fever should trigger the suspicion of PVE. As in 
NVE, diagnosis of PVE is based mainly on the results of echocardiog­
raphy and blood cultures. However, both are associated with a sensitiv­
ity of only 60% for the definite diagnosis of endocarditis.212
Although TOE is mandatory in suspected PVE (Figure 6), its diagnos­
tic value is lower than in NVE. Identification of a new periprosthetic leak 
is a major criterion of IE and urges additional imaging modality to con­
firm the diagnosis (see Section 5).533,626 Recently, nuclear techniques, 
particularly [18F]FDG-PET/CT, have been shown to improve the diag­
nostic accuracy of the Duke criteria and increase sensitivity.34,209
Combinations of different imaging techniques such as cardiac CT, nu­
clear imaging, and TOE, improve diagnostic accuracy and provide rele­
vant information in terms of prognosis.33,627 In select cases of 
suspected PVE, and non-diagnostic results for the above-listed exams, 
intracardiac echocardiography may be considered.
12.1.3. Prognosis and treatment
A high in-hospital mortality rate of 20–40% has been reported in 
PVE.628,629 Compared with NVE, PVE is associated with increased in- 
hospital mortality and morbidity as well as reduced long-term sur­
vival.88,630 Several factors have been associated with poor prognosis 
in PVE, including older age, diabetes mellitus, healthcare-associated in­
fections, and early PVE.312 Among the different causative organisms, 
staphylococcal or fungal infection seem to be more aggressive, whereas 
enterococcal infections are associated with similar mortality but higher 
recurrence 
rates.628
Haemodynamic 
instability, 
multivalvular 
involvement as well as involvement of the aortomitral fibrosa have 
been associated with worse outcomes. It is noteworthy that the 
most important risk factor for recurrent IE and mortality is withholding 
surgery despite an obvious indication.5
The best therapeutic option in PVE is still debated. Although surgery 
is generally considered the best option when PVE causes severe pros­
thetic dysfunction or HF, in the EURO-ENDO registry it was per­
formed in only 73% of patients with PVE despite a clear indication 
for surgical treatment.5 In a single-series study of 523 PVE patients, 
early surgery was a large independent predictor of early and 1-year sur­
vival.631 Conversely, after adjustment for differences in clinical charac­
teristics and survival bias, early valve replacement was not associated 
with lower mortality compared with medical therapy in a large inter­
national cohort.421 In this series, however, surgery was beneficial in 
the subgroup of patients with the strongest indications for surgery in­
cluding valve regurgitation, vegetation, and dehiscence or paravalvular 
abscess/fistula formation.421 Therefore, a surgical strategy is recom­
mended for PVE in high-risk subgroups identified by prognostic assess­
ment, i.e. PVE complicated with HF, severe prosthetic dysfunction, 
abscess, or persistent fever. Conversely, patients with uncomplicated 
non-staphylococcal late PVE can be managed conservatively.632–634
However, patients who are initially treated medically require close 
follow-up because of the risk of late events and the higher risk of re­
lapse or valvular dysfunction.
Surgery for PVE follows the general principles outlined for NVE. 
However, the reoperation setting and the higher incidence of peripros­
thetic tissue destruction increase the complexity of the procedure. 
Meticulous and radical debridement of the infected material, including 
the original prosthesis, suture, and pledgets, is recommended. The 
type of valve substitute used for PVE follows the same recommenda­
tions as for NVE (see also Section 10.3.1).
Early PVE following valve replacement surgery is a separate entity as­
sociated with a high mortality rate, where conservative treatment with 
antibiotics is unlikely to lead to a cure and repeat surgery should be per­
formed.621,635 Staphylococci, Cutibacteria, or similar species are the 
usual causative organisms.622,636
12.2. Endocarditis in the elderly
Characteristics of patients with IE have dramatically changed over re­
cent decades, with an increasing prevalence and specific features of IE 
in the elderly population.25,145,637,638 In this population, enterococci 
and S. aureus are reported to be the most frequent aetiological agents. 
In addition, the higher presence of intracardiac prosthetic devices 
(CIED and valvular prosthesis/repair including TAVI devices) and in­
creased incidence of healthcare-associated IE episodes are ob­
served.25,637 Finally, a lower risk of embolic episodes has been 
observed in this subgroup.462,639–641
Recommendation Table 19 — Recommendations for 
prosthetic valve endocarditis
Recommendations
Classa
Levelb
Surgery is recommended for early PVE (within 6 
months of valve surgery) with new valve replacement 
and complete debridement. 621,635
I
C
© ESC 2023
PVE, prosthetic valve endocarditis. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 54 -->

### Page 54

A number of studies have shown that cardiac surgery positively af­
fects the clinical outcome of IE patients. Nevertheless, old age, co- 
morbidities, and previous non-cardiac and cardiac procedures lead to 
surgical hesitancy by referring physicians, surgeons, and patients them­
selves.642 Moreover, these characteristics also influence the outcome of 
this fragile cohort.400,433 As a result, less frequent performance of cura­
tive surgery and increased mortality are typical hallmarks of IE episodes 
in elderly as compared with the younger population.640 In a recently 
published Swedish propensity analysis of IE patients from 2006 to 
2017, the authors found that surgery was underused in the elderly 
and that 1-year mortality was significantly higher in elderly patients 
who did not undergo surgery.641 In a sub-analysis of the ESC EORP 
EURO-ENDO registry, the indication for surgery was less often recog­
nized (51% vs. 57%) and surgery was far less frequently performed 
when indicated (35% vs. 68%) in patients >80 vs. <80 years. 
However, mortality of surgically treated patients was remarkably simi­
lar in patients <80 and >80 years after propensity matching (19.7% vs. 
20.0%). Age was also not demonstrated to be an independent predictor 
of mortality in this large prospective study.640,643 These findings suggest 
that performance of surgery in well-selected elderly patients is under­
utilized and may increase their chance of survival.
In elderly IE patients, functional and nutritional status are important 
predictors of outcomes.400 When considering cardiac surgery in elderly 
patients, functional and nutritional status, and their associated risks, 
should be accurately explored through a comprehensive assessment 
by geriatricians. In addition, the earliest possible discharge home to fa­
cilitate the patient’s functional recovery should be considered in this 
subgroup of patients.
12.3. Transcatheter prosthetic valve 
endocarditis
12.3.1. Endocarditis following transcatheter aortic 
valve implantation
The incidence of IE post-TAVI ranges from 0.3 to 1.9 per 100 patient- 
years,94,623,644–648 which is similar to that reported following surgical 
aortic valve replacement in both observational studies and 
RCTs.94,623,646,647 One recent study, however, reported a lower inci­
dence of PVE after TAVI compared with surgical prostheses.649 The 
risk of IE is higher within the first year following the procedure, and par­
ticularly within the initial 3 months.644,645,648,650–652 A modest decrease 
in the incidence of IE post-TAVI has been observed in recent years, par­
ticularly in the early period following the procedure, presumably related 
to multiple technical improvements, more streamlined procedures, and 
a reduction of periprocedural complications.650,652 A similar IE rate has 
been reported irrespective of transcatheter valve type,653 and predis­
posing factors, including younger age, male gender, renal dysfunction, 
and significant residual aortic regurgitation, have been identi­
fied.94,644–646,648,651,652
12.3.1.1. Diagnosis
The diagnosis of IE post-TAVI is challenging. The stent frame of trans­
catheter valves, with a much higher amount of metal surrounding the 
valve leaflets compared with surgical prostheses, and the characteristics 
of TAVI patients (frequently elderly with multiple co-morbidities) may 
increase the diagnostic challenges in this population. The clinical presen­
tation is frequently atypical, with fever lacking in 13–20% of pa­
tients.623,645,650 Enterococci and S. aureus are the two most common 
microorganisms involved in IE post-TAVI, followed by streptococci 
and CoNS.644–646,650
Some important aspects should be considered regarding TOE in pa­
tients with suspected IE post-TAVI: (i) no vegetations are detected in 
38–60% of cases;623,645,650,651 (ii) vegetations are located in the stent 
frame of the transcatheter valve (and not on the valve leaflets) in 
12% of cases, and this rate increases up to 19% in the presence of 
some self-expanding valve systems with a longer stent frame occupying 
the ascending aorta;653 and (iii) the vegetations are located outside the 
transcatheter valve in about one-third of cases, mainly at the level of the 
mitral valve.645,650,651 Nuclear imaging or CT have been useful to diag­
nose IE post-TAVI.654,655 The addition of [18F]FDG-PET/CT and/or 
CTA to the diagnostic work-up of IE in TAVI changed the final clinical 
diagnosis in 33% of patients.655 Intracardiac echocardiography may also 
be useful for detecting vegetations in patients with suspected IE after 
TAVI and negative TOE.165
12.3.1.2. Prognosis and treatment
Prognosis and treatment of post-TAVI PVE is complicated by the fact 
that patients are older and have more co-morbidities than post-surgical 
PVE patients. About two-thirds of patients with IE post-TAVI exhibit at 
least one complication, with acute kidney injury and HF being the most 
frequent adverse events.645,646,656 The in-hospital and 30-day mortality 
rates are very high, ranging from 16% to 36%,623,644–647,657 and increase 
up to 41–59% at 1-year follow-up.644,645,652,657 A higher patient risk 
profile, S. aureus, and the occurrence of IE complications have been 
identified as risk factors for increased mortality.645,652,657
Antimicrobial therapy for IE post-TAVI is similar to that of PVE (see 
Section 7). Similar to surgical PVE, cardiac surgery is considered the best 
option in the presence of IE complications, particularly severe prosthet­
ic failure or HF, but is infrequently performed. Surgery is performed in 
∼20% of cases (ranging from 3.8% to 31.3%),645,652,656 a much lower 
rate compared with NVE and surgical PVE. The characteristics of the 
TAVI population, with often advanced age and high or prohibitive sur­
gical risk, along with the potential difficulties associated with the re­
moval of some transcatheter valve systems (particularly those with a 
large amount of stent frame, frequently adherent to the ascending aorta 
after a few months following the TAVI procedure) may play a role in the 
low rate of surgical interventions.
To date, all studies but one failed to demonstrate the potential bene­
fit of surgery in IE post-TAVI patients,442,645,652,656,658 but the relatively 
small sample size of the studies and the multiplicity of potential con­
founders when comparing to those patients not receiving surgical treat­
ment precludes definite conclusions. The only study showing a 
beneficial effect of surgical intervention focused on those patients 
who had a local extension of the infection (i.e. abscess or fistula).442
The decision to proceed with surgery in IE post-TAVI patients should 
be individualized, balancing the surgical risks and the prognosis of med­
ical treatment alone. In cases with local extension of the infection, sur­
gery may be recommended in the absence of a prohibitive surgical risk. 
In cases with healed IE and valve prosthesis dysfunction, repeat trans­
catheter therapy (valve-in-valve procedure) can be performed in select 
patients.659 Such interventions should be performed at least 1–3 
months after the healed endocarditis episode and following a negative 
follow-up TOE.
12.3.2. Endocarditis following transcatheter 
pulmonary valve implantation
The incidence of IE post-transcatheter pulmonary valve implantation 
(TPVI) ranges from 1.6 to 4.0 per 100 patient-years,93,660–667 which 
seems to be higher than that reported following surgical pulmonary 
valve 
interventions 
(observational 
studies, 
no 
randomized 
data).662,663,667,668 While some studies suggest a higher risk associated 
with the use of bovine jugular vein valves,662,667,669 a recent large multi­
centre study including different transcatheter valve systems did not 
ESC Guidelines                                                                                                                                                                                          4001


<!-- PAGE 55 -->

### Page 55

observe differences between valve types.665 The most consistent fac­
tors associated with an increased risk of IE following TPVI have been 
younger age, a previous history of IE, and a higher transvalvular residual 
gradient.93,663,665
12.3.2.1. Diagnosis
The diagnosis of IE in TPVI recipients may be challenging, and the use of 
intracardiac echocardiography and [18F]FDG-PET/CT has been shown 
to be useful in cases with a clinical suspicion and negative TTE/ 
TOE.34,93,210,660,665,670 S. aureus and oral group streptococci species 
are the most common microorganisms causing IE post-TPVI.660,664–666
12.3.2.2. Prognosis and treatment
New moderate or severe prosthetic valve stenosis occurs much more 
frequently (one-third to one-half of patients) in post-TPVI PVE than in 
aortic PVE, and the rate of surgical valve replacement therapy ranges 
from 26% to 56%.93,660,661,664,665 The possibility of a transcatheter 
therapy (valve-in-valve intervention) for treating severe prosthesis dys­
function in cases with healed endocarditis or as an urgent treatment 
(balloon dilatation) in severe valve stenosis cases has also been re­
ported.660,665 A valve-in-valve intervention should be delayed at least 
1–3 months following antibiotic treatment of the endocarditis episode. 
The mortality rate related to the IE episode ranges from 0% to 
11%.93,660,661,664,665 This rate is much lower compared with TAVI pa­
tients, which is likely to be related to the younger and less co-morbid 
characteristics of the TPVI population.
12.4. Infective endocarditis affecting 
cardiac implantable electronic devices
Device-related infection is one of the most serious complications of 
CIED therapy and is associated with significant mortality and 
morbidity.671
12.4.1. Definitions of cardiac device infections
A recent EHRA consensus document has published criteria for CIED 
infection.130 Localized infections may be either superficial incisional in­
fections (acute infection without involvement of the pocket or hard­
ware) or isolated pocket infections (limited to the hardware in the 
pocket), and can be either acute or chronic. Systemic CIED infections 
may occur with or without pocket infection, and with or without visible 
vegetations on the tricuspid or pulmonary valves or pacing leads. 
Cardiovascular implanted electronic device-related IE is defined as evi­
dence of CIED infection with clinical signs of pocket infection and/or 
imaging findings (lead vegetations, positive FDG-PET on the gener­
ator/leads etc.) which fulfil the criteria for valvular IE (see Section 5).
12.4.2. Pathophysiology and microbiology
Cardiovascular implanted electronic device-related IE occurs by two 
mechanisms. Local infection usually results from bacterial flora from 
the patient’s skin that is introduced into the pocket at the time of inci­
sion despite surgical preparation.672 Seeding via bacteraemia from a dis­
tant focus is less frequent.673–676
Whereas CoNS are most frequently the cause of chronic pocket in­
fection, the most frequent agents identified with bacteraemia in CIED in­
fection are S. aureus and CoNS.677,678 Other causative organisms are 
Enterococcus spp., β-haemolytic streptococci, oral streptococci group, 
Cutibacterium acnes, and Corynebacterium spp.674,678,679 More rarely, sys­
temic infection is caused by Gram-negative (mainly P. aeruginosa or 
Serratia marcescens)680 or polymicrobial agents, whereas systemic fungal 
infections (Candida spp. and Aspergillus spp.)681 are exceptional.
12.4.3. Risk factors
Risk factors may be divided into patient-related, procedure-related, and 
device-related factors.118 The PADIT (Previous procedure on same 
pocket; Age; Depressed renal function; Immunocompromised; Type 
of procedure) study randomized 19 603 patients undergoing CIED im­
plantation to conventional treatment (pre-procedural cefazolin infu­
sion) vs. different regimens of incremental treatment.682 The primary 
outcome was 1-year hospitalization for device infection which was 
not significantly different between groups. A risk score for infection 
has been derived from the study (see Supplementary data online, 
Table S11)683 and has been validated externally.684 A web-based calcu­
lator is available (https://padit-calculator.ca).683
12.4.4. Prophylaxis
Antibiotic prophylaxis to prevent CIED-related IE before interventions, 
such as dental, respiratory, gastrointestinal, or genitourinary proce­
dures, is not warranted as the risk is very low.
Prevention of CIED infection at implantation hinges upon careful 
planning, pre-operative antibiotic prophylaxis, correction of modifiable 
risk factors, hygienic surgical environment and technique, ancillary mea­
sures in case of increased risk (e.g. use of an antibacterial envelope), and 
proper post-operative care.
Correction of modifiable risk factors includes general measures such 
as postponing the procedure in cases of fever or signs of infection and 
avoiding temporary pacing. Routine administration of prophylactic sys­
temic antibiotics within 1 h of incision is the standard of care.118 RCTs 
have used flucloxacillin (1–2 g i.v.)117 and first-generation cephalospor­
ins, such as cefazolin (1–2 g i.v.).116 Vancomycin (1–2 g over 60–90 min) 
may be used in case of allergy to cephalosporins with other alternatives, 
including teicoplanin and clindamycin.117 Coverage of MRSA should be 
guided by the prevalence in the implanting institution.
Haematoma is a major contributor to risk of infection, and all possible 
measures should be taken to avoid this complication.685,686 Another 
major risk factor is a revision with re-opening of the pocket (e.g. for 
lead repositioning). Technical aspects have recently been covered in de­
tail in an EHRA consensus document on CIED implantation.687
It is generally not recommended to wash the pocket with antibiotics, 
nor to administer antibiotic treatment post-operatively, as shown by 
the PADIT trial.682 An antibiotic mesh envelope, which locally releases 
minocycline and rifampin for a minimum of 7 days and is fully absorbed 
in ∼9 weeks, may, however, be useful to reduce risk of infection in se­
lected patients. The Worldwide Randomized Antibiotic Envelope 
Infection Prevention Trial (WRAP-IT) showed that the mesh envelope 
significantly reduces the incidence of CIED infection in patients at in­
creased risk (i.e. undergoing a pocket revision, generator replacement, 
system upgrade, or implantation of a cardiac resynchronization therapy 
[CRT]-implantable cardioverter defibrillator [ICD]).688 The number 
needed to treat was, however, high at 200, but is ∼50 in patients under­
going CRT reoperations (replacement/upgrade/revision) in a recent 
observational study.689
12.4.5. Diagnosis
Clinical presentation of CIED-associated IE is similar to valvular IE with 
patients frequently presenting with fever, chills, and embolic events. 
Signs of pocket infection (swelling, tenderness, erythema, purulent dis­
charge etc.) may or may not be present.
The probability that a positive blood culture in a CIED recipient re­
presents underlying device infection depends on the organism type and 
duration of bacteraemia. Suspicion of CIED-associated IE should be 
particularly high in the event of S. aureus bacteraemia.675 CIED infection 
is less likely with Gram-negative bacteraemia, and in these instances, the 
pocket usually shows signs of infection.680,690,691


<!-- PAGE 56 -->

### Page 56

Persistent/relapsing bacteraemia/fungaemia
Gram-negative
No vegetations and non-S. aureus
Vegetations and/or
S. aureus
Septic emboli or prosthetic valve
2 weeks of antibiotics
(Class IIb)
4 weeks of antibiotics
(Class IIa)
CIED reimplantationc
(Class I)
6 weeks of antibiotics
(Class IIa)
CIED extraction
Gram-positive or fungaemia
Antibiotic therapy covering MRSA
and Gram-negative bacteria
(Class I)
Suspicion of CIED-related IE
2023 ESC diagnostic criteria for IE
Repeat diagnostic tests within 7 days
Antimicrobial therapy
Bacteraemia/fungaemia without other major criteria or source of infection
Blood cultures
TTE and TOE (or intracardiac echocardiography)
[18F]FDG-PET/CT (or WBC SPECT)a
(Class I)
Possible IE
Definite IE
No IE
Cured
Probable isolated valve IEb
Definite CIED
involvement
(Class IIb)
(Class IIa)
(Class I)
Figure 13 Management of cardiovascular implanted electronic device-related infective endocarditis. [18F]FDG-PET/CT, 18F-fluorodeoxyglucose positron 
emission tomography/computed tomography; CIED, cardiovascular implanted electronic device; ESC, European Society of Cardiology; IE, infective endocar­
ditis; MRSA, methicillin-resistant S. aureus; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT/CT, white blood 
cell single photon emission tomography/computed tomography. aIf no signs of pocket infection and negative TOE. bTaking into account the identified patho­
gen, procedural risk, and requirement for valve surgery. cAt a distant site and postponed as long as possible (until signs and symptoms of infection have re­
solved and blood cultures are negative for >72 h in the absence of vegetations and /or ‘ghosts’, or otherwise after >2 weeks of negative blood cultures).
ESC Guidelines                                                                                                                                                                                          4003


<!-- PAGE 57 -->

### Page 57

Transthoracic echocardiography and TOE are both recommended 
in the case of suspected CIED-related IE.692–694 Intracardiac echocardi­
ography may also be used to visualize vegetations,695 and may be useful 
in patients in whom TOE is not possible. However, the absence of ve­
getations does not rule out IE, as these may be present on extracardiac 
segments of the lead which cannot be visualized. Repeating TTE and/or 
TOE within 5–7 days is recommended in case of initially negative exam­
ination when clinical suspicion of CIED-related IE remains high. It is im­
portant to note that fibrinous lead masses may be observed in 
asymptomatic CIED patients, and do not predict CIED-related IE 
over long-term follow-up.696
Diagnosis of CIED-related endocarditis by [18]FDG-PET/CT has 
good sensitivity and specificity,129 and is particularly useful in the setting 
of possible CIED-related IE without signs of pocket infection.238 Results 
should be interpreted with caution, however, if the CIED is recently im­
planted (<6 weeks).130
White blood cell SPECT/CT has also been used for diagnosing CIED 
infection but has limited availability.216,697 A chest X-ray or CT should 
be performed in all patients to evaluate the presence of pulmonary 
complications.
12.4.6. Antimicrobial therapy
Treatment of CIED infection involves early698,699 and complete removal of 
all parts of the system, combined with initial empirical antibiotic therapy 
directed at MRSA and Gram-negative bacteria, while awaiting identification 
of the pathogen.130,700,701 Antibiotic treatment follows the recommenda­
tions indicated in Section 7. In exceptional cases where complete device re­
moval is not possible, i.v. antibiotics for 4–6 weeks may be administered 
followed by close follow-up after interruption of antibiotic therapy or, al­
ternatively, individualized long-term suppressive oral therapy.
12.4.7. Device extraction
When CIED and lead extraction is required, such procedures should be 
performed in centres with the corresponding expertise. Complete 
CIED removal is recommended for all patients with confirmed infection 
of the lead(s), as conservative treatment is associated with increased mor­
tality.678,699 In patients with left-sided prosthetic heart valves and CIED in­
fection, complete CIED removal combined with prolonged (4–)6 week 
antibiotic therapy may prevent left-sided valve infection.130,702 Complete 
CIED extraction should also be considered in case of valvular IE without 
definite lead involvement, taking into account the identified pathogens 
(Staphylococcus spp. infections may be more prone to seed the 
CIED),673,675,676 procedural risk, and indication for valve surgery.
Complete device extraction should be considered even in the absence 
of vegetations in the setting of persistent or relapsing Gram-positive bac­
teraemia or fungaemia after a course of appropriate antibiotic therapy, if 
there is no other identified source (see Figure 13).681 In all instances of 
lead extraction, procedural risk should be carefully evaluated taking into ac­
count lead dwell time, pacemaker dependency, patient frailty, and other 
co-morbidities within the process of shared decision-making.703
Lead extraction should be performed, without delay (i.e. within the 
first days of admission), as this has been shown to be associated with 
improved outcomes.698,699,704 Percutaneous rather than surgical ex­
traction is the preferred procedure, but requires specialized tools 
and should be performed in centres with expertise in this technique 
and with onsite surgical backup, due to the risk of life-threatening tam­
ponade and vein laceration.
Large vegetations may be aspirated percutaneously before lead extrac­
tion to reduce risk associated with embolization.705 Surgical lead 
extraction should be considered in case of large vegetations (e.g. 
>20 mm)679 and if aspiration is not available or is unsuccessful. Surgical re­
moval is also the preferred technique if valve surgery is indicated. 
Hardware retrieved from extraction, especially the lead tip, should be cul­
tured.706 Sonication has been shown to increase diagnostic yield.707,708
12.4.8. Device reimplantation
The indication for reimplantation should always be carefully evaluated 
and no part of the removed CIED system should be reimplanted. 
Quality of evidence regarding timing of reimplantation is poor.709
Reimplantation should be performed at a site distant from that of the 
previous generator, and delayed until signs and symptoms of local 
and systemic infection have resolved and blood cultures are negative 
for at least 72 h after extraction in the absence of vegetations or 
‘ghosts’ (fibrous remnants after lead extraction, which have been asso­
ciated with death and reinfection),710 or after 2 weeks of negative blood 
cultures if vegetations were visualized.701,711
For patients with a high risk of sudden cardiac death, a wearable defib­
rillator is an option as a bridge to reimplantation. In pacemaker-dependent 
patients, an active-fixation lead may be introduced via the internal jugular 
vein and connected to an external pacemaker for up to 4–6 weeks, thereby 
preserving the contralateral side for definitive device reimplantation.712 As 
an alternative to delayed reimplantation in pacemaker-dependent patients, 
an epicardial pacemaker may be implanted before lead extraction, 
although this strategy has been associated with a higher risk of device 
re-intervention.713 Alternative devices such as leadless pacemakers714 or 
subcutaneous ICD715 may be implanted in selected patients if the risk of 
new infection is deemed high.
Recommendation Table 20 — Recommendations for 
cardiovascular implanted electronic device-related in­
fective endocarditis
Recommendations
Classa
Levelb
Antibiotic prophylaxis covering S. aureus is 
recommended for CIED implantation.118
I
A
TTE and TOE are both recommended in case of 
suspected CIED-related IE to identify 
vegetations.692–694
I
B
Complete system extraction without delay is 
recommended in patients with definite CIED-related 
IE under initial empirical antibiotic therapy.698,699
I
B
Obtaining at least three sets of blood cultures is 
recommended before prompt initiation of empirical 
antibiotic therapy for CIED infection,710 covering 
methicillin-resistant staphylococci and 
Gram-negative bacteria.
I
C
If CIED reimplantation is indicated after extraction 
for CIED-related IE, it is recommended to be 
performed at a site distant from the previous 
generator, as late as possible, once signs and 
symptoms of infection have abated and until blood 
cultures are negative for at least 72 h in the absence 
of vegetations, and negative for at least 2 weeks if 
vegetations were visualized.701,711
I
C
Continued


<!-- PAGE 58 -->

### Page 58

12.5. Infective endocarditis in patients 
admitted to intensive care units
Infective endocarditis is frequently associated with severe life-threatening 
cardiac and/or systemic complications and the number of patients requir­
ing intensive care unit (ICU) admission has steadily been growing in recent 
years, as shown in a large retrospective study.716 The need for ICU admis­
sion, advanced monitoring, vasoactive treatment, and organ support is 
most commonly prompted by the occurrence of septic shock, acute HF, 
and cardiogenic shock leading to multiorgan failure. Moreover, in recent 
years, an increase in healthcare-associated IE, usually of staphylococcal ori­
gin, predominantly in older patients with an increased number of co- 
morbidities, and more likely to lead to critical illness, has also been re­
ported.29,717–719Any IE patient requiring ICU admission should be urgently 
discussed within the Endocarditis Team.
In the largest multicentre retrospective series, focusing on critically 
ill IE patients with organ failure requiring ICU admission in France over 
an 18-year period, overall in-hospital mortality was 32%.716
Multivariate analysis showed age, Simplified Acute Physiology Score 
(SAPS) II score, organ failure, stroke, and Staphylococcus spp. to be as­
sociated with an increased risk of death. In contrast, cardiac surgery, 
CIED, male gender, and Streptococcus spp. as the causative micro­
organism of IE, were associated with a better survival.716 In another 
study that reported an even higher mortality (42%), four independent 
prognostic factors were identified: high SAPS II (>35 points) and 
Sequential Organ Failure Assessment (>8 points) scores, MRSA infec­
tion, and native valve IE.718
Right-sided IE, which is more commonly associated with PWID, ac­
counts for <10% of IE cases but is associated with high mortality in pa­
tients needing ICU admission.717
12.5.1. Causative microorganisms
The majority of retrospective series in the ICU setting point to 
Staphylococcus spp. as the main causative agent of IE episodes. Indeed, 
S. aureus has emerged as the most feared aetiological agent with the 
highest rates of complications and mortality, being responsible for up 
to 56% of IE cases in one observational study.719 Streptococcus spp., 
Enterococcus spp., Gram-negative bacilli, and Candida spp. are less fre­
quently reported.718,719 Identification of the infecting microorganism 
remains the mainstay of effective therapy in complicated IE cases. 
Hence, in patients with negative blood cultures, serological or molecu­
lar testing by PCR should be considered (see Section 5.3).
12.5.2. Diagnosis
The diverse nature, epidemiological profile, and presentation pheno­
type of IE in the ICU setting may hinder early diagnosis. In particular, 
pyrexial episodes suggestive of an alternative infective source and 
neurological manifestations, such as confusion, delirium, or focal symp­
toms may initially mislead the clinician from a diagnosis of IE.
The diagnosis of IE in ICUs follows the same modified criteria as in 
non-ICU patients (see Section 5). Transoesophageal echocardiography 
has a prominent role as a tool for diagnosis of IE and its complications in 
the ICU.720
12.5.3. Management
Antimicrobial therapy and indications for surgery in patients with IE are 
described in Sections 7 and 10, respectively. Surgical therapy has been 
associated with an improved early and late outcome both in the general 
population and in patients admitted to ICUs. Although surgery is the 
treatment of choice in about one-half of patients, surgical therapy in 
ICU patients is characterized by more complex procedures with in­
creased peri-operative mortality, as well as difficult post-operative 
care due to higher requirements of circulatory and pulmonary support. 
Five independent predictors of post-operative need for advanced circu­
latory support were found in one study of patients with IE: male sex, 
increased surgery duration, renal dysfunction (pre-operative estimated 
glomerular filtration <60 mL/min/m2), HF prior to surgery, and lower 
pre-operative platelet count.721
Extracorporeal membrane oxygenation is occasionally required in 
patients post-surgery but is associated with poor outcomes.722
Decision-making in ICU patients with IE should always be a product of 
consensus of the Endocarditis Team to determine the best management 
strategy. Pre-operative haemodynamic optimization and goal-directed 
therapy protocols including vasoactive drugs and mechanical circulatory 
support may be considered in these complex high-risk patients.721
12.6. Right-sided infective endocarditis
Right-sided IE accounts for ∼5–10% of patients with IE,723 but its fre­
quency may be increasing as its risk factors are increasing in some coun­
tries.133,724 Risk factors for right-sided IE include patients with CHD, 
indwelling catheters, and CIED, as well as immunocompromised and 
PWID patients. Of these, PWID is an increasingly common risk 
Complete CIED extraction should be considered in 
case of valvular IE, even without definite lead 
involvement, taking into account the identified 
pathogen and requirement for valve surgery.
IIa
C
In cases of possible CIED-related IE with occult 
Gram-positive bacteraemia or fungaemia, complete 
system removal should be considered in case 
bacteraemia/fungaemia persists after a course of 
antimicrobial therapy.673–676
IIa
C
Extension of antibiotic treatment of CIED-related 
endocarditis to (4–6) weeks following device 
extraction should be considered in the presence of 
septic emboli or prosthetic valves.702
IIa
C
Use of an antibiotic envelope may be considered in 
select high-risk patients undergoing CIED 
reimplantation to reduce risk of infection.688,689
IIb
B
In cases of possible CIED-related IE with occult 
Gram-negative bacteraemia, complete system 
removal may be considered in case of persistent/ 
relapsing bacteraemia after a course of antimicrobial 
therapy.680,690,691
IIb
C
In non-S. aureus CIED-related endocarditis without 
valve involvement or lead vegetations, and if 
follow-up blood cultures are negative without septic 
emboli, 2 weeks of antibiotic treatment may be 
considered following device extraction.
IIb
C
Removal of CIED after a single positive blood culture, 
with no other clinical evidence of infection, is not 
recommended.675
III
C
© ESC 2023
CIED, cardiovascular implanted electronic device; IE, infective endocarditis; TOE, 
transoesophageal echocardiography; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4005


<!-- PAGE 59 -->

### Page 59

factor,133,723 while patients with indwelling vascular catheters have the 
worst prognosis.725 IE of transcatheter pulmonary valves is covered in 
Section 12.2, whereas CIED-related right-sided IE is covered in Section 12.3.
The most common microorganism causing right-sided IE is S. aureus, 
accounting for the majority of patients.723,726 The tricuspid valve is 
much more commonly infected than the pulmonary valve in patients 
with right-sided IE.723,727 Right-sided IE may also involve non-functional 
embryonic remnants of the right atrium (e.g. Eustachian valve).723,727
Right-sided IE rarely spreads to involve the left-sided cardiac structures, 
whereas spread from left- to right-sided structures is not 
uncommon.728
12.6.1. Diagnosis and complications
Right-sided IE patients present with fever, bacteraemia, and pulmonary 
complaints (i.e. cough, chest pain, or haemoptysis). Right-sided HF may 
also occur due to tricuspid or pulmonary regurgitation, or to pulmon­
ary hypertension induced by multiple pulmonary septic emboli.133
Diagnosis is most frequently confirmed by echocardiographic findings of 
vegetations on the tricuspid valve or, less frequently, pulmonary valve. 
Adequate evaluation of the tricuspid valve may be performed with TTE, 
due to the anterior location of the valve and the large vegetations frequent­
ly observed in right-sided IE. Transoesophageal echocardiography is fre­
quently required, however, particularly for evaluation of the pulmonary 
valve or in patients with indwelling venous catheters or intracardiac de­
vices.729 Intracardiac echocardiography may also be helpful in select pa­
tients. Vegetations may be challenging to identify on the pulmonary valve 
even with TOE, especially in patients with a prosthetic valve in the pulmon­
ary position. [18]FDG-PET imaging may be very helpful in such pa­
tients.34,730 Perivalvular abscess formation and invasion into surrounding 
structures is rarely seen in right-sided IE, unless it is a secondary conse­
quence of left-sided IE.728 CT is useful in order to identify concomitant pul­
monary disease, including infarcts and abscess formation.
12.6.2. Endocarditis in people who inject drugs
Infective endocarditis in PWID is an increasing global phenom­
enon.10,132,133,141 Repeat i.v. injections result in contaminated particles 
that reach the tricuspid valve and right-heart chambers and can also 
lead to infection of left-heart structures, which is associated with worse 
prognosis.614 PWID patients also have an increased rate of human 
immunodeficiency virus (HIV) and hepatitis than other patients with 
right-sided IE.731 The majority of right-sided IE in PWID can be treated 
successfully with antibiotic therapy. Mortality rates of PWID are rela­
tively low, even when surgery is required, probably due to the young 
patient age.723 However, PWID have a markedly increased rate of IE 
recurrence, particularly in the first 6 months post-surgery.133,614,723,732
12.6.3. Prognosis and treatment
Right-sided IE is generally a more benign clinical entity than left-sided IE 
and can be medically managed in ∼90% of patients, with surgery re­
served for those who fail medical therapy.733
Patients with 
CIED-related right-sided IE have a worse prognosis as compared 
with non-CIED-related right-sided IE (see Section 12.4).723
725
Right-sided IE in immunocompromised patients, particularly fungal in­
fections, carries a very poor prognosis.
12.6.3.1. Antimicrobial therapy
S. aureus and CoNS are the cause of right-sided IE in a large proportion 
of cases, with S. aureus predominating in PWID and CoNS being more 
common in patients with indwelling devices.723,726 MRSA rates may be 
increasing over time, particularly in PWID.133 Right-sided IE due to 
Streptococcus spp. is unusual but can be observed in alcoholics and dia­
betics. P. aeruginosa and other Gram-negative organisms are rare causes 
of right-sided IE, while Candida albicans is mostly seen in immunocom­
promised patients.
Empirical antimicrobial therapy depends on the suspected micro­
organism, the type of drug and solvent used by the PWID, and the in­
fection location,734 but S. aureus must be initially covered in all cases. 
Initial treatment consists of penicillinase-resistant penicillin, vancomy­
cin, or daptomycin, depending on the local prevalence of MRSA,735 in 
combination with gentamicin. If the patient is a pentazocine addict, an 
anti-Pseudomonas agent may also be required, as the use of recreational 
drugs may also entail infections with Gram-negative bacteria.735 Very 
large vegetations and history of brown heroin use dissolved in lemon 
juice suggest infection for Candida spp. (not C. albicans), and therefore 
antifungal treatment should be added.736 Antifungals may be necessary 
in selected PWID, particularly if immunocompromised.737
Once the causative organisms have been isolated, therapy has to be 
adjusted. An RCT demonstrated that a 2-week treatment course may 
be sufficient and that aminoglycosides may be unnecessary.738 717
Two-week treatment with oxacillin (or cloxacillin) without gentamicin 
is effective when: 
(i) MSSA is the causative organism;
(ii) There is good clinical and microbiological response to treatment 
(>96 h);739
(iii) The vegetation size is ≤20 mm; and
(iv) There is an absence of metastatic sites of infection or empyema 
and cardiac or extracardiac complications,739,740 prosthetic valve 
or left-sided valve infection,741 and severe immunosuppression.742
Glycopeptides (vancomycin) should not be used in a 2-week treatment. 
The standard 4–6-week regimen should be used in the remaining patients 
or when therapy with antibiotics other than penicillinase-resistant penicil­
lins are used.330,739–744 When the conventional i.v. route therapy is not 
possible, S. aureus right-sided IE in PWID may also be treated with oral ci­
profloxacin (750 mg twice a day) plus rifampin (300 mg twice a day) if the 
strain is susceptible to both drugs, the case is uncomplicated, and patient 
adherence is monitored carefully.745 Partial oral antibiotic treatment 
may also be beneficial for PWID with IE.746
For organisms other than S. aureus, therapy in PWID does not differ 
from that in other patients.
12.6.3.2. Surgery
The commonly accepted indications for surgical treatment of right- 
sided IE in patients who are receiving appropriate antibiotic therapy 
are (see Recommendation Table 19): 
• Persistent bacteraemia after at least 1 week of appropriate antibiotic 
therapy.10
• Tight ventricular dysfunction secondary to acute severe tricuspid re­
gurgitation non-responsive to diuretics.479
• Respiratory insufficiency requiring ventilatory support after recur­
rent pulmonary emboli.747
• Involvement of left-sided structures;748,749 and
• Large residual tricuspid vegetations (>20 mm) after recurrent pul­
monary emboli.145,471
Patients should be individually assessed by the Endocarditis Team. An 
isolated vegetation is not an indication for surgery. Patients with


<!-- PAGE 60 -->

### Page 60

residual large vegetations frequently present with right-heart and/or re­
spiratory failure, as well as persistent sepsis.750
The common surgical strategies for tricuspid valve IE include valve re­
pair, replacement and, less commonly, surgical valvectomy.751 Tricuspid 
valve repair is more frequently performed than valve replacement in 
right-sided IE, although the extent of valve destruction may make repair 
impossible.725,752 Tricuspid valve repair may also be associated with 
better short- and long-term outcomes than replacement for right-sided 
IE, particularly with regards to recurrent infection and need for repeat 
surgery.479,723
When valve replacement for right-sided IE is required, bioprostheses 
are frequently preferred due to concerns with the management and 
risks of lifelong anticoagulation, especially in PWID, and the risks of 
thrombo-embolism for mechanical valves in the right heart.726
Prophylactic placement of permanent epicardial leads should be per­
formed at the time of tricuspid valve surgery for right-sided IE, particu­
larly if heart block is present in the operating room to prevent damage 
of a replaced valve during subsequent transvenous lead displacement 
and to lower the risk of reinfection.733
Recently, interest has been generated in the extraction of large vege­
tations using percutaneous extracorporeal circuitry for aspiration.753
The main goals have been debulking of septic intracardiac masses, redu­
cing the infectious load, and achieving clinical stability.754
12.7. Infective endocarditis in congenital 
heart disease
Although the incidence of CHD is relatively constant, the overall popu­
lation with CHD is constantly increasing due to increased survival fol­
lowing CHD surgery in childhood and increased longevity of adults 
with CHD. The presence of CHD, even after repair, is recognized as 
a lifelong potential substrate for IE. Congenital heart disease predis­
poses to IE via several mechanisms including turbulent non-laminar 
blood flow causing shear stress and endothelial damage, the presence 
of intracardiac foreign material such as prosthetic valves or CIED, cyan­
osis, and recurrent exposure to cardiac procedures.98
There are marked variations in susceptibility to IE between CHD 
lesions. Some simple conditions, such as secundum atrial septal defect, 
patent ductus arteriosus, and pulmonary valve stenosis, carry a low risk 
of IE, while others, such as bicuspid aortic valve carry a somewhat 
increased risk.8 However, CHD often presents with multiple cardiac 
lesions, each adding to the total risk of IE.8,756 In general terms, IE is 
more common in CHD with multiple defects and in patients with 
more complex CHD.757
Specific high-risk conditions are prosthetic valves, including transcath­
eter valves, valve repair using a prosthetic ring, previous IE, any unre­
paired cyanotic CHD, and any CHD repaired with prosthetic material 
for up to 6 months after the procedure, or lifelong if residual shunt or 
valvar regurgitation remains.758 Contemporary studies confirm the rela­
tively high risk of IE in CHD patients after valve surgery.8,47,90,759 Specific 
awareness is needed after TPVI (see Section 12.3.2).666,759,760
The distribution of causative microorganisms does not differ from 
the pattern found in acquired heart disease, with Streptococcus spp. 
and Staphylococcus spp. being the most common strains.98,757,761,762
As in other groups, the diagnosis of IE is often made late,757 highlighting 
the need to consider the diagnosis of IE in any CHD patient presenting 
with persisting fever or other signs of ongoing infection. Multiple blood 
cultures are essential before starting antibiotic treatment. The principal 
symptoms, complications, and basis for diagnosis do not differ from IE 
in general. However, in CHD right-sided IE is more frequent than in 
non-CHD-acquired cardiac disease.
Transthoracic echocardiography is sufficient in many cases to image 
the infectious lesions and their complications. However, complex anat­
omy and the presence of artificial material may reduce the rate of vege­
tation detection and other features of IE, thus favouring the addition of 
TOE, particularly in adults and larger children. Despite the improved 
sensitivity of TOE for the detection of IE, TOE may only perform simi­
larly to TTE for anterior structures of the heart, such as the right ven­
tricular outflow tract, or infected sites at distal structures, such as stents 
or other prosthetic material within branch pulmonary arteries. Hence, 
a negative study does not exclude the diagnosis of IE. In patients with 
prosthetic material advanced imaging such as [18F]FDG-PET/CT and 
PET/CTA, can increase the diagnostic accuracy.223
In addition to the usual Endocarditis Team (see Section 4), multidis­
ciplinary care of CHD patients with IE from diagnosis to treatment 
should be provided in specialized CHD centres with expertise in 
CHD cardiac imaging, CHD surgery, infectious disease, and intensive 
care. Surgical indications do not differ from those of acquired heart dis­
ease IE. Mortality rates in CHD vary from 6% to 15%.757,761–764 This 
better prognosis compared with acquired heart disease IE may reflect 
the higher proportion of right-heart IE, younger overall patient age, or 
the comprehensive care in CHD centres.
Primary prevention of IE in CHD patients and corresponding patient 
education is essential (see Section 3).765
Recommendation Table 21 — Recommendations for 
the 
surgical 
treatment 
of 
right-sided 
infective 
endocarditis
Recommendations
Classa
Levelb
Surgery is recommended in patients with right-sided IE who are receiving 
appropriate antibiotic therapy for the following scenarios:
Right ventricular dysfunction secondary to acute 
severe tricuspid regurgitation non-responsive to 
diuretics.479
I
B
Persistent vegetation with respiratory insufficiency 
requiring ventilatory support after recurrent 
pulmonary emboli.479,755
I
B
Large residual tricuspid vegetations (>20 mm) 
after recurrent septic pulmonary emboli.145,471
I
C
Patients with simultaneous involvement of 
left-heart structures.749
I
C
Tricuspid valve repair should be considered instead 
of valve replacement, when possible.479
IIa
B
Surgery should be considered in patients with 
right-sided IE who are receiving appropriate 
antibiotic therapy and present persistent 
bacteraemia/sepsis after at least 1 week of 
appropriate antibiotic therapy.436,755
IIa
C
Prophylactic placement of an epicardial pacing lead 
should be considered at the time of tricuspid valve 
surgical procedures.733
IIa
C
Debulking of right intra-atrial septic masses by 
aspiration may be considered in selected patients 
who are high risk for surgery.753
IIb
C
© ESC 2023
IE: infective endocarditis. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4007


<!-- PAGE 61 -->

### Page 61

12.8. Infective endocarditis in rheumatic 
heart disease
Infective endocarditis is a known complication of RHD,766 and acute 
rheumatic fever (the antecedent of RHD) may even present with con­
comitant IE.767 Of the 3343 participants enrolled in The Global 
Rheumatic Heart Disease Registry (REMEDY),768 133 (2.4%) had a his­
tory of IE at enrolment,769 and 20 (0.7%; 3.65 per 1000 patient-years) 
developed IE during the 27-month follow-up.770 These participants 
were young with a median age of 28 years (interquartile range 18–40 
years), 66.2% were women, and over 30% were children. The majority 
of the over 40 million patients with RHD771 live in low- and 
middle-income countries and face socioeconomic and health-system 
barriers772 to adequate prevention, early diagnosis, and advanced 
care and, therefore, are at particular risk of IE.773
Global access to surgery for RHD and RHD-associated complications 
is extremely limited.774 RHD patients presenting with fever, changing or 
new murmurs should be investigated for IE. In studies from RHD- 
endemic regions, RHD is the most common underlying cardiac condition, 
with significant mortality and morbidity.775–784 In those affected with oral 
bacteria-related IE linked to RHD, oral Streptococcus spp. was the main 
cause of IE associated with poor oral health status.785 In RHD-endemic 
countries, IE in children is strongly linked to RHD,786–788 and when caus­
ing HF, carries the highest case fatality rate.789 IE is associated with en­
hanced risk of death among patients with RHD undergoing isolated 
mitral valve replacement (odds ratio 5.22, 95% confidence interval 
[CI], 1368–19 915; P = 0.008).790 Pregnancy is a particularly high-risk 
period for women with RHD, with an increased risk of developing 
IE.791,792 However, high-income countries or countries with emerging 
economies are seeing less IE linked to RHD, as the incidence rates of 
RHD in these regions decrease.793–796
12.9. Infective endocarditis during 
pregnancy
Infective endocarditis in pregnancy is a rare but extremely serious con­
dition with high maternal and foetal morbidity and mortality, and is es­
timated to complicate ∼1 in 100 000 pregnancies.797–799 Maternal 
mortality approaches 18%, with most deaths relating to HF or an em­
bolic event, while pre-term birth is reported at 55.7% and foetal mor­
tality at 29%.800 Recurrent infective complications can occur in up to 
27% of women post-partum.801
The diagnosis must be considered in pregnant women with unex­
plained fever and cardiac signs (especially tachycardia), new or changing 
cardiac murmurs, and peripheral signs of septic emboli.802 Women with 
CHD, RHD,803 and structural heart disease, together with those with 
prosthetic heart valves and with PWID are at particular risk.800,804–807
The gravity of the condition requires the inclusion of gynaecologists, obste­
tricians, and neonatologists in the Endocarditis Team in any suspected cases, 
and a diagnosis and treatment plan should be formulated without delay, as 
this is key to saving the lives of mothers and infants.799,808,809 Management 
can be challenging, especially when the pregnant patient warrants a cardiac 
operation under CPB. Although this poses a considerable risk to the foetus, 
urgent surgery when indicated should not be delayed.799,810
12.10. Infective endocarditis in 
immunocompromised patients
12.10.1. Solid organ transplant recipients
The incidence of IE in recipients of solid organ transplantation (SOT) 
ranges between 1% and 2%.107 SOT recipients with IE are younger 
and have higher prevalence of co-morbidities (particularly renal and 
liver disease) compared with non-SOT patients with IE. Among the 
SOT patients with IE, the most common transplanted organ is the 
kidney (72%), followed by liver (17%), and pancreas (8%).811 Similar 
to non-SOT patients, aortic followed by mitral IE are the most common 
forms of IE while right-sided IE is uncommon. Interestingly, SOT pa­
tients with IE more frequently have atrial or ventricular vegetations 
without 
valve 
involvement 
(mural 
IE).107
In-hospital 
and 
healthcare-related IE are the most frequent causes of IE in recipients 
of SOT and the most frequent microorganism involved is S. aureus 
(34%), followed by Enterococcus spp. (17%), and Streptococcus spp. 
(11%).107,811
Surgical valve repair/replacement is less frequently performed in SOT 
patients with IE as compared with non-SOT patients. Interestingly, the 
outcomes of IE in patients with SOT do not differ from those of 
non-SOT with IE.107,811 The reasons for the similar outcomes may 
rely on the younger age of the SOT patients, the frequent contact 
with the healthcare system which may lead to early diagnosis and treat­
ment of IE, and the frequent involvement of infectious disease specialists 
in the care of hospitalized SOT patients. However, compared with SOT 
patients without IE, those who develop IE during the index transplant 
hospitalization have worse outcomes.811 The high levels of immunosup­
pression probably negatively impact the IE course in these patients.
Heart transplant recipients represent 10% of SOT with IE pa­
tients.811 Among 57 heart transplant recipients who developed IE, 
the most frequent organism was S. aureus (26%), followed by A. fumiga­
tus (19%), and E. faecalis (12%).105 The median time to IE presentation 
after heart transplant was 8 years and the mitral valve was the most fre­
quently affected, followed by mural and tricuspid valve IE. All-cause 
mortality in this group of patients is high (45%), and fungal aetiology 
is associated with worse outcomes. Similar to other SOT recipients, 
heart transplant recipients were not frequently referred to surgery 
(35%).105
12.10.2. Patients with human immunodeficiency virus
The advent of combined antiretroviral treatment has led to a reduction 
in the risk of developing acquired immune deficiency syndrome (AIDS) 
but people living with HIV remain a vulnerable population for IE.812 The 
incidence of IE in people living with HIV has decreased over the last two 
decades. A retrospective study from Spain has shown a reduction in the 
incidence of IE from 18.2 per 100 000 patient-years between 1997 and 
1999 to 2.9 events per 100 000 patient-years between 2000 and 
2014.813 Similarly, a registry from the United States of America 
reported a reduction in the incidence of IE from 148 in 2007 to 112 
in 2017.141 Patients living with HIV and presenting with IE are becoming 
older, and have a higher percentage of substance abuse and co- 
morbidities.141,813 Of importance, the number of patients living with 
HIV who are admitted with IE have higher frequency of CHD, prior 
valve surgery, CIED infection, and haemodialysis.141,813 The most fre­
quent microorganisms causing IE are Staphylococcus spp. (the majority 
of which is S. aureus), followed by Streptococcus spp., Gram-negative 
bacilli, and enterococci. It is important to note that over the last two 
decades, the frequency of CoNS as a cause of IE has decreased whereas 
the frequency of streptococci, Gram-negative bacilli, enterococci, and 
fungus has increased.813 Community-acquired IE has become the 
most frequent form while healthcare-associated IE rates have signifi­
cantly decreased over time.
The outcomes of IE in people living with HIV have improved over the 
years (from 23.9 to 5.5 deaths per 100 000 patient-years) and surgical


<!-- PAGE 62 -->

### Page 62

treatment should follow the same indications as in patients without 
HIV.813
12.10.3. Patients with neutropaenia
Neutropaenia is common in patients with haematological malignan­
cies and in patients receiving chemotherapy for other malignancies, 
but is rare in patients presenting with IE.814 Neutrophils play an im­
portant role in the pathogenesis of IE by producing layers of extracel­
lular traps that entrap bacteria-platelet aggregates, leading to 
expansion of these aggregates, vegetation growth, and the destruction 
of tissues.814 The diagnosis of IE can therefore be challenging in pa­
tients with neutropaenia, delaying the appropriate treatment, and 
worsening outcomes. Series reporting the clinical characteristics 
and outcomes of IE in patients with neutropaenia are anecdotal.814
As in any other immunocompromised patient with IE, antibiotic and 
surgical treatment are the same as in patients without neutropaenia. 
It is important to take into consideration the side effects of some anti­
biotics which may worsen the neutropaenia, such as cloxacillin and 
ceftaroline.815,816
12.11. Antithrombotic and anticoagulant 
therapy in infective endocarditis
Infective endocarditis by itself is not an indication for antithrombotics 
or anticoagulants, and bleeding complications or stroke may in contrast 
justify discontinuation or interruption of such therapies. Indications for 
antithrombotic therapy or anticoagulants (e.g. atrial fibrillation, valve 
prostheses, ischaemic heart disease, prior stroke, etc.) are prevalent 
in the general population and, as a result, the clinician is often faced 
with the challenge of these therapies in patients presenting with IE, es­
pecially in cases where surgery is part of the treatment course. For pa­
tients with IE and stroke, thrombolytic therapy is not recommended 
(see Section 9.1). However, thrombectomy may be considered in se­
lected cases with large vessel occlusion.
The level of evidence underlying the recommendations for 
antithrombotic and anticoagulant therapy in IE is low and should 
be discussed within the Endocarditis Team. Bridging with low- 
molecular-weight heparin/unfractionated heparin instead of oral antic­
oagulants should be considered early on in the IE course, especially for 
patients in whom surgery is indicated. To date, no data support initi­
ation of either antithrombotics nor anticoagulants for treatment or 
prevention of stroke in IE.
12.12. Non-bacterial thrombotic 
endocarditis
Non-bacterial thrombotic endocarditis (NBTE) is a rare condition with 
an incidence varying from 1.1% to 1.6% in patient-series from autopsy 
studies.818,819 Non-bacterial thrombotic endocarditis occurs in patients 
with a predisposing factor and/or a hypercoagulable state, such as sys­
temic lupus erythematous (SLE), APLs (Libman–Sacks endocarditis), 
cancer (marantic endocarditis), disseminated intravascular coagulation 
(DIC), or various other chronic diseases (tuberculosis or autoimmune 
disease).820,821 Increased production of coagulation factors, of cyto­
kines, and high tissue factor expression are potential mechanisms 
underlying NBTE in cancer patients.822
In a recent contemporary registry, 41% of NBTE patients had cancer, 
33% SLE, and 36% APLs, with 21% of patients having both SLE and 
APLs.823 Among the patients with malignancies, the three most fre­
quent cancers were lung adenocarcinoma, breast, and pancreatic can­
cer. Stroke was the most frequent clinical presentation at admission 
(60%), while HF was observed in 21% and acute coronary syndrome 
in 7% of patients. Transthoracic echocardiography was able to confirm 
the diagnosis in 45% of patients. The mitral valve was more often af­
fected (62%) than the aortic valve (24%).823
The diagnosis of NBTE remains challenging and should be suspected 
in patients presenting with systemic embolization and a predisposing 
factor (i.e. cancer, APLs, SLE). Laboratory findings of a hypercoagulable 
state (eg. lupus anticoagulant, anti-cardiolipin antibodies, and 
anti-β2-glycoprotein 1 antibodies or DIC) may be present, but are non- 
specific and may also be demonstrated in other IE patients with embolic 
events.162
Echocardiography diagnosis should attempt to differentiate 
non-bacterial thrombotic vegetation from IE, Lambl excrescences, or 
fibroelastoma, or other benign intracardiac masses/tumours.824
Libman–Sacks vegetations may present with various shapes (sessile, 
tubular, or coalescent), various levels of echogenicity (heterogeneously 
or homogeneously), could be nodular or protuberant, are generally lo­
cated near the leaflet’s edge of coaptation, and frequently have exten­
sions to the mid and basal portions of the leaflet. They are rarely 
associated with valve dysfunction and never with valve perforation, 
which is an important method of differentiating from bacterial IE.824
Compared with TOE, TTE has a lower sensitivity (63%), specificity 
(58%), negative predictive value (40%), and a moderate positive predict­
ive value (78%) for the detection of NBTE.823,824 Compared with 
two-dimensional TOE, three-dimensional TOE provides additional in­
formation and allows a better characterization of the vegetation.823
The treatment of the underlying cause (i.e. SLE or cancer) is crucial to 
prevent recurrent NBTE. Anticoagulant treatment should be consid­
ered in all patients and should be balanced against the individual 
Recommendation Table 22 — Recommendations for 
the use of antithrombotic therapy in infective 
endocarditis
Recommendation
Classa
Levelb
Interruption of antiplatelet or anticoagulant therapy 
is recommended in the presence of major bleeding 
(including intracranial haemorrhage).482,483
I
C
In patients with intracranial haemorrhage and a 
mechanical valve, reinitiating unfractionated heparin 
should be considered as soon as possible following 
multidisciplinary discussion.817
IIa
C
Continued
In the absence of stroke, replacement of oral 
anticoagulant therapy by unfractionated heparin 
under close monitoring should be considered in 
cases where indication for surgery is likely (e.g. S. 
aureus IE).451,817
IIa
C
Thrombolytic therapy is not recommended in 
patients with IE.481,491
III
C
© ESC 2023
IE, infective endocarditis. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4009


<!-- PAGE 63 -->

### Page 63

patient’s bleeding risk.821 Patients may be anticoagulated with 
low-molecular-weight heparin, vitamin K antagonists, or unfractionated 
heparin. There are no data to support the use of direct oral 
anticoagulants in NBTE. In a randomized open-label multicentre study 
comparing rivaroxaban and warfarin in patients with thrombotic APLs, 
the use of rivaroxaban was associated with an increased rate of 
thrombo-embolic events and major bleeding.825 The role of surgery 
is controversial and remains to be clarified. However, surgery should 
be considered in patients with severe valve dysfunction or with large 
vegetations.823
12.13. Infective endocarditis and 
malignancy
There are limited data on the prevalence, clinical presentation, manage­
ment, and outcome of IE in patients with malignancy. In a retrospective 
Japanese cohort study including 170 patients, 17.6% had active malig­
nancy.826 Compared with patients without malignancy, patients with 
malignancies were older, nosocomial IE was more frequent, and proce­
dures before IE (non-dental, i.v. catheter insertion, invasive endoscopic, 
or genitourinary procedures) were more frequent.826 Another recent 
study from the EURO-ENDO registry of 3085 patients with IE found a 
history of malignancy in 11.6% of patients.827 Patients with a history of 
malignancy had a similar rate of theoretical indications for surgery, but 
surgery was performed less often in this group. Mortality was higher in 
the malignancy group with independent predictors for mortality being 
elevated creatinine >2 mg/dL, congestive HF, and unperformed cardiac 
surgery when indicated.827 In IE patients with concomitant cancer, indi­
cations for valve surgery should be discussed within the Endocarditis 
Team, including a cardio-oncologist and the oncologist in charge of 
the patient, in order to take into account the risks and benefits of sur­
gery and cancer prognosis.
13. Patient-centred care and 
shared decision-making in infective 
endocarditis
13.1. What is patient-centred care and 
shared decision-making and why is it 
important?
Patient-centred care encourages involvement and collaboration be­
tween patients, families, and healthcare providers during all stages of 
diagnosis, treatment, and recovery.828–831 Core elements of patient- 
centred care include: involvement of family and caregivers, respect 
for patients’ preferences and values, care co-ordination and continuity, 
information and education, as well as physical comfort and emotional 
support (Figure 14).828–830
Shared decision-making involves a bidirectional process where pa­
tients, family, and healthcare providers share information and discuss 
care options in the context of the patients’ preferences, beliefs and va­
lues, and the best available evidence ensuring that the patient under­
stands the risks,832,833 benefits, and possible consequences of the 
different options.834–836 The majority of patients prefer sharing deci­
sions about their own health, if they are sufficiently informed and pre­
pared.837,838 Patient-centred care and shared decision-making have 
been shown to contribute to improved concordance between care 
providers and patients on treatment plans, as well as increased patient 
satisfaction, quality of life, and health outcomes.830,839–843
13.2. Patient-centred care and shared 
decision-making in infective endocarditis
The severity of IE, the complex and comprehensive diagnostics and 
treatment, as well as the long illness trajectory, put special emphasis 
on patient-centred care and shared decision-making in IE (Figure 14). 
Quality of life appears to be impaired in IE survivors, with a significant 
number of patients developing symptoms of anxiety, depression, or 
even post-traumatic stress disorder following IE treatment.604,844
The time of diagnosis is often emotionally distressing to the patient 
and family, as they face a life-threatening condition and lengthy 
treatment.845
During the diagnostic and active treatment phase, healthcare provi­
ders should make every effort to minimize patient discomfort (e.g. re­
lated to symptoms and diagnostic procedures), and alleviate distress in 
both patient and family by providing support and comprehensive and 
timely information about the patient’s condition, therapeutic options, 
and prognosis. Independent of the therapeutic strategy (i.e. surgical 
vs. conservative), patient-centred care is key to ensure a good physical 
and mental outcome during a lengthy treatment and hospitalization as­
sociated with IE. Maintaining continuity of care, when possible, by min­
imizing the number of providers the patient encounters and minimizing 
transfers between and within units, is all part of a patient-centred care 
approach. Allowing family visits at any time and providing the opportun­
ity to uphold personal integrity and autonomy are important issues for 
patients. National patient organizations and associations may be an op­
tion for offering information and support to patients and their families.
The role of outpatient antimicrobial treatment options in IE should 
be discussed using a shared decision-making approach, involving the pa­
tient’s partner or family if possible. The outpatient treatment should be 
in concordance with the patient’s and family’s preferences, also consid­
ering transportation and self-care abilities. To monitor possible compli­
cations, it is important to inform and educate patients and caregivers 
about the signs and symptoms of disease progression or recurrence.
The early period after discharge can be challenging for patients and their 
families, and patients report slow physical and mental recovery after IE, of­
ten extending longer than anticipated.603,604,846,847 Patient-centred care 
should therefore extend further than the clinical treatment at the hospital 
to ensure a good outcome after discharge. Though little research has ex­
plored patients’ and families’ needs for recovery and rehabilitation follow­
ing IE, patients with heart disease report experiencing new and continuous 
challenges and a lack of knowledge and understanding after discharge, 
which should be addressed to optimize recovery.848
It is recommended that a recovery plan is developed in collaboration 
with the patient and their caregivers and that the plan is reviewed and 
potentially adjusted following a short period after discharge.849
Physical exercise should be recommended based on an individual as­
sessment of functional capacity (guided by physicians and physiothera­
pists), and patient education and psychosocial support should address 
the main problems and concerns patients and families have. 
Importantly, patient education should also include information about 
the risk of recurrence and preventive measures described in Sections 3 
and 11. Special consideration should be taken for patients with no close 
relatives. Self-support groups or mentors may be introduced to patients 
without support networks. Also, follow-up by telephone from the ward 
staff, until full recovery has been reached, may be an option.
A palliative approach aims to improve the quality of life of patients 
and their families who are facing problems associated with life- 
threatening illness, which is relevant for many patients with IE. This ap­
proach includes a holistic, needs-based perspective with the aims of


<!-- PAGE 64 -->

### Page 64

assessing and improving symptom management, communication, 
advanced care planning, as well as psychosocial and spiritual needs.850
14. Sex differences
Female sex is less common in patients diagnosed with IE, being present 
in approximately one-third of cases; a finding that has been demon­
strated in multiple IE patient subpopulations and across different re­
gions.5,59,723,851,852 The reason why female sex is observed less 
frequently in IE is unknown and deserves further investigation. 
Possible reasons include underdiagnosis of IE in women, referral bias 
in published studies, intrinsic protective mechanisms against IE in 
women, and decreased incidence of risk factors for IE in women (e.g. 
bicuspid aortic valve disease, previous heart valve replacement surgery), 
among others. A recent nationwide population study of individual 
patient-level linkage data of 7513 patients hospitalized for IE in 
Scotland, however, demonstrated roughly equal proportions of male 
and female patients throughout the 25-year study period.27
Female patients with IE have been demonstrated to have a higher preva­
lence of several risk factors for IE in comparison to their male counterparts 
including older age, mitral valve involvement, S. aureus infection, neuro­
logical symptoms, and haemodialysis.853–856 However, men have a higher 
prevalence of other important risk factors including previous prosthetic 
valve replacement, periannular complications, CAD, and liver cirrhosis.855
Some studies have demonstrated higher mortality rates for female 
patients with IE,856 while others have demonstrated no differences in 
Family and caregiver involvement
Patients’
preferences and values
Care coordination and integration
Information and education
Physical comfort and emotional support
Continuity and transition
P
a ti e
n tc e
n tr e
d
 c a
r e
S
h a
r e
d
 
d e
ci si o
n
-
m a
k i
n g
Figure 14 Concept of patient-centred care in infective endocarditis.
ESC Guidelines                                                                                                                                                                                          4011


<!-- PAGE 65 -->

### Page 65

early and 1-year mortality rates between males and females.853,855,857
The abovementioned population study from Scotland showed lower 
mortality rates for women during the study period.27
Although surgery has been demonstrated to be protective against 
mortality in several clinical scenarios (see Section 8), surgery is per­
formed less frequently in female patients with IE.855,856 In a study using 
the National Inpatient Sample of 81 942 patients hospitalized for IE 
over an 11-year period, women were 43% less likely to undergo valve 
replacement surgery, a significant difference that remained after adjust­
ing for confounding factors.855 The reason for decreased surgery in fe­
male IE patients is unknown and requires further investigation.
Female sex has also been identified as an independent risk factor for 
mortality in prediction models for patients with IE undergoing sur­
gery.416 However, a single-centre study suggested that worse observed 
surgical outcomes in female patients with IE was related to their in­
creased risk factors and severity of presentation, rather than gender 
per se.854 In addition, a large multicentre registry of 4300 patients 
undergoing surgery for IE failed to identify female gender as an inde­
pendent predictor of mortality.852
15. Key messages
Prevention: 
• Populations at high risk of IE include patients with previous IE, pa­
tients with surgical or transcatheter prosthetic valves or post-cardiac 
valve repair, and patients with untreated CHD and surgically cor­
rected CHD.
• Prevention of IE comprise hygienic measures (including oral hygiene) 
for all individuals and antibiotic prophylaxis for patients at high risk of 
IE undergoing oro-dental procedures.
The Endocarditis Team: 
• The diagnosis and management of patients with IE should be dis­
cussed with the Endocarditis Team, which includes healthcare pro­
fessionals with the expertise to diagnose and treat IE and its 
complications.
• Uncomplicated IE can be managed in a Referring Centre that remains 
in early and regular communication with the Endocarditis Team of 
the Heart Valve Centre.
• Patients with complicated IE should be treated in the Heart Valve 
Centre, which must offer a wide range of ancillary specialty support 
including onsite cardiac surgery expertise.
Diagnosis: 
• The diagnosis of IE is based on major criteria, which include positive 
blood cultures and valvular and perivalvular/periprosthetic anatomic 
and metabolic lesions detected on imaging, and on minor criteria 
which have been updated to include frequent embolic vascular dis­
semination including asymptomatic lesions detected by imaging only.
• Clear diagnostic algorithms have been established to diagnose NVE, 
PVE, and right-sided IE.
Antimicrobial therapy – principles and methods: 
• Successful treatment of IE relies on microbial eradication by anti­
microbial drugs. Surgery contributes by removing infected material 
and draining abscesses.
• Antibiotic treatment of PVE should last longer (≥6 weeks) than that 
of NVE (2–6 weeks).
• In both NVE and PVE, the duration of treatment is based on the first 
day of effective antibiotic therapy (negative blood culture in the case 
of initial positive blood culture), not on the day of surgery.
• The initial choice of empirical treatment depends on the use of pre­
vious antibiotic therapy, whether IE is NVE or PVE (and if so, when 
surgery was performed [early vs. late PVE]), the place where the in­
fection took place (community, nosocomial, or non-nosocomial 
healthcare-associated IE), and knowledge of the local epidemiology.
• The antibiotic treatment of IE has two phases. The first phase con­
sists of 2 weeks of in-hospital i.v. treatment. In this initial phase, car­
diac surgery should be performed if indicated, infected foreign bodies 
should be removed, and cardiac as well as extracardiac abscesses 
should be drained. In the second phase, in selected patients, the anti­
biotic treatment can be completed within an outpatient parenteral or 
oral antibiotic programme for up to 6 weeks.
• Aminoglycosides are not recommended in staphylococcal NVE be­
cause their clinical benefits have not been demonstrated. In IE caused 
by other microorganisms in which aminoglycosides are indicated, 
they should be prescribed in a single daily dose to reduce 
nephrotoxicity.
• Rifampin should be used only in IE involving foreign material, such as 
PVE, after 3–5 days of effective antibiotic therapy.
• When daptomycin is indicated, it must be given at high doses (10 mg/ 
kg once daily) and combined with a second antibiotic (beta-lactams or 
fosfomycin in beta-lactam allergic patients) to increase activity and 
avoid the development of resistance.
• OPAT can only start when a TOE shows absence of local progression 
and complications (e.g. severe valvular dysfunction).
• In the OPAT programme, patients continue with the same antibiotics 
administered in the acute phase, if possible.
Indications for surgery and management of main infective 
endocarditis complications: 
• There are three main reasons to undergo surgery in the setting of 
acute IE: HF, uncontrolled infection, and prevention of septic 
embolization.
• While surgery during the acute phase of IE is usually performed on an 
urgent basis (i.e. the patient undergoes surgery within 3–5 days), 
some cases require emergency surgery (i.e. within 24 h), irrespective 
of the pre-operative duration of antibiotic treatment.
Other complications of infective endocarditis: 
• Stroke may be the first presenting symptom in patients with IE. 
Unexplained fever accompanying a stroke in a patient with risk fac­
tors for IE should trigger the suspicion of IE.
• Epicardial pacemaker implantation should be considered in patients 
undergoing surgery for IE with complete AVB and other risk factors.
• MRI or PET/CT are indicated in patients with suspected spondylodis­
citis and vertebral osteomyelitis complicating IE.
Surgical therapy principles and methods: 
• The indication to perform invasive coronary angiography or CTA 
prior to surgery for IE should be based on the presence of cardiovas­
cular risk factors in patients with aortic valve IE.
• Surgery should not be delayed in patients with non-haemorrhagic 
stroke and clear indications for surgery. In patients with significant


<!-- PAGE 66 -->

### Page 66

pre-operative haemorrhagic stroke, a delay in operative management 
(≥4 weeks) is generally recommended.
• The decision of not offering surgery when indicated should be made 
in the setting of an Endocarditis Team.
Outcome after discharge – follow-up and long-term 
prognosis: 
• Relapse is a repeat episode of IE caused by the same microorganism 
and represents a failure of treatment, and mandates a search for a 
persistent focus of infection and an evaluation towards surgical 
therapy.
• Reinfection is an infection caused by a different microorganism, usu­
ally more than 6 months after the initial episode.
• Once antibiotic treatment has been completed, blood cultures 
should be performed.
• Patients discharged after the first episode of IE should remain under 
close surveillance for potential long-term complications.
Management of specific situations: 
• Antibiotic prophylaxis to prevent CIED-related IE before dental and 
other non-cardiac interventions is not warranted.
• A single positive blood culture with no other clinical evidence of in­
fection should not result in removal of the CIED. Complete CIED re­
moval is recommended for all patients with confirmed infection of 
the lead(s).
• The indication for CIED reimplantation should always be re- 
evaluated and no part of the removed system should be reimplanted. 
In pacemaker-dependent patients, an active-fixation lead may be in­
troduced and connected to an external pacemaker for up to 6 weeks.
• Surgical treatment of right-sided IE is indicated in patients with per­
sistent bacteraemia, right ventricular dysfunction, recurrent septic 
pulmonary embolism and respiratory compromise, and involvement 
of left-sided structures.
• Multidisciplinary care of CHD patients with IE, from diagnosis to 
treatment, should be provided in specialized CHD centres with ex­
pertise in CHD cardiac imaging, CHD surgery, and intensive care.
Patient-centred care and shared decision-making in 
infective endocarditis: 
• In patients with IE, shared decision-making enables the integration of 
patients’ preferences, values, and priorities to achieve a good treat­
ment decision.
• In patients with IE and without support networks or severely 
impacted by social determinants, a recovery plan developed in 
collaboration with the patient should be established, highlighting 
the information about the risk of recurrence and preventive 
measures.
Sex differences: 
• Female sex is less common in patients diagnosed with IE, being pre­
sent in approximately one-third of cases.
16. Gaps in evidence
• The majority of the recommendations with a level of evidence B are 
based on observational studies rather than single RCTs or 
meta-analyses from RCTs.
Prevention: 
• In the intermediate or unknown risk condition groups, there is no evi­
dence to recommend antibiotic prophylaxis.
• There is currently no evidence to support the use of antibiotic prophy­
laxis after the implantation of a left atrial appendage occlusion device.
Diagnosis: 
• More data on the accuracy of diagnosis of culture-negative IE using 
molecular biology techniques, or the determination of bacterial/fun­
gal cell-free DNA in blood samples, is required.
• Standardization of the methodology to assess the size of the vegeta­
tions has not been established.
• More data on the diagnostic performance of intracardiac echocardi­
ography in PVE are needed.
• The role of [18F]FDG-PET/CT(A) in NVE needs to be established.
• Routine use of imaging tests to screen the presence of embolic 
events, especially brain imaging, is not well established.
• In fungal endocarditis, the role of molecular and biochemical indica­
tors to establish the diagnosis is not well studied.
Antimicrobial therapy – principles and methods: 
• Clinical trials are needed to assess the efficacy and safety of recom­
mended antimicrobial treatment regimens and new combinations 
or antimicrobials. Many recommendations come from clinical trials 
for bacteraemia and not for IE.
• Effective antibiotic treatment in patients with highly penicillin- 
resistant oral streptococci should be investigated.
• Randomized data to establish the best medical strategy in staphylo­
coccal IE are required.
• Effective antibiotic treatments for patients with HLAR E. faecalis IE 
and hypersensitivity to beta-lactams need further research.
• Effective treatments for vancomycin-resistant enterococcal IE need 
further research.
• Randomized head-to-head comparisons of different antibiotics to better 
judge efficacy and toxicity (e.g. for aminoglycosides) are needed.
• The duration of antibiotic treatment has been established empirically 
and no randomized data have been published.
• The efficacy of combined antifungal therapy has not been studied.
• The empirical use of an aminoglycoside-sparing empirical combin­
ation regimen has not been extensively studied.
• More data on implementation of oral treatment in large studies are 
needed.
Indications for surgery and management of main infective 
endocarditis complications: 
• The indication of surgical treatment in patients with IE rely mainly on 
expert opinion based on observational studies.
• RCTs are required to establish the indication and timing of surgery in 
patients with: 
• Increased surgical risk.
• Large vegetations but without other indications for surgery.
• Cerebral emboli or bleeding.
• Patients with uncontrolled infection.
• More data on the need and timing of coronary angiogram before 
endocarditis surgery.
• There is a lack of information on timing and sequence of interven­
tions in patients with multiple septic sources.
• More data are needed on the efficacy and safety of vegetation extrac­
tion systems in right-sided IE.
ESC Guidelines                                                                                                                                                                                          4013


<!-- PAGE 67 -->

### Page 67

Other complications of infective endocarditis: 
• There is limited information on the safety and efficacy of mechanical 
thrombectomy in IE-related embolic strokes.
• There are no prospective data on the timing and safety of splenec­
tomy for splenic abscess, complicating IE in relation to surgical valve 
treatment.
Surgical therapy principles and methods: 
• There is a significant need for scores to predict futility of surgical 
management in very high-risk patients.
• There is a lack of data on the most appropriate anticoagulation regi­
men in patients with PVE complicated by haemorrhagic stroke.
Outcome after discharge: follow-up and long-term 
prognosis: 
• Clinical trials are required to assess the efficacy of rehabilitation, 
including optimal timing, duration, methods, and components.
• Data on patient-reported outcomes during short- and long-term 
follow-up are needed.
Management of specific situations: 
• Additional data on the incidence, characteristics, and outcomes of IE 
in patients treated with transcatheter valve therapies or left atrial ap­
pendage occluders are needed.
• There is an unmet clinical question on the efficacy and safety of sur­
gical treatment of IE in patients previously treated with transcatheter 
valve therapies.
• Randomized data on the timing of CIED reimplantation after device 
removal after CIED infection are needed.
• There is a lack of evidence on whether or not CIED removal should 
be routinely performed in patients with left-sided IE.
• Randomized data on surgery in right-sided IE are required.
Patient-centred care and shared decision-making in 
infective endocarditis: 
• As no disease-specific evidence exists, data on patient-centred care 
and shared decision-making in IE is needed.
• Data on how patient-centred care and shared decision-making in pa­
tients with social and mental health vulnerabilities can improve their 
outcomes are lacking.
• Data on the effect of patient-centred care and shared decision- 
making interventions are required to implement effective strategies.
Sex differences: 
• Further data are required to determine why IE is less frequently ob­
served, and why the outcomes are worse, in female patients.
• The reasons for lower referral to surgery in female patients with IE as 
compared with male patients need to be determined and addressed.
Table 14 ‘What to do’ and ‘What not to do’
Recommendations
Classa
Levelb
Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing oro-dental procedures at increased 
risk of infective endocarditis
Antibiotic prophylaxis is recommended in patients with previous IE.
I
B
General prevention measures are recommended in individuals at high and intermediate risk of IE.
I
C
Antibiotic prophylaxis is recommended in patients with surgically implanted prosthetic valves and with any material used for surgical 
cardiac valve repair.
I
C
Antibiotic prophylaxis is recommended in patients with transcatheter implanted aortic and pulmonary valvular prostheses.
I
C
Antibiotic prophylaxis is recommended in patients with untreated cyanotic CHD, and patients treated with surgery or transcatheter 
procedures with post-operative palliative shunts, conduits, or other prostheses. After surgical repair, in the absence of residual defects 
or valve prostheses, antibiotic prophylaxis is recommended only for the first 6 months after the procedure.
I
C
Antibiotic prophylaxis is recommended in patients with ventricular assist devices.
I
C
Antibiotic prophylaxis is not recommended in other patients at low risk of IE.
III
C
Recommendations for infective endocarditis prevention in high-risk patients
Antibiotic prophylaxis is recommended in dental extractions, oral surgery procedures, and procedures requiring manipulation of the 
gingival or periapical region of the teeth.
I
B
Recommendations for infective endocarditis prevention in cardiac procedures
Pre-operative screening for nasal carriage of S. aureus is recommended before elective cardiac surgery or transcatheter valve 
implantation to treat carriers.
I
A
Peri-operative antibiotic prophylaxis is recommended before placement of a CIED.
I
A
Optimal pre-procedural aseptic measures of the site of implantation are recommended to prevent CIED infections.
I
B
Periprocedural antibiotic prophylaxis is recommended in patients undergoing surgical or transcatheter implantation of a prosthetic 
valve, intravascular prosthetic, or other foreign material.
I
B
Continued
17. ‘What to do’ and ‘What not to do’ messages from the Guidelines


<!-- PAGE 68 -->

### Page 68

Surgical standard aseptic measures are recommended during the insertion and manipulation of catheters in the catheterization 
laboratory environment.
I
C
Systematic skin or nasal decolonization without screening for S. aureus is not recommended.
III
C
Recommendations for the Endocarditis Team
Diagnosis and management of patients with complicated IE are recommended to be performed at an early stage in a Heart Valve 
Centre, with immediate surgical facilities and an ‘Endocarditis Team’ to improve the outcomes.
I
B
For patients with uncomplicated IE managed in a Referring Centre, early and regular communication between the local and the Heart 
Valve Centre endocarditis teams is recommended to improve the outcomes of the patients.
I
B
Recommendations for the role of echocardiography in infective endocarditis
A. Diagnosis
TTE is recommended as the first-line imaging modality in suspected IE.
I
B
TOE is recommended in all patients with clinical suspicion of IE and a negative or non-diagnostic TTE.
I
B
TOE is recommended in patients with clinical suspicion of IE, when a prosthetic heart valve or an intracardiac device is present.
I
B
Repeating TTE and/or TOE within 5–7 days is recommended in cases of initially negative or inconclusive examination when clinical 
suspicion of IE remains high.
I
C
TOE is recommended in patients with suspected IE, even in cases with positive TTE, except in isolated right-sided native valve IE with 
good quality TTE examination and unequivocal echocardiographic findings.
I
C
B. Follow-up under medical therapy
Repeating TTE and/or TOE is recommended as soon as a new complication of IE is suspected (new murmur, embolism, persisting 
fever and bacteraemia, HF, abscess, AVB).
I
B
TOE is recommended when the patient is stable before switching from intravenous to oral antibiotic therapy.
I
B
C. Intra-operative echocardiography
Intra-operative echocardiography is recommended in all cases of IE requiring surgery.
I
C
D. Following completion of therapy
TTE and/or TOE are recommended at completion of antibiotic therapy for evaluation of cardiac and valve morphology and function in 
patients with IE who did not undergo heart valve surgery.
I
C
Recommendations for the role of computed tomography, nuclear imaging, and magnetic resonance in infective endocarditis
Cardiac CTA is recommended in patients with possible NVE to detect valvular lesions and confirm the diagnosis of IE.
I
B
[18F]FDG-PET/CT(A) and cardiac CTA are recommended in possible PVE to detect valvular lesions and confirm the diagnosis of IE.
I
B
Cardiac CTA is recommended in NVE and PVE to diagnose paravalvular or periprosthetic complications if echocardiography is 
inconclusive.
I
B
Brain and whole-body imaging (CT, [18F]FDG-PET/CT, and/or MRI) are recommended in symptomatic patients with NVE and PVE to 
detect peripheral lesions or add minor diagnostic criteria.
I
B
Recommendations for antibiotic treatment of infective endocarditis due to oral streptococci and Streptococcus gallolyticus group
Penicillin-susceptible oral streptococci and Streptococcus gallolyticus group
Standard treatment: 4-week duration in NVE or 6-week duration in PVE
In patients with IE due to oral streptococci and S. gallolyticus group, penicillin G, amoxicillin, or ceftriaxone are recommended for 4 (in 
NVE) or 6 weeks (in PVE), using the following doses:
I
B
Adult antibiotic dosage and route
Penicillin G
12–18 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Paediatric antibiotic dosage and route
Penicillin G
200 000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg/day i.v. in 1 dose
Standard treatment: 2-week duration (not applicable to PVE)
2-week treatment with penicillin G, amoxicillin, ceftriaxone combined with gentamicin is recommended only for the treatment of 
non-complicated NVE due to oral streptococci and S. gallolyticus in patients with normal renal function using the following doses:
I
B
Adult antibiotic dosage and route
Penicillin G
12–18 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Continued
ESC Guidelines                                                                                                                                                                                          4015


<!-- PAGE 69 -->

### Page 69

Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Penicillin G
200 000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. in 1 dose
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose or 3 equally divided doses
Allergy to beta-lactams
In patients allergic to beta-lactams and with IE due to oral streptococci and S. gallolyticus, vancomycin for 4 weeks in NVE or for 6 
weeks in PVE is recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 or 3 equally divided doses
Oral streptococci and Streptococcus gallolyticus group susceptible, increased exposure or resistant to penicillin
In patients with NVE due to oral streptococci and S. gallolyticus, penicillin G, amoxicillin, or ceftriaxone for 4 weeks in combination with 
gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Penicillin G
24 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
In patients with PVE due to oral streptococci and S. gallolyticus, penicillin G, amoxicillin, or ceftriaxone for 6 weeks combined with 
gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Penicillin G
24 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Allergy to beta-lactams
In patients with NVE due to oral streptococci and S. gallolyticus and who are allergic to beta-lactams, vancomycin for 4 weeks is 
recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
In patients with PVE due to oral streptococci and S. gallolyticus and who are allergic to beta-lactams, vancomycin for 6 weeks combined 
with gentamicin for 2 weeks is recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus spp.
IE caused by methicillin-susceptible staphylococci
In patients with NVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin is recommended for 4–6 weeks using the 
following doses:
I
B
Adult antibiotic dosage and route
(Flu)cloxacillin
12 g/day i.v. in 4–6 doses
Cefazolin
6 g/day i.v. in 3 doses
Paediatric antibiotic dosage and route
(Flu)cloxacillin
200–300 mg/kg/day i.v. in 4–6 equally divided doses
Cefazolin
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
Continued


<!-- PAGE 70 -->

### Page 70

In patients with PVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin with rifampin for at least 6 weeks and 
gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
(Flu)cloxacillin
12 g/day i.v. in 4–6 doses
Cefazolin
6 g/day i.v. in 3 doses
Rifampin
900 mg/day i.v. or orally in 3 equally divided doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
(Flu)cloxacillin
200–300 mg/kg/day i.v. in 4–6 equally divided doses
Cefazolin
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Allergy to beta-lactams
In patients with NVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin for 4–6 weeks is 
recommended using the following doses:
I
B
Adult antibiotic dosage and route
Cefazolin
6 g/day i.v. in 3 doses
Paediatric antibiotic dosage and route
Cefazolin
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
In patients with PVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin combined with rifampin for at 
least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Cefazolin
6 g/day i.v. in 3 doses
Rifampin
900 mg/day i.v. or orally in 3 equally divided doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
Cefazolin
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
IE caused by methicillin-resistant staphylococci
In patients with NVE due to methicillin-resistant staphylococci, vancomycin is recommended for 4–6 weeks using the following doses:
I
B
Adult antibiotic dosage and route
Vancomycin
30–60 mg/kg/day i.v. in 2–3 doses
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2–3 equally divided doses
In patients with PVE due to methicillin-resistant staphylococci, vancomycin with rifampin for at least 6 weeks and gentamicin for 2 
weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Vancomycin
30–60 mg/kg/day i.v. in 2–3 doses
Rifampin
900–1200 mg/day i.v. or orally in 2 or 3 divided doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2–3 equally divided doses
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Recommendations for antibiotic treatment of infective endocarditis due to Enterococcus spp.
Beta-lactam and gentamicin-susceptible strains
In patients with NVE due to non-HLAR Enterococcus spp., the combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks or 
with gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Amoxicillin
12 g/day i.v. in 4–6 doses
Ampicillin
12 g/day i.v. in 4–6 doses
Continued
ESC Guidelines                                                                                                                                                                                          4017


<!-- PAGE 71 -->

### Page 71

Ceftriaxone
4 g/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 3 equally divided doses
In patients with PVE and patients with complicated NVE or >3 months of symptoms due to non-HLAR Enterococcus spp., the combination 
of ampicillin or amoxicillin with ceftriaxone for 6 weeks or with gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Amoxicillin
12 g/day i.v. in 4–6 doses
Ampicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 3 equally divided doses
High-level aminoglycoside resistance
In patients with NVE or PVE due to HLAR Enterococcus spp., the combination of ampicillin or amoxicillin and ceftriaxone for 6 weeks is 
recommended using the following doses:
I
B
Adult antibiotic dosage and route
Ampicillin
12 g/day i.v. in 4–6 doses
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. or i.m. in 2 doses
Paediatric antibiotic dosage and route
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. or i.m. in 2 doses
Beta-lactam-resistant Enterococcus spp. (E. faecium)
In patients with IE due to beta-lactam-resistant Enterococcus spp. (E. faecium), vancomycin for 6 weeks combined with gentamicin for 2 
weeks is recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2–3 equally divided doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Vancomycin-resistant Enterococcus spp.
In patients with IE due to vancomycin-resistant Enterococcus spp., daptomycin combined with beta-lactams (ampicillin, ertapenem, or 
ceftaroline) or fosfomycin is recommended using the following doses:
I
C
Adult antibiotic dosage and route
Daptomycin
10–12 mg/kg/day i.v. in 1 dose
Ampicillin
12 g/day i.v. in 4–6 doses
Fosfomycin
12 g/day i.v. in 4 doses
Ceftaroline
1800 mg/day i.v. in 3 doses
Ertapenem
2 g/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Daptomycin
10–12 mg/kg/day i.v. in 1 dose (age-adjusted)
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to a maximum of 12 g/day
Fosfomycin
2–3 g/day i.v. in 1 dose
Ceftaroline
24–36 mg/kg/day in 3 doses
Ertapenem
1 g/day i.v. or i.m. in 1 dose (if younger than 12 years, 15 mg/kg/dose [to a maximum of 500 mg] twice daily)
Continued


<!-- PAGE 72 -->

### Page 72

Recommendations for outpatient antibiotic treatment of infective endocarditis
Outpatient parenteral antibiotic treatment is not recommended in patients with IE caused by highly difficult-to-treat microorganisms, 
liver cirrhosis (Child–Pugh B or C), severe cerebral nervous system emboli, untreated large extracardiac abscesses, heart valve 
complications, or other severe conditions requiring surgery, severe post-surgical complications, and PWID-related IE.
III
C
Recommendations for the main indications of surgery in infective endocarditis (native valve endocarditis and prosthetic valve 
endocarditis)
(i) Heart failure
Emergency surgery is recommended in aortic or mitral NVE or PVE with severe acute regurgitation, obstruction, or fistula causing 
refractory pulmonary oedema or cardiogenic shock.
I
B
Urgent surgery is recommended in aortic or mitral NVE or PVE with severe acute regurgitation or obstruction causing symptoms of 
HF or echocardiographic signs of poor haemodynamic tolerance.
I
B
(ii) Uncontrolled infection
Urgent surgery is recommended in locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation, prosthetic 
dehiscence, new AVB).
I
B
Urgent or non-urgent surgery is recommended in IE caused by fungi or multiresistant organisms according to the haemodynamic 
condition of the patient.
I
C
(iii) Prevention of embolism
Urgent surgery is recommended in aortic or mitral NVE or PVE with persistent vegetations ≥10 mm after one or more embolic 
episodes despite appropriate antibiotic therapy.
I
B
Urgent surgery is recommended in IE with vegetation ≥10 mm and other indications for surgery.
I
C
Recommendations for the treatment of neurological complications of infective endocarditis
Brain CT or MRA is recommended in patients with IE and suspected infective cerebral aneurysms.
I
B
Neurosurgery or endovascular therapy is recommended for large aneurysms, those with continuous growth despite optimal antibiotic 
therapy, and ruptured intracranial infective cerebral aneurysms.
I
C
Thrombolytic therapy is not recommended in embolic stroke due to IE.
III
C
Recommendations for patients with musculoskeletal manifestations of infective endocarditis
MRI or PET/CT is recommended in patients with suspected spondylodiscitis and vertebral osteomyelitis complicating IE.
I
C
TTE/TOE is recommended to rule out IE in patients with spondylodiscitis and/or septic arthritis with positive blood cultures for typical 
IE microorganisms.
I
C
Recommendations for pre-operative coronary anatomy assessment in patients requiring surgery for infective endocarditis
In haemodynamically stable patients with aortic valve vegetations who require cardiac surgery and are high risk of CAD, a 
high-resolution multislice coronary CTA is recommended.
I
B
Invasive coronary angiography is recommended in patients requiring heart surgery who are high risk of CAD, in the absence of aortic 
valve vegetations.
I
C
Indications and timing of cardiac surgery after neurological complications in active infective endocarditis
After a transient ischaemic attack, cardiac surgery, if indicated, is recommended without delay.
I
B
After a stroke, surgery is recommended without any delay in the presence of HF, uncontrolled infection, abscess, or persistent high 
embolic risk, as long as coma is absent and the presence of cerebral haemorrhage has been excluded by cranial CT or MRI.
I
B
Recommendations for post-discharge follow-up
Patient education on the risk of recurrence and preventive measures, with emphasis on dental health, and based on the individual risk 
profile is recommended during follow-up.
I
C
Addiction treatment for patients following PWID-related IE is recommended.
I
C
Recommendations for prosthetic valve endocarditis
Surgery is recommended for early PVE (within 6 months of valve surgery) with new valve replacement and complete debridement.
I
C
Recommendations for cardiovascular implanted electronic device-related infective endocarditis
Antibiotic prophylaxis covering S. aureus is recommended for CIED implantation.
I
A
TTE and TOE are both recommended in cases of suspected CIED-related IE to identify vegetations.
I
B
Complete system extraction without delay is recommended in patients with definite CIED-related IE under initial empirical antibiotic 
therapy.
I
B
Continued
ESC Guidelines                                                                                                                                                                                          4019


<!-- PAGE 73 -->

### Page 73

### 18 Supplementary data

Supplementary data are available at European Heart Journal online.
19. Data availability
No new data were generated or analysed in support of this research.
20. Author information
Author/Task Force Member Affiliations: Nina Ajmone 
Marsan, Leiden University Medical Center, Leiden, Netherlands; 
Suzanne de Waha, Heart Center Leipzig at University of Leipzig, 
Leipzig, Germany; Nikolaos Bonaros, Medical University of 
Innsbruck, Innsbruck, Austria and University Hospital Innsbruck, 
Innsbruck, Austria; Margarita Brida, Medical Faculty University of 
Rijeka, Rijeka, Croatia and Adult Congenital Heart Centre and 
National Centre for Pulmonary Hypertension, Royal Brompton & 
Harefield Hospitals, London, United Kingdom; Haran Burri, 
University Hospital of Geneva, Geneva, Switzerland; Stefano 
Caselli, Hirslanden Klinik im Park, Zurich, Switzerland and University 
Heart Center, University Hospital Zurich, Zurich, Switzerland; 
Torsten Doenst, Friedrich-Schiller-University Jena, University 
Hospital, Jena, Germany; Stephane Ederhy, Hopital Saint-Antoine, 
Paris, France and Unité de cardio-oncologie, UNICO-GRECO, 
Hopital Saint-Antoine, Paris, France and Groupe de recherche clinique 
en cardio-oncologie, GRC n°27, Hopital Saint-Antoine, Paris, France; 
Paola Anna Erba, University of Milan Bicocca, Milan, Italy and 
Nuclear Medicine Department, ASST – Ospedale Papa Giovanni 
XXIII, Bergamo, Italy and Medical Imaging Center, Department of 
Nuclear Medicine & Molecular Imaging, University Medical Center 
Groningen, Groningen, Netherlands; Dan Foldager, ESC Patient 
Forum, Sophia Antipolis, France; Emil L. Fosbøl, University 
Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark; Jan 
Kovac, University of Leicester, Leicester, United Kingdom and 
RRCV Glenfield, University Hospitals of Leicester NHS Trust, 
Leicester, United Kingdom; Carlos A. Mestres, The University of 
the Free State, Bloemfontein, South Africa and Cardiac Surgery, 
University Hospital Zurich, Zurich, Switzerland; Owen I. Miller, 
Evelina London Children’s Hospital, London, United Kingdom and 
Department of Women and Children’s Health, Kings College 
London, London, United Kingdom; Jose M. Miro, Hospital Clinic - 
IDIBAPS, Barcelona, Spain and Faculty of Medicine, University of 
Barcelona, Barcelona, Spain and Centro de Investigación Biomédica 
en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud 
Carlos III, Madrid, Spain; Michal Pazdernik, Institute for Clinical 
and Experimental Medicine (IKEM), Prague, Czech Republic; Maria 
Nazarena Pizzi, Vall d´Hebron University Hospital, Barcelona, 
Spain; Eduard Quintana, Hospital Clínic de Barcelona, Barcelona, 
Spain 
and 
Departament 
de 
Cirurgia 
i 
Especialitats 
Medicoquirúrgiques, Facultat de Medicina i Ciències de la Salut, 
University of Barcelona, Barcelona, Spain; Trine Bernholdt 
Rasmussen, Herlev and Gentofte University Hospital, Hellerup, 
Denmark and Department of Clinical Medicine, Faculty of Health and 
Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 
Arsen D. Ristić, University Clinical Center of Serbia, Belgrade, 
Serbia and Faculty of Medicine, University of Belgrade, Belgrade, 
Serbia; Josep Rodés-Cabau, Quebec Heart and Lung Institute, 
Laval University, Quebec, Canada and Research and Innovation, 
Clínic Barcelona, Barcelona, Spain; Alessandro Sionis, Hospital de 
la Santa Creu i Sant Pau, Barcelona, Spain and Universitat Autònoma 
de Barcelona, Barcelona, Spain; Liesl Joanna Zühlke, Francie van 
Zijl Drive Parowvallei, Cape Town; PO Box 19070, Cape Town, 
South Africa and Division of Paediatric Cardiology, Department of 
Paediatrics, Institute of Child Health, Faculty of Health Sciences, 
University of Cape Town, Cape Town, South Africa.
Obtaining at least three sets of blood cultures is recommended before prompt initiation of empirical antibiotic therapy for CIED 
infection, covering methicillin-resistant staphylococci and Gram-negative bacteria.
I
C
If CIED reimplantation is indicated after extraction for CIED-related IE, it is recommended to be performed at a site distant from the 
previous generator, as late as possible, once signs and symptoms of infection have abated, and until blood cultures are negative for at 
least 72 h in the absence of vegetations, and negative for at least 2 weeks if vegetations were visualized.
I
C
Removal of CIED after a single positive blood culture, with no other clinical evidence of infection, is not recommended.
III
C
Recommendations for the surgical treatment of right-sided infective endocarditis
Surgery is recommended in patients with right-sided IE who are receiving appropriate antibiotic therapy for the following scenarios:
Right ventricular dysfunction secondary to acute severe tricuspid regurgitation non-responsive to diuretics.
I
B
Persistent vegetation with respiratory insufficiency requiring ventilatory support after recurrent pulmonary emboli.
I
B
Large residual tricuspid vegetations (>20 mm) after recurrent septic pulmonary emboli.
I
C
Patients with simultaneous involvement of left-heart structures.
I
C
Recommendations for the use of antithrombotic therapy in infective endocarditis
Interruption of antiplatelet or anticoagulant therapy is recommended in the presence of major bleeding (including intracranial 
haemorrhage).
I
C
Thrombolytic therapy is not recommended in patients with IE.
III
C
© ESC 2023
[18F]FDG-PET, 18F-fluorodeoxyglucose positron emission tomography; AVB, atrioventricular block; CAD, coronary artery disease; CHD, congenital heart disease; CIED, cardiovascular 
implanted electronic device; CT, computed tomography; CTA, computed tomography angiography; HF, heart failure; HLAR, high-level aminoglycoside resistance; IE, infective 
endocarditis; i.m., intramuscular; i.v., intravenous; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; NVE, native valve endocarditis; PET, positron emission 
tomography; PVE, prosthetic valve endocarditis; PWID, people who inject drugs; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 74 -->

### Page 74

### 21 Appendix

ESC Society Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document 
Reviewers: 
Bernard 
Iung 
(CPG 
Review 
Co-ordinator) 
(France), 
Bernard 
Prendergast 
(CPG 
Review 
Co-ordinator) (United Kingdom), Magdy Abdelhamid (Egypt), 
Marianna Adamo (Italy), Riccardo Asteggiano (Italy), Larry 
M. Baddour (United States of America), Jelena Čelutkienė (Lithuania), 
John Chambers (United Kingdom), Jean-Claude Deharo (France), 
Wolfram Doehner (Germany), Laura Dos Subira (Spain), Xavier 
Duval (France), Volkmar Falk (Germany), Laurent Fauchier (France), 
Nuria Fernandez-Hidalgo (Spain), Christian Giske (Sweden), Anežka 
Gombošová (Czechia), Gilbert Habib (France), Borja Ibanez (Spain), 
Tiny Jaarsma (Sweden), Lars Køber (Denmark), Konstantinos 
C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf 
Landmesser (Germany), Sandra B. Lauck (Canada), Basil S. Lewis 
(Israel), Maja-Lisa Løchen (Norway), John William McEvoy (Ireland), 
Borislava Mihaylova (United Kingdom), Richard Mindham (United 
Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen 
(Denmark), Jean-François Obadia (France), Agnes A. Pasquet 
(Belgium), Steffen Petersen (United Kingdom), Eva Prescott 
(Denmark), Susanna Price (United Kingdom), Amina Rakisheva 
(Kazakhstan), Archana Rao (United Kingdom), François Rouzet 
(France), Jonathan Sandoe (United Kingdom), Renate B. Schnabel 
(Germany), Christine Selton-Suty (France), Lars Sondergaard 
(Denmark), Martin Thornhill (United Kingdom), Konstantinos 
Toutouzas (Greece), Nico Van de Veire (Belgium), Isidre Vilacosta 
(Spain), Christiaan Vrints (Belgium), Olaf Wendler (United Kingdom).
ESC National Cardiac Societies actively involved in the review 
process of the 2023 Guidelines for the management of endocarditis.
Algeria: Algerian Society of Cardiology, Yasmina Benchabi; 
Armenia: Armenian Cardiologists Association, Aram Chilingaryan; 
Austria: Austrian Society of Cardiology, Sebastian J. Reinstadler; 
Azerbaijan: Azerbaijan Society of Cardiology, Fuad Samadov; 
Belgium: Belgian Society of Cardiology, Bernard Paelinck; Bosnia 
and Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Zumreta Kušljugić; Bulgaria: Bulgarian Society of 
Cardiology, Elena Kinova; Croatia: Croatian Cardiac Society, Maja 
Cikes; Cyprus: Cyprus Society of Cardiology, Ioannis Michaloliakos; 
Czechia: Czech Society of Cardiology, Martin Mates; Denmark: 
Danish Society of Cardiology, Jonas Agerlund Povlsen; Egypt: 
Egyptian Society of Cardiology, Mohammad Abdelghani; Estonia: 
Estonian Society of Cardiology, Liisi Küünal-Arge; Finland: Finnish 
Cardiac Society, Helena Rajala; France: French Society of 
Cardiology, Christine Selton-Suty; Georgia: Georgian Society of 
Cardiology, Zurab Pagava; Germany: German Cardiac Society, 
Marcus Franz; Greece: Hellenic Society of Cardiology, Alexandros 
Patrianakos Hungary: Hungarian Society of Cardiology, Judit Barta; 
Iceland: Icelandic Society of Cardiology, Þórdís Jóna Hrafnkelsdóttir; 
Ireland: Irish Cardiac Society, David Moore; Israel: Israel Heart 
Society, Katia Orvin; Italy: Italian Federation of Cardiology, Fabrizio 
Oliva; Kazakhstan: Association of Cardiologists of Kazakhstan, 
Gyulnar Zhussupova; Kosovo (Republic of): Kosovo Society of 
Cardiology, Gani Bajraktari; Kyrgyzstan: Kyrgyz Society of 
Cardiology, Alina Kerimkulova, Latvia: Latvian Society of Cardiology, 
Ginta Kamzola; Lebanon: Lebanese Society of Cardiology, Pierrette 
Habib; Lithuania: Lithuanian Society of Cardiology, Vaida Mizarienė; 
Luxembourg: Luxembourg Society of Cardiology, Rouguiatou Sow; 
Malta: Maltese Cardiac Society, Daniela Cassar Demarco; Moldova 
(Republic of): Moldavian Society of Cardiology, Elena Panfile; 
Morocco: Moroccan Society of Cardiology, Laila Bendriss; 
Netherlands: Netherlands Society of Cardiology, Wilco Tanis; 
North Macedonia: The National Society of Cardiology of North 
Macedonia, Irena Mitevska; Norway: Norwegian Society of 
Cardiology, Erlend Aune; Portugal: Portuguese Society of 
Cardiology, Manuel Antunes; Romania: Romanian Society of 
Cardiology, Bogdan A. Popescu; San Marino: San Marino Society of 
Cardiology, Roberto Bini; Serbia: Cardiology Society of Serbia, 
Milorad Tesic; Slovakia: Slovak Society of Cardiology, Marek Orban; 
Slovenia: Slovenian Society of Cardiology, Mojca Bervar; Spain: 
Spanish Society of Cardiology, Isidre Vilacosta; Sweden: Swedish 
Society of Cardiology, Christina Christersson; Switzerland: Swiss 
Society of Cardiology, Michelle Frank; Tunisia: Tunisian Society of 
Cardiology and Cardiovascular Surgery, Lilia Zakhama; Türkiye: 
Turkish Society of Cardiology, Gamze Babur Guler; Ukraine: 
Ukrainian Association of Cardiology, Sergii Cherniuk; United 
Kingdom of Great Britain and Northern Ireland: British 
Cardiovascular Society, Simon Woldman, Uzbekistan: Association 
of Cardiologists of Uzbekistan, Nigora Srojidinova.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
